BACKGROUND O
: O
Ischemic O
heart O
disease O
is O
the O
primary O
cause O
of O
morbidity O
and O
mortality O
among O
diabetics O
, O
especially O
those O
who O
became O
ill O
at O
a O
young O
age O
. O

More O
importantly O
, O
this O
fusion O
converted O
a O
less O
effective O
vaccine O
into O
one O
with O
significant O
potency O
against O
established O
E7 I-GENE
- I-GENE
expressing O
metastatic O
tumors O
. O

Reverse O
transcription O
- O
PCR O
analysis O
of O
mRNA O
from O
patients O
shows O
that O
each O
of O
these O
five O
mutations O
results O
in O
aberrant O
splicing O
. O

Using O
the O
postural O
and O
force O
data O
as O
input O
to O
a O
3 I-GENE
- I-GENE
D I-GENE
biomechanical I-GENE
model I-GENE
, I-GENE
the I-GENE
lumbosacral I-GENE
spinal I-GENE
compression I-GENE
was I-GENE
calculated I-GENE
. I-GENE

Sequence O
analysis O
revealed O
significant O
differences O
between O
the O
5 O
' O
region O
of O
the O
beta I-GENE
subunit I-GENE
gene I-GENE
and O
the O
corresponding O
regions O
of O
the I-GENE
homologous I-GENE
GlyR I-GENE
alpha I-GENE
subunit I-GENE
genes I-GENE
; I-GENE
it I-GENE
also I-GENE
identified I-GENE
a I-GENE
novel I-GENE
exon I-GENE
( I-GENE
exon I-GENE
0 I-GENE
) I-GENE
that I-GENE
encodes I-GENE
most I-GENE
of I-GENE
the I-GENE
5 I-GENE
'- I-GENE
untranslated I-GENE
portion I-GENE
of I-GENE
the I-GENE
GlyR I-GENE
beta I-GENE
mRNA I-GENE
. I-GENE

Therefore O
, O
we O
suggested O
that O
both O
proteins O
might O
belong O
to I-GENE
the I-GENE
PLTP I-GENE
family I-GENE
. I-GENE

Influence O
of O
compression O
therapy O
on O
symptoms O
following O
soft O
tissue O
injury O
from O
maximal O
eccentric O
exercise O
. O

STAT5A I-GENE
mutations I-GENE
in I-GENE
the I-GENE
Src I-GENE
homology I-GENE
2 I-GENE
( I-GENE
SH2 I-GENE
) I-GENE
and I-GENE
SH3 I-GENE
domains I-GENE
did I-GENE
not I-GENE
alter I-GENE
the I-GENE
BTK I-GENE
- I-GENE
mediated I-GENE
tyrosine I-GENE
phosphorylation I-GENE
. I-GENE

In O
the O
present O
work O
, O
the O
complete O
genome O
sequences I-GENE
of I-GENE
Pyrococcus I-GENE
horikoshii I-GENE
and I-GENE
Pyrococcus I-GENE
abyssi I-GENE
, I-GENE
two I-GENE
species I-GENE
in I-GENE
a I-GENE
genus I-GENE
of I-GENE
hyperthermophilic I-GENE
archaeon I-GENE
( I-GENE
archaebacterium I-GENE
), I-GENE
were I-GENE
compared I-GENE
to I-GENE
detect I-GENE
large I-GENE
genome I-GENE
polymorphisms I-GENE
linked I-GENE
with I-GENE
restriction I-GENE
- I-GENE
modification I-GENE
gene I-GENE
homologs I-GENE
. I-GENE

In I-GENE
addition I-GENE
, I-GENE
these I-GENE
patients I-GENE
show I-GENE
both I-GENE
quantitative I-GENE
and I-GENE
qualitative I-GENE
differences I-GENE
in I-GENE
their I-GENE
infectious I-GENE
microbiological I-GENE
spectrum I-GENE
, I-GENE
mainly I-GENE
in I-GENE
clean I-GENE
- I-GENE
contaminated I-GENE
, I-GENE
contaminated I-GENE
and I-GENE
dirty I-GENE
surgical I-GENE
procedures I-GENE
. I-GENE

Here O
we O
show O
that O
PKC I-GENE
and O
p44 I-GENE
/ I-GENE
p42MAPK I-GENE
signalings I-GENE
are I-GENE
required I-GENE
for I-GENE
the I-GENE
HBx I-GENE
- I-GENE
induced I-GENE
Sp1 I-GENE
- I-GENE
mediated I-GENE
IGF I-GENE
- I-GENE
II I-GENE
P4 I-GENE
transcriptional I-GENE
activity I-GENE
since I-GENE
( I-GENE
i I-GENE
) I-GENE
PKC I-GENE
activation I-GENE
by I-GENE
PMA I-GENE
or I-GENE
PKC I-GENE
expression I-GENE
vector I-GENE
increases I-GENE
Sp1 I-GENE
phosphorylation I-GENE
and I-GENE
P4 I-GENE
activity I-GENE
in I-GENE
HBx I-GENE
- I-GENE
transfected I-GENE
HepG2 I-GENE
cells I-GENE
; I-GENE
( I-GENE
ii I-GENE
) I-GENE
PKC I-GENE
inhibition I-GENE
by I-GENE
PKC I-GENE
inhibitor I-GENE
Go6976 I-GENE
reduces I-GENE
Sp1 I-GENE
phosphorylation I-GENE
, I-GENE
P4 I-GENE
activity I-GENE
, I-GENE
and I-GENE
IGF I-GENE
- I-GENE
II I-GENE
mRNA I-GENE
in I-GENE
HBx I-GENE
- I-GENE
transfected I-GENE
HepG2 I-GENE
cells I-GENE
; I-GENE
and I-GENE
( I-GENE
iii I-GENE
) I-GENE
the I-GENE
inhibition I-GENE
of I-GENE
MEK I-GENE
activation I-GENE
by I-GENE
U0126 I-GENE
reduces I-GENE
Sp1 I-GENE
phosphorylation I-GENE
, I-GENE
P4 I-GENE
activity I-GENE
and I-GENE
IGF I-GENE
- I-GENE
II I-GENE
mRNA I-GENE
in I-GENE
HBx I-GENE
- I-GENE
transfected I-GENE
HepG2 I-GENE
cells I-GENE
. I-GENE

We O
show O
that O
p73 I-GENE
can O
transcriptionally O
inhibit O
a O
number O
of O
cellular O
and O
viral O
promoters O
. O

Similarly I-GENE
, I-GENE
curcumin I-GENE
( I-GENE
diferuloylmethane I-GENE
), I-GENE
an I-GENE
anti I-GENE
- I-GENE
inflammatory I-GENE
agent I-GENE
, I-GENE
suppressed I-GENE
OSM I-GENE
- I-GENE
stimulated I-GENE
STAT1 I-GENE
phosphorylation I-GENE
, I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
activity I-GENE
of I-GENE
STAT1 I-GENE
, I-GENE
and I-GENE
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
activation I-GENE
without I-GENE
affecting I-GENE
JAK1 I-GENE
, I-GENE
JAK2 I-GENE
, I-GENE
JAK3 I-GENE
, I-GENE
ERK1 I-GENE
/ I-GENE
2 I-GENE
, I-GENE
and I-GENE
p38 I-GENE
phosphorylation I-GENE
. I-GENE

The O
effects O
of O
the O
transfected O
receptors O
were O
associated O
with O
antagonism O
of O
activator I-GENE
protein I-GENE
1 I-GENE
( I-GENE
AP I-GENE
- I-GENE
1 I-GENE
) O
activity O
. O

Furthermore O
, O
the I-GENE
soluble I-GENE
forms I-GENE
of I-GENE
ATF6 I-GENE
and I-GENE
the I-GENE
G13 I-GENE
gene I-GENE
product I-GENE
are I-GENE
unable I-GENE
to I-GENE
bind I-GENE
to I-GENE
several I-GENE
point I-GENE
mutants I-GENE
of I-GENE
the I-GENE
cis I-GENE
- I-GENE
acting I-GENE
ER I-GENE
stress I-GENE
response I-GENE
element I-GENE
in I-GENE
vitro I-GENE
that I-GENE
hardly I-GENE
respond I-GENE
to I-GENE
ER I-GENE
stress I-GENE
in I-GENE
vivo I-GENE
. I-GENE

PURPOSE O
: O
The O
objective O
of O
this O
study O
was O
to O
assess O
first O
embryo O
cleavage I-GENE
( I-GENE
FEC I-GENE
) I-GENE
25 I-GENE
- I-GENE
27 I-GENE
h I-GENE
after I-GENE
intracytoplasmic I-GENE
sperm I-GENE
injection I-GENE
( I-GENE
ICSI I-GENE
) I-GENE
as I-GENE
a I-GENE
parameter I-GENE
for I-GENE
the I-GENE
embryo I-GENE
selection I-GENE
process I-GENE
. I-GENE

RESULTS O
: O
A O
significant O
correlation O
( O
p O
< O
0 O
. O
001 O
) O
was O
observed O
for O
mean O
wall O
thickness O
and O
vessel O
wall O
area O
between O
MRI O
and O
histopathology O
( O
r O
= O
0 O
. O
87 O
and O
r O
= O
0 O
. O
85 O
, O
respectively O
). O

Molecular O
cloning O
, O
genomic O
mapping O
, O
and O
expression O
of O
two O
secretor O
blood O
group O
alpha I-GENE
( I-GENE
1 I-GENE
, O
2 I-GENE
) I-GENE
fucosyltransferase I-GENE
genes I-GENE
differentially O
regulated O
in O
mouse O
uterine O
epithelium O
and O
gastrointestinal O
tract O
. O

We O
show O
that O
several O
heme O
- O
responsive O
mechanisms O
combine O
to O
regulate O
DAN O
/ O
TIR O
gene O
expression O
. O

No O
' O
TATA O
' O
motif O
was O
identified O
near O
either O
the O
GABPalpha I-GENE
or I-GENE
ATPsynCF6 I-GENE
transcription I-GENE
start I-GENE
sites I-GENE
. I-GENE

These O
results O
indicate O
the O
presence O
of O
TATA O
- O
unified O
transcription O
systems O
in O
contemporary O
eukaryotes O
and O
provide O
insight O
into O
the O
residual O
need O
for I-GENE
TBP I-GENE
by I-GENE
all I-GENE
three I-GENE
Pols I-GENE
in I-GENE
other I-GENE
eukaryotes I-GENE
despite I-GENE
a I-GENE
lack I-GENE
of I-GENE
TATA I-GENE
elements I-GENE
in I-GENE
their I-GENE
promoters I-GENE
. I-GENE

Different I-GENE
thermoluminescent I-GENE
detectors I-GENE
( I-GENE
TLD I-GENE
) I-GENE
have I-GENE
been I-GENE
used I-GENE
to I-GENE
measure I-GENE
the I-GENE
contribution I-GENE
of I-GENE
the I-GENE
low I-GENE
linear I-GENE
energy I-GENE
transfer I-GENE
component I-GENE
( I-GENE
LET I-GENE
< I-GENE
10 I-GENE
keV I-GENE
/ I-GENE
micrometer I-GENE
) I-GENE
and I-GENE
plastic I-GENE
nuclear I-GENE
track I-GENE
detectors I-GENE
( I-GENE
PNTD I-GENE
) I-GENE
for I-GENE
the I-GENE
high I-GENE
linear I-GENE
energy I-GENE
tranfer I-GENE
( I-GENE
LET I-GENE
) I-GENE
component I-GENE
. I-GENE

However O
, I-GENE
the I-GENE
beta5L I-GENE
splice I-GENE
variant I-GENE
was I-GENE
found I-GENE
only I-GENE
in I-GENE
the I-GENE
retina I-GENE
. I-GENE

This O
analysis O
supports O
the O
use O
of O
fluticasone O
propionate O
88 O
microg O
twice O
daily O
as O
first O
- O
line O
treatment O
in O
patients O
with O
persistent O
asthma O
previously O
treated O
with O
short O
- O
acting O
beta2 I-GENE
- I-GENE
agonist O
alone O
. O

The O
mice O
are O
phenotypically O
normal O
and O
do O
not O
develop O
spontaneous O
tumors O
at O
an O
early O
age O
, I-GENE
in I-GENE
contrast I-GENE
to I-GENE
knock I-GENE
- I-GENE
out I-GENE
( I-GENE
p53 I-GENE
(-/-)) I-GENE
strains I-GENE
with I-GENE
a I-GENE
defective I-GENE
p53 I-GENE
gene I-GENE
. I-GENE

Furthermore O
, O
stable O
expression O
of O
a O
constitutively O
active O
form O
of O
chicken I-GENE
Notch1 I-GENE
or I-GENE
Notch2 I-GENE
in I-GENE
a I-GENE
B I-GENE
cell I-GENE
line I-GENE
results I-GENE
in I-GENE
a I-GENE
down I-GENE
- I-GENE
regulation I-GENE
of I-GENE
surface I-GENE
IgM I-GENE
expression I-GENE
, I-GENE
which I-GENE
is I-GENE
accompanied I-GENE
by I-GENE
the I-GENE
reduction I-GENE
of I-GENE
IgH I-GENE
gene I-GENE
transcripts I-GENE
. I-GENE

On O
Cox O
proportional O
hazards O
regression O
adenocarcinoma O
( O
P O
= O
0 O
. O
006 O
), I-GENE
the I-GENE
development I-GENE
of I-GENE
BPF I-GENE
( I-GENE
P I-GENE
= I-GENE
0 I-GENE
. I-GENE
003 I-GENE
), I-GENE
older I-GENE
age I-GENE
( I-GENE
P I-GENE
= I-GENE
0 I-GENE
. I-GENE
03 I-GENE
) I-GENE
and I-GENE
higher I-GENE
pathological I-GENE
stage I-GENE
( I-GENE
P I-GENE
= I-GENE
0 I-GENE
. I-GENE
02 I-GENE
) I-GENE
were I-GENE
independent I-GENE
adverse I-GENE
predictors I-GENE
of I-GENE
survival I-GENE
. I-GENE

We O
found O
that O
RhoA I-GENE
can O
initiate O
a O
linear O
kinase O
cascade O
leading O
to O
the O
activation I-GENE
of I-GENE
ERK6 I-GENE
( I-GENE
p38 I-GENE
gamma I-GENE
), I-GENE
a I-GENE
recently I-GENE
identified I-GENE
member I-GENE
of I-GENE
the I-GENE
p38 I-GENE
family I-GENE
of I-GENE
MAPKs I-GENE
. I-GENE

Twenty O
- O
six O
( O
55 O
%) O
( O
95 O
% O
CI O
, O
41 O
- I-GENE
69 I-GENE
%) I-GENE
patients I-GENE
experienced I-GENE
> I-GENE
or I-GENE
= I-GENE
grade I-GENE
3 I-GENE
acute I-GENE
toxicity I-GENE
( I-GENE
RTOG I-GENE
). I-GENE

We I-GENE
hypothesize I-GENE
that I-GENE
proprioception I-GENE
may I-GENE
be I-GENE
used I-GENE
to I-GENE
calibrate I-GENE
the I-GENE
efference I-GENE
copy I-GENE
during I-GENE
development I-GENE
and I-GENE
in I-GENE
response I-GENE
to I-GENE
perturbations I-GENE
by I-GENE
signaling I-GENE
potential I-GENE
mismatches I-GENE
between I-GENE
eye I-GENE
movement I-GENE
information I-GENE
derived I-GENE
from I-GENE
the I-GENE
efferent I-GENE
command I-GENE
and I-GENE
the I-GENE
actual I-GENE
motion I-GENE
of I-GENE
the I-GENE
eye I-GENE
transduced I-GENE
by I-GENE
the I-GENE
proprioceptive I-GENE
organs I-GENE
. I-GENE

Thus O
, O
BALB O
/ O
c O
mice O
appear O
to O
be O
the O
most O
appropriate O
strain O
of O
mice O
to O
perform O
studies O
on O
the O
possible O
connection O
between O
infection O
with O
T O
. O
canis I-GENE
and O
allergic O
asthma O
. O

They O
correspond O
to O
nucleotides O
equivalent O
to O
base O
- O
pair O
C1 I-GENE
- I-GENE
G72 I-GENE
and I-GENE
discriminator I-GENE
base I-GENE
A73 I-GENE
in I-GENE
the I-GENE
amino I-GENE
acid I-GENE
- I-GENE
acceptor I-GENE
branch I-GENE
of I-GENE
the I-GENE
molecule I-GENE
. I-GENE

Our O
results O
suggest O
that O
the O
central O
role O
of O
the O
Notch I-GENE
- I-GENE
CBF1 I-GENE
/ I-GENE
RBP I-GENE
- I-GENE
Jkappa I-GENE
signaling O
pathway O
in I-GENE
cell I-GENE
fate I-GENE
decisions I-GENE
renders I-GENE
it I-GENE
susceptible I-GENE
to I-GENE
pathways I-GENE
of I-GENE
viral I-GENE
replication I-GENE
and I-GENE
oncogenic I-GENE
conversion I-GENE
. I-GENE

High O
- O
affinity O
binding O
of O
NF I-GENE
- I-GENE
1 I-GENE
to O
PSE I-GENE
- I-GENE
B I-GENE
, O
but O
not O
to O
PSE O
- O
A O
, O
was O
confirmed O
by O
competition O
of O
DNA O
- O
protein O
interactions O
by O
using O
NF I-GENE
- I-GENE
1 I-GENE
DNA I-GENE
elements I-GENE
and O
antibodies I-GENE
. O

The O
first O
case O
of I-GENE
HCV I-GENE
seroconversion I-GENE
in I-GENE
Portugal I-GENE
after I-GENE
the I-GENE
introduction I-GENE
of I-GENE
HCV I-GENE
NAT I-GENE
screening I-GENE
. I-GENE

Substitutions O
in I-GENE
the I-GENE
YFV I-GENE
Ag I-GENE
- I-GENE
binding I-GENE
region I-GENE
( I-GENE
ABR I-GENE
) I-GENE
occur I-GENE
at I-GENE
four I-GENE
of I-GENE
the I-GENE
eight I-GENE
highly I-GENE
conserved I-GENE
residues I-GENE
that I-GENE
are I-GENE
essential I-GENE
for I-GENE
binding I-GENE
of I-GENE
peptide I-GENE
- I-GENE
Ag I-GENE
in I-GENE
the I-GENE
class I-GENE
Ia I-GENE
molecules I-GENE
. I-GENE

The I-GENE
Novacor I-GENE
Left I-GENE
Ventricular I-GENE
Assist I-GENE
System I-GENE
( I-GENE
LVAS I-GENE
) I-GENE
( I-GENE
Novacor I-GENE
Corp I-GENE
, I-GENE
Oakland I-GENE
, I-GENE
CA I-GENE
) I-GENE
was I-GENE
initially I-GENE
console I-GENE
- I-GENE
based I-GENE
and I-GENE
has I-GENE
been I-GENE
available I-GENE
since I-GENE
1993 I-GENE
in I-GENE
a I-GENE
wearable I-GENE
configuration I-GENE
. I-GENE

Ileal I-GENE
digestibilities I-GENE
of I-GENE
DM I-GENE
, I-GENE
OM I-GENE
, I-GENE
CP I-GENE
, I-GENE
total I-GENE
dietary I-GENE
fiber I-GENE
( I-GENE
TDF I-GENE
), I-GENE
fat I-GENE
and I-GENE
gross I-GENE
energy I-GENE
( I-GENE
GE I-GENE
) I-GENE
were I-GENE
lower I-GENE
( I-GENE
P I-GENE
< I-GENE
0 I-GENE
. I-GENE
05 I-GENE
) I-GENE
for I-GENE
dogs I-GENE
fed I-GENE
diets I-GENE
containing I-GENE
supplemental I-GENE
fiber I-GENE
compared I-GENE
with I-GENE
dogs I-GENE
fed I-GENE
the I-GENE
control I-GENE
diet I-GENE
. I-GENE

In O
addition O
, O
the O
consensus O
amino O
acid O
motif O
for O
serine I-GENE
threonine I-GENE
receptor I-GENE
kinases I-GENE
was O
also O
present O
. O

Here O
, O
we O
show O
that O
the O
phorbol O
ester O
PMA O
decreases O
both O
basal O
and O
dexamethasone O
/ O
cAMP O
- O
induced O
expression O
of O
a O
luciferase I-GENE
gene I-GENE
under O
the O
control O
of O
the O
G6Pase I-GENE
promoter I-GENE
in O
transiently O
transfected O
H4IIE O
hepatoma O
cells O
. O

The O
difference O
between O
the O
patients O
and O
the O
controls O
was O
statistically O
significant O
( O
p O
= O
0 O
. O
03 O
). O

Altogether O
, O
we O
confirm O
that O
all O
genes I-GENE
of I-GENE
the I-GENE
Rad52 I-GENE
recombinational I-GENE
repair I-GENE
pathway I-GENE
are I-GENE
required I-GENE
for I-GENE
the I-GENE
survival I-GENE
of I-GENE
rad27 I-GENE
Delta I-GENE
strains I-GENE
at I-GENE
both I-GENE
permissive I-GENE
( I-GENE
23 I-GENE
degrees I-GENE
C I-GENE
) I-GENE
and I-GENE
semipermissive I-GENE
( I-GENE
30 I-GENE
degrees I-GENE
C I-GENE
) I-GENE
temperatures I-GENE
for I-GENE
growth I-GENE
. I-GENE

Neuron I-GENE
- I-GENE
specific I-GENE
Bcl I-GENE
- I-GENE
2 I-GENE
homology I-GENE
3 I-GENE
domain I-GENE
- I-GENE
only I-GENE
splice I-GENE
variant I-GENE
of I-GENE
Bak I-GENE
is I-GENE
anti I-GENE
- I-GENE
apoptotic I-GENE
in I-GENE
neurons I-GENE
, I-GENE
but I-GENE
pro I-GENE
- I-GENE
apoptotic I-GENE
in I-GENE
non I-GENE
- I-GENE
neuronal I-GENE
cells I-GENE
. I-GENE

The O
mechanism O
of O
the O
induction O
of O
3beta I-GENE
- I-GENE
HSD I-GENE
type I-GENE
1 I-GENE
gene I-GENE
expression I-GENE
was I-GENE
further I-GENE
characterized I-GENE
in I-GENE
ZR I-GENE
- I-GENE
75 I-GENE
- I-GENE
1 I-GENE
human I-GENE
breast I-GENE
cancer I-GENE
cells I-GENE
. I-GENE

Contagious I-GENE
bovine I-GENE
pleuropneumonia I-GENE
is I-GENE
a I-GENE
major I-GENE
threat I-GENE
for I-GENE
cattle I-GENE
in I-GENE
Africa I-GENE
. I-GENE

Treatment O
includes O
both O
medical O
and O
surgical O
options O
, O
with O
medical O
therapy O
further O
subclassified O
into O
pharmacologic O
and O
pneumatic O
dilation O
. O

Since O
the O
latter O
is O
very O
small O
for O
physiological O
flows O
, O
the O
result O
is O
that O
alpha O
< O
1 O
even O
at O
relatively O
high O
values O
of O
the O
Reynolds O
number O
( O
i O
. O
e O
., O
for O
non I-GENE
- I-GENE
negligible I-GENE
inertia I-GENE
) I-GENE
and I-GENE
we I-GENE
validate I-GENE
our I-GENE
perturbation I-GENE
theory I-GENE
results I-GENE
by I-GENE
comparison I-GENE
with I-GENE
a I-GENE
numerical I-GENE
integration I-GENE
of I-GENE
the I-GENE
full I-GENE
model I-GENE
. I-GENE

This O
plus O
the O
reduced O
phosphorylation O
of O
p27 I-GENE
by O
MAPK I-GENE
enhanced O
the O
stability O
of O
p27 I-GENE
that O
associated O
with O
nuclear I-GENE
Cdk2 I-GENE
at O
high O
stoichiometry O
and O
inhibited O
its O
kinase O
activity O
. O

Similar O
data O
were O
also O
obtained O
when O
either O
dominant O
negative O
EGFR I-GENE
- I-GENE
CD533 I-GENE
or I-GENE
dominant I-GENE
negative I-GENE
Ras I-GENE
N17 I-GENE
were I-GENE
used I-GENE
to I-GENE
block I-GENE
MAPK I-GENE
activation I-GENE
. I-GENE

The O
assay O
herein O
described O
allows O
the O
comparison O
of O
relative O
FGFR I-GENE
expression O
levels O
, O
both O
within O
a O
single O
RNA O
pool O
and O
among O
multiple O
RNA O
pool O
samples O
. O

This O
was O
most O
pronounced O
during O
the O
initial O
phase O
of O
Erk I-GENE
activation O
. O

DESIGN I-GENE
: I-GENE
Prospective I-GENE
cohort I-GENE
study I-GENE
with I-GENE
a I-GENE
20 I-GENE
y I-GENE
follow I-GENE
- I-GENE
up I-GENE
period I-GENE
, I-GENE
the I-GENE
First I-GENE
National I-GENE
Health I-GENE
and I-GENE
Examination I-GENE
Survey I-GENE
( I-GENE
NHANES I-GENE
1 I-GENE
) I-GENE
Epidemiologic I-GENE
Follow I-GENE
- I-GENE
up I-GENE
Study I-GENE
( I-GENE
NHEFS I-GENE
). I-GENE

To O
assess O
the O
maximum O
oxygen O
uptake O
( O
V O
' O
O2 O
max O
) O
of O
Hong O
Kong O
Chinese O
children O
and I-GENE
to I-GENE
explore I-GENE
its I-GENE
association I-GENE
with I-GENE
respiratory I-GENE
illnesses I-GENE
, I-GENE
we I-GENE
conducted I-GENE
the I-GENE
Multistage I-GENE
Fitness I-GENE
Test I-GENE
( I-GENE
MFT I-GENE
), I-GENE
a I-GENE
20 I-GENE
- I-GENE
m I-GENE
shuttle I-GENE
run I-GENE
test I-GENE
, I-GENE
in I-GENE
1 I-GENE
, I-GENE
427 I-GENE
schoolchildren I-GENE
aged I-GENE
between I-GENE
8 I-GENE
- I-GENE
12 I-GENE
years I-GENE
. I-GENE

After O
all O
doses O
of O
d O
- O
amphetamine O
, O
responding O
occurred O
largely O
on O
the O
saline O
key O
under O
both O
schedules O
. O

A O
novel O
myeloid O
- O
restricted O
zebrafish I-GENE
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
with O
a O
potent O
transcriptional O
activation O
domain O
. O

METHODS I-GENE
: I-GENE
Humphrey I-GENE
Field I-GENE
Analyzer I-GENE
model I-GENE
630 I-GENE
( I-GENE
HFA I-GENE
I I-GENE
, I-GENE
program I-GENE
30 I-GENE
- I-GENE
2 I-GENE
with I-GENE
a I-GENE
rectangular I-GENE
6 I-GENE
degrees I-GENE
x I-GENE
6 I-GENE
degrees I-GENE
grid I-GENE
) I-GENE
was I-GENE
used I-GENE
as I-GENE
the I-GENE
conventional I-GENE
perimetric I-GENE
method I-GENE
. I-GENE

These O
data O
reveal O
a O
complex O
network O
of O
interactions O
between O
GTPases I-GENE
in O
the O
ARF I-GENE
family I-GENE
and O
their O
effectors O
and O
reveal O
a O
potential O
for O
cross O
- O
talk O
not O
demonstrated O
previously O
. O

Net I-GENE
lift I-GENE
and I-GENE
combined I-GENE
drag I-GENE
from I-GENE
all I-GENE
8 I-GENE
bearings I-GENE
of I-GENE
the I-GENE
4 I-GENE
- I-GENE
bladed I-GENE
impeller I-GENE
are I-GENE
compared I-GENE
with I-GENE
predictions I-GENE
based I-GENE
on I-GENE
2 I-GENE
- I-GENE
D I-GENE
theory I-GENE
. I-GENE

In O
the O
course O
of O
screening O
for O
transcription O
factors O
which O
interact O
with O
the O
human I-GENE
myeloperoxidase I-GENE
( I-GENE
MPO I-GENE
) I-GENE
promoter I-GENE
we O
, O
for O
the O
first O
time O
, O
identified O
and O
cloned O
the O
cDNA O
and O
genomic O
DNA O
for I-GENE
human I-GENE
HBP1 I-GENE
( I-GENE
HMG I-GENE
- I-GENE
Box I-GENE
containing I-GENE
protein I-GENE
1 I-GENE
), I-GENE
a I-GENE
member I-GENE
of I-GENE
the I-GENE
high I-GENE
mobility I-GENE
group I-GENE
of I-GENE
non I-GENE
- I-GENE
histone I-GENE
chromosomal I-GENE
proteins I-GENE
. I-GENE

Therefore O
, O
vitamin I-GENE
D3 I-GENE
analogues I-GENE
have I-GENE
a I-GENE
substantial I-GENE
antipsoriatic I-GENE
effect I-GENE
. I-GENE

Methylation I-GENE
at I-GENE
both I-GENE
cytosine I-GENE
residues I-GENE
in I-GENE
the I-GENE
E2F I-GENE
element I-GENE
(( I-GENE
m I-GENE
) I-GENE
CG I-GENE
( I-GENE
m I-GENE
) I-GENE
CG I-GENE
) I-GENE
generated I-GENE
a I-GENE
new I-GENE
methylcytosine I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
- I-GENE
protein I-GENE
complex I-GENE
. I-GENE

Hepatitis I-GENE
A I-GENE
infected I-GENE
food I-GENE
handler I-GENE
at I-GENE
an I-GENE
Edmonton I-GENE
, I-GENE
Alberta I-GENE
retail I-GENE
food I-GENE
facility I-GENE
: I-GENE
public I-GENE
health I-GENE
protection I-GENE
strategies I-GENE
. I-GENE

The O
co I-GENE
- I-GENE
existence I-GENE
of I-GENE
TE I-GENE
domains I-GENE
within I-GENE
modular I-GENE
PKSs I-GENE
along I-GENE
with I-GENE
physically I-GENE
separated I-GENE
, I-GENE
monofunctional I-GENE
TEs I-GENE
( I-GENE
TE I-GENE
IIs I-GENE
) I-GENE
has I-GENE
been I-GENE
reported I-GENE
for I-GENE
a I-GENE
number I-GENE
of I-GENE
modular I-GENE
polyketide I-GENE
and I-GENE
non I-GENE
- I-GENE
ribosomal I-GENE
peptide I-GENE
synthases I-GENE
( I-GENE
NRPS I-GENE
). I-GENE

Two O
independent O
transgenic O
lines O
were O
produced O
, O
and O
both O
showed O
expression O
of I-GENE
the I-GENE
Gus I-GENE
gene I-GENE
specifically I-GENE
in I-GENE
the I-GENE
endosperm I-GENE
during I-GENE
mid I-GENE
- I-GENE
development I-GENE
( I-GENE
first I-GENE
detected I-GENE
10 I-GENE
- I-GENE
12 I-GENE
d I-GENE
after I-GENE
anthesis I-GENE
). I-GENE

Treadmill I-GENE
training I-GENE
at I-GENE
least I-GENE
for I-GENE
2 I-GENE
weeks I-GENE
can I-GENE
reduce I-GENE
the I-GENE
infarction I-GENE
size I-GENE
and I-GENE
edema I-GENE
caused I-GENE
by I-GENE
MCA I-GENE
occlusion I-GENE
( I-GENE
P I-GENE
< I-GENE
0 I-GENE
. I-GENE
01 I-GENE
). I-GENE

Mechanism O
in O
the O
sequential O
control O
of O
cell O
morphology O
and O
S O
phase O
entry O
by O
epidermal I-GENE
growth I-GENE
factor I-GENE
involves O
distinct O
MEK I-GENE
/ I-GENE
ERK I-GENE
activations I-GENE
. I-GENE

We O
randomly O
assigned O
1 I-GENE
, I-GENE
219 I-GENE
subjects I-GENE
to I-GENE
receive I-GENE
either I-GENE
the I-GENE
standard I-GENE
three I-GENE
- I-GENE
times I-GENE
- I-GENE
weekly I-GENE
( I-GENE
TIW I-GENE
) I-GENE
interferon I-GENE
alfa I-GENE
- I-GENE
2b I-GENE
dose I-GENE
( I-GENE
3 I-GENE
MIU I-GENE
) I-GENE
or I-GENE
the I-GENE
once I-GENE
- I-GENE
weekly I-GENE
( I-GENE
QW I-GENE
) I-GENE
peginterferon I-GENE
alfa I-GENE
- I-GENE
2b I-GENE
( I-GENE
0 I-GENE
. I-GENE
5 I-GENE
, I-GENE
1 I-GENE
. I-GENE
0 I-GENE
, I-GENE
or I-GENE
1 I-GENE
. I-GENE
5 I-GENE
microg I-GENE
/ I-GENE
kg I-GENE
). I-GENE

These O
data O
suggest O
that O
proper O
direct O
binding O
of O
Nhp2p I-GENE
to O
H I-GENE
/ I-GENE
ACA I-GENE
snoRNAs I-GENE
is O
required O
for O
the O
assembly O
of O
H O
/ O
ACA O
snoRNPs O
and O
hence O
for O
the O
stability O
of O
some O
of O
their O
components O
. O

The I-GENE
decrements I-GENE
in I-GENE
cerebrovascular I-GENE
resistance I-GENE
induced I-GENE
by I-GENE
hexamethonium I-GENE
, I-GENE
in I-GENE
mm I-GENE
Hg I-GENE
ml I-GENE
(- I-GENE
1 I-GENE
). I-GENE
min I-GENE
(- I-GENE
1 I-GENE
), I-GENE
were I-GENE
: I-GENE
under I-GENE
control I-GENE
. I-GENE

Here O
we O
provide O
the O
first O
evidence O
for O
the O
involvement O
of O
GCN1 I-GENE
- I-GENE
GCN2 I-GENE
interaction O
in O
activation O
of O
GCN2 I-GENE
per O
se O
. O

As O
a O
reflection O
of O
uncertainties O
in O
the O
estimates O
for O
individual O
sources O
, I-GENE
the I-GENE
90th I-GENE
percentiles I-GENE
of I-GENE
PCDD I-GENE
/ I-GENE
F I-GENE
releases I-GENE
for I-GENE
1999 I-GENE
ranged I-GENE
up I-GENE
to I-GENE
4 I-GENE
. I-GENE
1 I-GENE
g I-GENE
I I-GENE
- I-GENE
TEQ I-GENE
/ I-GENE
y I-GENE
. I-GENE

To O
test O
the O
hypothesis O
that O
these O
elements O
are O
required O
for O
promoter O
activity O
, O
we O
compared O
the O
reporter O
expression O
activity O
of O
segments O
containing O
mutations O
of O
these O
elements O
with O
activity O
of I-GENE
the I-GENE
parent I-GENE
Hlx I-GENE
promoter I-GENE
sequence I-GENE
. I-GENE

Using O
RACE O
techniques O
we O
have O
cloned O
and O
sequenced O
one O
of O
the O
hamster O
liver O
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
hexobarbital I-GENE
dehydrogenases I-GENE
which I-GENE
catalyze I-GENE
not I-GENE
only I-GENE
cyclic I-GENE
alcohols I-GENE
but I-GENE
also I-GENE
17beta I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
steroids I-GENE
and I-GENE
3alpha I-GENE
- I-GENE
hydroxysteroids I-GENE
. I-GENE

Concerted O
transcriptional O
activation O
of O
the O
low O
density I-GENE
lipoprotein I-GENE
receptor I-GENE
gene I-GENE
by O
insulin I-GENE
and O
luteinizing I-GENE
hormone I-GENE
in O
cultured O
porcine O
granulosa O
- O
luteal O
cells O
: O
possible O
convergence O
of O
protein I-GENE
kinase I-GENE
a O
, O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
, O
and O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
signaling O
pathways O
. O

Human I-GENE
T I-GENE
- I-GENE
cell I-GENE
leukemia I-GENE
virus I-GENE
type I-GENE
I I-GENE
( I-GENE
HTLV I-GENE
- I-GENE
I I-GENE
) I-GENE
Tax I-GENE
is O
a O
potent O
transcriptional O
regulator O
that O
can O
activate O
or O
repress O
specific O
cellular O
genes O
and O
that O
has O
been O
proposed O
to O
contribute O
to O
leukemogenesis O
in O
adult O
T O
- O
cell O
leukemia O
. O

Also O
, O
small O
, O
sense O
and O
antisense O
approximately O
22 O
nt O
RNAs O
, O
derived O
from I-GENE
the I-GENE
satRNA I-GENE
, I-GENE
were I-GENE
associated I-GENE
with I-GENE
the I-GENE
replicating I-GENE
satellite I-GENE
. I-GENE

Deletional I-GENE
analyses I-GENE
of I-GENE
VDR I-GENE
indicated I-GENE
that I-GENE
GRIP1 I-GENE
and I-GENE
RAC3 I-GENE
required I-GENE
an I-GENE
intact I-GENE
VDR I-GENE
activation I-GENE
function I-GENE
( I-GENE
AF I-GENE
- I-GENE
2 I-GENE
) I-GENE
domain I-GENE
for I-GENE
efficient I-GENE
interaction I-GENE
as I-GENE
well I-GENE
as I-GENE
additional I-GENE
but I-GENE
distinct I-GENE
regions I-GENE
of I-GENE
the I-GENE
VDR I-GENE
. I-GENE

RESULTS O
: O
During O
the O
stabilization O
period O
, O
PaCO2 O
( O
mean O
+/- O
SD O
) O
was O
33 O
+/- O
5 O
mm O
Hg O
, O
and O
arrhythmias O
were O
not O
detected O
. O

TT O
cells O
, O
a I-GENE
human I-GENE
MTC I-GENE
cell I-GENE
line I-GENE
expressing I-GENE
MEN I-GENE
2A I-GENE
type I-GENE
RET I-GENE
, I-GENE
display I-GENE
transcriptionally I-GENE
active I-GENE
RelA I-GENE
( I-GENE
p65 I-GENE
) I-GENE
in I-GENE
the I-GENE
nucleus I-GENE
. I-GENE

The O
human O
protein O
sequence O
exhibits O
a O
putative O
DNA O
- O
binding O
domain O
similar O
to O
that O
seen O
in I-GENE
rat I-GENE
HBP1 I-GENE
and I-GENE
shows I-GENE
homology I-GENE
with I-GENE
the I-GENE
activation I-GENE
and I-GENE
repressor I-GENE
domains I-GENE
previously I-GENE
demonstrated I-GENE
in I-GENE
the I-GENE
rat I-GENE
protein I-GENE
. I-GENE

In O
contrast O
the O
human I-GENE
and I-GENE
mouse I-GENE
BCNT I-GENE
proteins I-GENE
contain I-GENE
one I-GENE
repeat I-GENE
unit I-GENE
and I-GENE
lack I-GENE
the I-GENE
RTE I-GENE
- I-GENE
1 I-GENE
- I-GENE
derived I-GENE
portion I-GENE
. I-GENE

Direct I-GENE
superoxide I-GENE
scavenging O
activity O
of O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
: O
determination O
by O
electron O
spin O
resonance O
using O
the O
spin O
trap O
method O
. O

A I-GENE
single I-GENE
nucleotide I-GENE
polymorphism I-GENE
( I-GENE
SNP I-GENE
) I-GENE
in I-GENE
exon I-GENE
2 I-GENE
, I-GENE
which I-GENE
is I-GENE
tightly I-GENE
liked I-GENE
to I-GENE
another I-GENE
SNP I-GENE
( I-GENE
GTG83 I-GENE
/ I-GENE
ATG83 I-GENE
), I-GENE
creates I-GENE
an I-GENE
additional I-GENE
alternative I-GENE
in I-GENE
- I-GENE
frame I-GENE
AUG I-GENE
in I-GENE
B I-GENE
- I-GENE
type I-GENE
MTH1 I-GENE
mRNAs I-GENE
yielding I-GENE
the I-GENE
fourth I-GENE
MTH1 I-GENE
polypeptide I-GENE
, I-GENE
p26 I-GENE
that I-GENE
possesses I-GENE
an I-GENE
additional I-GENE
mitochondrial I-GENE
targeting I-GENE
signal I-GENE
. I-GENE

Six O
of I-GENE
the I-GENE
gstC I-GENE
' I-GENE
mutants I-GENE
, I-GENE
primarily I-GENE
in I-GENE
the I-GENE
C I-GENE
- I-GENE
terminal I-GENE
half I-GENE
of I-GENE
C I-GENE
', I-GENE
exhibited I-GENE
a I-GENE
defect I-GENE
in I-GENE
the I-GENE
ability I-GENE
to I-GENE
bind I-GENE
L I-GENE
protein I-GENE
. I-GENE

We O
developed O
a O
system O
for I-GENE
domain I-GENE
shuffling I-GENE
to I-GENE
establish I-GENE
the I-GENE
function I-GENE
of I-GENE
C1 I-GENE
domains I-GENE
from I-GENE
human I-GENE
Raf I-GENE
kinase I-GENE
and I-GENE
rat I-GENE
PKC I-GENE
eta I-GENE
in I-GENE
yeast I-GENE
. I-GENE

Expression O
of O
herpes I-GENE
simplex I-GENE
virus I-GENE
type I-GENE
2 I-GENE
US3 I-GENE
affects I-GENE
the I-GENE
Cdc42 I-GENE
/ I-GENE
Rac I-GENE
pathway I-GENE
and I-GENE
attenuates I-GENE
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
activation I-GENE
. I-GENE

Inhibition O
of O
constitutive O
NF I-GENE
- I-GENE
kappaB I-GENE
activity O
results O
in O
cell O
death O
of O
TT O
cells O
and O
blocks O
focus O
formation O
induced O
by O
oncogenic O
forms O
of O
RET I-GENE
in O
NIH O
3T3 O
cells O
. O

Corneal I-GENE
scrapping I-GENE
and I-GENE
deep I-GENE
stromal I-GENE
biopsy I-GENE
were I-GENE
obtained I-GENE
and I-GENE
stained I-GENE
for I-GENE
microscopic I-GENE
evaluation I-GENE
with I-GENE
periodic I-GENE
acid I-GENE
- I-GENE
Schiff I-GENE
, I-GENE
Giemsa I-GENE
, I-GENE
and I-GENE
Gomori I-GENE
' I-GENE
s I-GENE
methenamine I-GENE
silver I-GENE
stains I-GENE
. I-GENE

ICAM I-GENE
- I-GENE
1 I-GENE
has O
been O
suggested O
a O
predictor O
of O
the O
onset O
of O
GO O
. O

Once I-GENE
ICP I-GENE
reaches I-GENE
critical I-GENE
values I-GENE
(> I-GENE
30 I-GENE
mm I-GENE
Hg I-GENE
) I-GENE
herniation I-GENE
occurs I-GENE
, I-GENE
usually I-GENE
within I-GENE
2 I-GENE
to I-GENE
5 I-GENE
days I-GENE
. I-GENE

The O
present O
data O
also O
demonstrate O
that O
ectopic O
expression I-GENE
of I-GENE
blr1 I-GENE
increased I-GENE
JNK I-GENE
/ I-GENE
SAPK I-GENE
activity I-GENE
, I-GENE
but I-GENE
JNK I-GENE
/ I-GENE
SAPK I-GENE
activation I-GENE
was I-GENE
not I-GENE
needed I-GENE
for I-GENE
accelerated I-GENE
RA I-GENE
- I-GENE
induced I-GENE
differentiation I-GENE
and I-GENE
growth I-GENE
arrest I-GENE
. I-GENE

Here I-GENE
, I-GENE
we I-GENE
identify I-GENE
Rsc3 I-GENE
and I-GENE
Rsc30 I-GENE
as I-GENE
novel I-GENE
components I-GENE
of I-GENE
the I-GENE
essential I-GENE
yeast I-GENE
remodeler I-GENE
RSC I-GENE
complex I-GENE
. I-GENE

The I-GENE
pharmacokinetic I-GENE
profiles I-GENE
of I-GENE
digoxin I-GENE
and I-GENE
warfarin I-GENE
were I-GENE
not I-GENE
altered I-GENE
by I-GENE
the I-GENE
simultaneous I-GENE
and I-GENE
continued I-GENE
administration I-GENE
of I-GENE
sevelamer I-GENE
. I-GENE

Forskolin O
treatment O
( O
10 O
microM O
) O
of O
the O
transfected O
cells O
for O
3 O
-- O
6 O
h O
maximally O
induced O
luciferase I-GENE
threefold O
. O

E2F1 I-GENE
- I-GENE
mediated O
transcriptional O
inhibition O
of O
the O
plasminogen I-GENE
activator I-GENE
inhibitor I-GENE
type I-GENE
1 I-GENE
gene I-GENE
. O

In O
this O
report O
this O
technique O
was O
applied O
to I-GENE
human I-GENE
breast I-GENE
carcinoma I-GENE
MDA I-GENE
- I-GENE
MB231 I-GENE
cells I-GENE
overexpressing I-GENE
human I-GENE
MPG I-GENE
in I-GENE
order I-GENE
to I-GENE
assess I-GENE
whether I-GENE
up I-GENE
- I-GENE
regulation I-GENE
of I-GENE
the I-GENE
initial I-GENE
step I-GENE
in I-GENE
BER I-GENE
alters I-GENE
the I-GENE
activity I-GENE
of I-GENE
selected I-GENE
other I-GENE
BER I-GENE
( I-GENE
hOGG1 I-GENE
and I-GENE
APE I-GENE
/ I-GENE
ref I-GENE
- I-GENE
1 I-GENE
) I-GENE
or I-GENE
direct I-GENE
reversal I-GENE
( I-GENE
MGMT I-GENE
) I-GENE
repair I-GENE
activities I-GENE
. I-GENE

Chlamydia O
and O
cervical O
cancer O
: O
a O
real O
association O
? O

In I-GENE
children I-GENE
unable I-GENE
to I-GENE
perform I-GENE
forced I-GENE
expiratory I-GENE
maneuvers I-GENE
( I-GENE
n I-GENE
= I-GENE
25 I-GENE
), I-GENE
FOT I-GENE
, I-GENE
contrary I-GENE
to I-GENE
the I-GENE
interrupter I-GENE
technique I-GENE
, I-GENE
clearly I-GENE
identified I-GENE
a I-GENE
subgroup I-GENE
of I-GENE
young I-GENE
children I-GENE
with I-GENE
high I-GENE
resistance I-GENE
values I-GENE
at I-GENE
baseline I-GENE
, I-GENE
which I-GENE
returned I-GENE
to I-GENE
normal I-GENE
after I-GENE
bronchodilation I-GENE
. I-GENE

Together O
, O
these O
results O
identify O
HPK1 I-GENE
as O
a O
new O
component O
of O
TCR I-GENE
signaling O
. O

Pro O
- O
inflammatory O
cytokine O
, O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( I-GENE
TNF I-GENE
- I-GENE
alpha I-GENE
), O
produced O
from O
adipose O
tissues O
in O
obese O
subjects O
, O
is O
known O
to O
play O
a O
predominant O
role O
in O
inducing O
insulin I-GENE
resistance I-GENE
. O

The O
Schistosoma O
mansoni O
homologue I-GENE
( I-GENE
SmSmad2 I-GENE
) I-GENE
was I-GENE
overexpressed I-GENE
in I-GENE
bacteria I-GENE
as I-GENE
a I-GENE
Sj26 I-GENE
- I-GENE
GST I-GENE
fusion I-GENE
protein I-GENE
and I-GENE
used I-GENE
to I-GENE
raise I-GENE
specific I-GENE
antibodies I-GENE
. I-GENE

To O
study O
the O
in O
vivo O
role O
of O
p16 I-GENE
. O
7 I-GENE
, I-GENE
a I-GENE
phi29 I-GENE
mutant I-GENE
containing I-GENE
a I-GENE
suppressible I-GENE
mutation I-GENE
in I-GENE
gene I-GENE
16 I-GENE
. I-GENE
7 I-GENE
was I-GENE
constructed I-GENE
. I-GENE

The O
differences O
in I-GENE
the I-GENE
CPIgG I-GENE
, I-GENE
CRP I-GENE
, I-GENE
and I-GENE
fibrinogen I-GENE
levels I-GENE
in I-GENE
patients I-GENE
who I-GENE
were I-GENE
diagnosed I-GENE
with I-GENE
ACS I-GENE
versus I-GENE
those I-GENE
who I-GENE
were I-GENE
not I-GENE
( I-GENE
non I-GENE
- I-GENE
ACS I-GENE
) I-GENE
were I-GENE
evaluated I-GENE
. I-GENE

There I-GENE
are I-GENE
many I-GENE
different I-GENE
proposals I-GENE
for I-GENE
the I-GENE
statistical I-GENE
analysis I-GENE
of I-GENE
data I-GENE
to I-GENE
determine I-GENE
early I-GENE
onset I-GENE
of I-GENE
action I-GENE
. I-GENE

Coexpression O
of O
the O
p120 I-GENE
( I-GENE
ctn I-GENE
) I-GENE
protein I-GENE
with I-GENE
an I-GENE
N I-GENE
- I-GENE
terminal I-GENE
deletion I-GENE
, I-GENE
which I-GENE
eliminates I-GENE
some I-GENE
potential I-GENE
tyrosine I-GENE
phosphorylation I-GENE
sites I-GENE
, I-GENE
or I-GENE
the I-GENE
protein I-GENE
with I-GENE
a I-GENE
single I-GENE
amino I-GENE
acid I-GENE
substitution I-GENE
( I-GENE
tyrosine I-GENE
at I-GENE
217 I-GENE
to I-GENE
phenylalanine I-GENE
) I-GENE
resulted I-GENE
in I-GENE
an I-GENE
increase I-GENE
in I-GENE
the I-GENE
aggregation I-GENE
of I-GENE
v I-GENE
- I-GENE
Src I-GENE
- I-GENE
transformed I-GENE
EL I-GENE
and I-GENE
EalphaCL I-GENE
cells I-GENE
. I-GENE

We I-GENE
find I-GENE
that I-GENE
our I-GENE
response I-GENE
function I-GENE
is I-GENE
well I-GENE
approximated I-GENE
by I-GENE
the I-GENE
GSER I-GENE
only I-GENE
within I-GENE
a I-GENE
particular I-GENE
frequency I-GENE
range I-GENE
determined I-GENE
by I-GENE
the I-GENE
material I-GENE
parameters I-GENE
of I-GENE
both I-GENE
the I-GENE
bead I-GENE
and I-GENE
the I-GENE
network I-GENE
. I-GENE

The O
novel O
approach O
to I-GENE
insulin I-GENE
administration I-GENE
known I-GENE
as I-GENE
chronic I-GENE
intermittent I-GENE
intravenous I-GENE
insulin I-GENE
therapy I-GENE
( I-GENE
CIIIT I-GENE
) I-GENE
delivers I-GENE
insulin I-GENE
in I-GENE
a I-GENE
pulsatile I-GENE
fashion I-GENE
and I-GENE
achieves I-GENE
physiological I-GENE
insulin I-GENE
concentration I-GENE
in I-GENE
the I-GENE
portal I-GENE
vein I-GENE
. I-GENE

This I-GENE
article I-GENE
comparatively I-GENE
evaluates I-GENE
five I-GENE
Generic I-GENE
Systems I-GENE
that I-GENE
describe I-GENE
the I-GENE
basic I-GENE
alternatives I-GENE
to I-GENE
composting I-GENE
facility I-GENE
design I-GENE
and I-GENE
control I-GENE
. I-GENE

With O
a O
GC O
content O
of O
45 O
% O
the O
one O
segment O
would O
correspond O
to O
" O
isochore O
H1 O
" O
and O
the O
other O
segment O
( O
39 O
% O
GC O
in O
human O
, O
40 O
% O
GC O
in O
mouse O
) O
to O
" O
isochore O
L1 O
/ O
L2 O
". O

A O
review O
of I-GENE
the I-GENE
literature I-GENE
identified I-GENE
8 I-GENE
comprehensive I-GENE
clinical I-GENE
studies I-GENE
, I-GENE
all I-GENE
of I-GENE
which I-GENE
failed I-GENE
to I-GENE
document I-GENE
any I-GENE
relationship I-GENE
between I-GENE
NF1 I-GENE
and I-GENE
intracranial I-GENE
aneurysms I-GENE
. I-GENE

Serial O
US O
images O
were O
obtained O
before O
and O
20 O
, O
30 O
, O
40 O
, O
50 O
, O
60 O
, O
90 O
, O
120 O
, O
150 O
, O
180 O
, O
240 O
, O
and O
300 O
s O
after O
intravenous O
injection O
of O
2 O
g O
of O
contrast O
agent O
using O
conventional O
and O
harmonic O
PD O
US O
. O

Eight O
CAD O
patients O
who O
were O
matched O
to O
the O
treated O
patients O
for O
age O
(+/- O
3 O
years O
), O
baseline O
low O
density O
lipoprotein O
(+/- O
5 O
mg O
/ O
dL O
), O
and O
triglycerides O
(+/- O
50 O
mg O
/ O
dL O
) O
but O
who O
had O
never O
been O
treated O
with O
lipid O
- O
lowering O
drugs O
were O
selected O
as O
controls O
. O

Here O
we O
present O
evidence O
that O
the O
distal O
half I-GENE
( I-GENE
Stem I-GENE
2 I-GENE
) I-GENE
of I-GENE
the I-GENE
conserved I-GENE
base I-GENE
- I-GENE
paired I-GENE
stem I-GENE
structure I-GENE
found I-GENE
in I-GENE
all I-GENE
hY I-GENE
RNAs I-GENE
also I-GENE
plays I-GENE
a I-GENE
critical I-GENE
role I-GENE
in I-GENE
the I-GENE
export I-GENE
process I-GENE
. I-GENE

The O
contrasting O
effects O
of O
dopaminergic O
stimulation O
on O
the O
motor O
performance O
and O
on O
some O
aspects O
of O
cognitive O
processing O
suggest O
the O
existence O
of O
complex O
interactions O
within O
pre O
- O
and O
postsynaptic O
brain O
dopamine O
receptors O
, O
and O
an O
intervention O
of O
segregated O
basal O
ganglia O
- O
prefrontal O
cortex O
loops O
in O
motor O
and O
cognitive O
behaviour O
. O

The O
size O
of O
the O
infarct O
was O
determined O
using O
the O
creatine I-GENE
kinase I-GENE
integral O
method O
. O

These O
corrections O
do O
not O
involve O
sequences O
predicted O
to O
function O
as O
transcription I-GENE
factor I-GENE
binding I-GENE
sites I-GENE
. O

A O
comprehensive O
neuropsychological O
battery O
was O
administered O
to I-GENE
48 I-GENE
veterans I-GENE
with I-GENE
Gulf I-GENE
War I-GENE
Illness I-GENE
( I-GENE
GWI I-GENE
) I-GENE
characterized I-GENE
by I-GENE
severe I-GENE
fatigue I-GENE
( I-GENE
GV I-GENE
- I-GENE
F I-GENE
) I-GENE
and I-GENE
39 I-GENE
healthy I-GENE
veterans I-GENE
( I-GENE
GV I-GENE
- I-GENE
H I-GENE
). I-GENE

Quantitative O
PCR O
studies O
indicated O
that O
synthesis O
and O
transport O
of O
vector O
DNA O
into O
the O
nucleus O
were O
similar O
for O
macrophages O
infected O
with O
the I-GENE
clone I-GENE
239 I-GENE
and I-GENE
316 I-GENE
pseudotypes I-GENE
, I-GENE
suggesting I-GENE
that I-GENE
the I-GENE
restriction I-GENE
for I-GENE
SIVmac239 I-GENE
infection I-GENE
is I-GENE
after I-GENE
reverse I-GENE
transcription I-GENE
and I-GENE
nuclear I-GENE
import I-GENE
of I-GENE
viral I-GENE
DNA I-GENE
. I-GENE

EXAFS I-GENE
measurements I-GENE
around I-GENE
the I-GENE
Ge I-GENE
- I-GENE
K I-GENE
edge I-GENE
have I-GENE
been I-GENE
carried I-GENE
out I-GENE
for I-GENE
liquid I-GENE
Ge I-GENE
- I-GENE
Si I-GENE
alloys I-GENE
for I-GENE
the I-GENE
first I-GENE
time I-GENE
to I-GENE
investigate I-GENE
the I-GENE
local I-GENE
structure I-GENE
around I-GENE
a I-GENE
Ge I-GENE
atom I-GENE
. I-GENE

Hp I-GENE
positive I-GENE
relatives I-GENE
of I-GENE
gastric I-GENE
cancer I-GENE
had I-GENE
a I-GENE
markedly I-GENE
higher I-GENE
prevalence I-GENE
of I-GENE
atrophy I-GENE
than I-GENE
those I-GENE
with I-GENE
Hp I-GENE
negativity I-GENE
without I-GENE
cancer I-GENE
relatives I-GENE
( I-GENE
29 I-GENE
vs I-GENE
. I-GENE

Thus O
, O
replication I-GENE
fork I-GENE
movement I-GENE
near I-GENE
HML I-GENE
pauses I-GENE
at I-GENE
a I-GENE
silent I-GENE
origin I-GENE
which I-GENE
is I-GENE
competent I-GENE
for I-GENE
replication I-GENE
initiation I-GENE
but I-GENE
kept I-GENE
silent I-GENE
through I-GENE
Orc2p I-GENE
, I-GENE
a I-GENE
component I-GENE
of I-GENE
the I-GENE
replication I-GENE
initiator I-GENE
. I-GENE

Cardiac O
markers O
troponin I-GENE
T I-GENE
, O
CK I-GENE
- I-GENE
MB I-GENE
mass O
and O
myoglobin I-GENE
were O
helpful O
in I-GENE
the I-GENE
differential I-GENE
diagnosis I-GENE
of I-GENE
chest I-GENE
pain I-GENE
, I-GENE
even I-GENE
when I-GENE
the I-GENE
ECG I-GENE
was I-GENE
unremarkable I-GENE
or I-GENE
nonspecific I-GENE
. I-GENE

RESULTS O
: O
A O
novel O
gene O
was O
cloned O
. O

Both O
pancreatic O
and O
intestinal O
cell O
lines O
were O
found O
to O
express O
a O
number O
of O
POU I-GENE
( I-GENE
OCT I-GENE
binding I-GENE
) I-GENE
homeodomain I-GENE
proteins I-GENE
examined O
by O
electrophoretic O
mobility O
shift O
assay O
. O

In I-GENE
conclusion I-GENE
, I-GENE
USPIO I-GENE
- I-GENE
enhanced I-GENE
MRI I-GENE
data I-GENE
were I-GENE
capable I-GENE
to I-GENE
characterize I-GENE
tumor I-GENE
microvessel I-GENE
properties I-GENE
in I-GENE
this I-GENE
breast I-GENE
cancer I-GENE
model I-GENE
: I-GENE
microvascular I-GENE
permeability I-GENE
( I-GENE
determined I-GENE
using I-GENE
USPIO I-GENE
) I-GENE
correlated I-GENE
significantly I-GENE
with I-GENE
tumor I-GENE
grade I-GENE
. I-GENE

Radiolabeled I-GENE
biantennary I-GENE
N I-GENE
- I-GENE
glycans I-GENE
synthesized I-GENE
by I-GENE
Pro I-GENE
(-) I-GENE
5Lec20 I-GENE
were I-GENE
proportionately I-GENE
less I-GENE
ricin I-GENE
- I-GENE
bound I-GENE
than I-GENE
similar I-GENE
species I-GENE
from I-GENE
parental I-GENE
CHO I-GENE
cells I-GENE
, I-GENE
and I-GENE
Lec20 I-GENE
cell I-GENE
extracts I-GENE
had I-GENE
a I-GENE
markedly I-GENE
reduced I-GENE
ability I-GENE
to I-GENE
transfer I-GENE
Gal I-GENE
to I-GENE
GlcNAc I-GENE
- I-GENE
terminating I-GENE
acceptors I-GENE
. I-GENE

CONCLUSION I-GENE
: I-GENE
The I-GENE
training I-GENE
of I-GENE
novices I-GENE
using I-GENE
MIST I-GENE
- I-GENE
VR I-GENE
yields I-GENE
quantifiable I-GENE
changes I-GENE
in I-GENE
skill I-GENE
that I-GENE
are I-GENE
transferable I-GENE
to I-GENE
a I-GENE
simple I-GENE
real I-GENE
task I-GENE
and I-GENE
are I-GENE
similar I-GENE
to I-GENE
the I-GENE
results I-GENE
achieved I-GENE
with I-GENE
conventional I-GENE
training I-GENE
. I-GENE

To O
investigate O
the O
convergent O
role O
of O
the O
insulin I-GENE
/ I-GENE
IGF I-GENE
- I-GENE
I I-GENE
effector I-GENE
pathway I-GENE
mediating I-GENE
bihormonal I-GENE
stimulation I-GENE
of I-GENE
LDL I-GENE
receptor I-GENE
promoter I-GENE
expression I-GENE
, I-GENE
transfected I-GENE
granulosa I-GENE
- I-GENE
luteal I-GENE
cells I-GENE
were I-GENE
pretreated I-GENE
for I-GENE
30 I-GENE
min I-GENE
with I-GENE
two I-GENE
specific I-GENE
inhibitors I-GENE
of I-GENE
phophatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
, I-GENE
wortmannin I-GENE
( I-GENE
100 I-GENE
nM I-GENE
) I-GENE
and I-GENE
LY I-GENE
294002 I-GENE
( I-GENE
10 I-GENE
microM I-GENE
), I-GENE
or I-GENE
of I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
kinase I-GENE
, I-GENE
PD I-GENE
98059 I-GENE
( I-GENE
50 I-GENE
microM I-GENE
), I-GENE
U0126 I-GENE
( I-GENE
10 I-GENE
microM I-GENE
), I-GENE
or I-GENE
the I-GENE
latter I-GENE
' I-GENE
s I-GENE
inactive I-GENE
derivative I-GENE
, I-GENE
U0124 I-GENE
( I-GENE
10 I-GENE
microM I-GENE
). I-GENE

Instead O
, O
affective O
flattening O
was O
associated O
with O
both O
dopamine O
receptor O
sensitivity O
and O
psychomotor O
slowing O
. O

Other I-GENE
therapies I-GENE
are I-GENE
also I-GENE
available I-GENE
, I-GENE
including I-GENE
hypertonic I-GENE
saline I-GENE
solution I-GENE
, I-GENE
THAM I-GENE
( I-GENE
Tris I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
methyl I-GENE
- I-GENE
aminomethane I-GENE
) I-GENE
buffer I-GENE
, I-GENE
and I-GENE
high I-GENE
- I-GENE
dose I-GENE
barbiturates I-GENE
. I-GENE

CONCLUSION O
: O
There O
are O
no O
differences O
in O
the O
measurement O
data O
derived O
from O
this O
method O
and O
actual O
measurement O
data O
from O
an O
object O
created O
by O
the O
computer O
- O
aided O
dental O
design O
program O
. O

NF I-GENE
- I-GENE
kappaB I-GENE
pathway O
activation O
occurs O
during O
transformation O
induced O
by O
a O
number O
of O
classical O
oncogenes O
, O
including O
Bcr I-GENE
/ I-GENE
Abl I-GENE
, O
Ras I-GENE
and O
Rac I-GENE
, O
and O
is O
necessary O
for O
full O
transforming O
potential O
. O

Our I-GENE
results I-GENE
indicate I-GENE
that I-GENE
Gab1 I-GENE
is I-GENE
involved I-GENE
in I-GENE
the I-GENE
control I-GENE
of I-GENE
egr I-GENE
- I-GENE
1 I-GENE
expression I-GENE
regulated I-GENE
by I-GENE
insulin I-GENE
. I-GENE

The O
human O
cytomegalovirus O
( O
HCMV O
) O
major O
immediate I-GENE
- I-GENE
early I-GENE
protein I-GENE
IE2 I-GENE
is O
a O
nuclear O
phosphoprotein O
that O
is O
believed O
to O
be O
a O
key O
regulator O
in O
both O
lytic O
and O
latent O
infections O
. O

Unexpectedly I-GENE
, I-GENE
Arg1 I-GENE
- I-GENE
expressing I-GENE
COS1 I-GENE
cells I-GENE
showed I-GENE
no I-GENE
significant I-GENE
proteinase I-GENE
activity I-GENE
to I-GENE
various I-GENE
synthesized I-GENE
substrates I-GENE
under I-GENE
neutral I-GENE
or I-GENE
acidic I-GENE
conditions I-GENE
in I-GENE
this I-GENE
study I-GENE
. I-GENE

METHODS O
: O
126 O
patients O
with O
histologically O
confirmed O
MFH O
were O
analyzed O
. O

Regression I-GENE
analyses I-GENE
showed I-GENE
that I-GENE
SOREMP I-GENE
dream I-GENE
occurrences I-GENE
were I-GENE
significantly I-GENE
related I-GENE
to I-GENE
the I-GENE
amount I-GENE
of I-GENE
REM I-GENE
sleep I-GENE
, I-GENE
while I-GENE
NREMP I-GENE
dream I-GENE
occurrences I-GENE
were I-GENE
related I-GENE
to I-GENE
arousals I-GENE
from I-GENE
NREM I-GENE
sleep I-GENE
. I-GENE

[ I-GENE
Diabetologia I-GENE
( I-GENE
2001 I-GENE
) I-GENE
44 I-GENE
[ I-GENE
Suppl I-GENE
3 I-GENE
]: I-GENE
B37 I-GENE
- I-GENE
B44 I-GENE
] I-GENE

RESULTS O
: O
In O
vivo O
, O
there O
was O
a O
wide O
distribution O
with O
the O
coefficient O
of O
variation O
( O
SD O
/ O
mean O
x O
100 O
%) O
for O
different O
valve O
sizes O
ranging O
from O
21 O
% O
to O
39 O
% O
in I-GENE
the I-GENE
St I-GENE
Jude I-GENE
Medical I-GENE
valve I-GENE
and I-GENE
from I-GENE
25 I-GENE
% I-GENE
to I-GENE
33 I-GENE
% I-GENE
in I-GENE
the I-GENE
Omnicarbon I-GENE
valve I-GENE
. I-GENE

A I-GENE
microsporidian I-GENE
, I-GENE
Nosema I-GENE
algerae I-GENE
Vavra I-GENE
and I-GENE
undeen I-GENE
, I-GENE
was I-GENE
found I-GENE
parasitizing I-GENE
larvae I-GENE
and I-GENE
adults I-GENE
of I-GENE
a I-GENE
laboratory I-GENE
colony I-GENE
of I-GENE
Culex I-GENE
pipiens I-GENE
L I-GENE
. I-GENE
originated I-GENE
from I-GENE
Gharbia I-GENE
Governorate I-GENE
. I-GENE

Nearly I-GENE
all I-GENE
isolates I-GENE
of I-GENE
S I-GENE
. I-GENE
intermedius I-GENE
and I-GENE
most I-GENE
isolates I-GENE
of I-GENE
S I-GENE
. I-GENE
constellatus I-GENE
, I-GENE
but I-GENE
only I-GENE
19 I-GENE
% I-GENE
of I-GENE
those I-GENE
of I-GENE
S I-GENE
. I-GENE
anginosus I-GENE
, I-GENE
were I-GENE
associated I-GENE
with I-GENE
abscess I-GENE
. I-GENE

One O
of O
the O
conserved O
RNA O
subdomains O
, O
designated O
P3 O
, O
has O
previously O
been O
shown O
to O
be O
required O
for O
nucleolar O
localization O
. O

A O
total O
of O
25 O
patients O
with O
malignant O
brain O
tumours O
were O
investigated O
. O

Interventions I-GENE
aimed I-GENE
at I-GENE
these I-GENE
specific I-GENE
mediators I-GENE
and I-GENE
processes I-GENE
may I-GENE
be I-GENE
successful I-GENE
in I-GENE
reducing I-GENE
the I-GENE
very I-GENE
significant I-GENE
human I-GENE
and I-GENE
economic I-GENE
costs I-GENE
of I-GENE
vascular I-GENE
access I-GENE
dysfunction I-GENE
. I-GENE

We O
used O
stored O
plasma O
samples O
from O
409 O
patients O
in I-GENE
the I-GENE
National I-GENE
Institute I-GENE
of I-GENE
Neurological I-GENE
Diseases I-GENE
and I-GENE
Stroke I-GENE
( I-GENE
NINDS I-GENE
) I-GENE
tissue I-GENE
plasminogen I-GENE
activator I-GENE
( I-GENE
t I-GENE
- I-GENE
PA I-GENE
) I-GENE
Stroke I-GENE
Trial I-GENE
to I-GENE
examine I-GENE
the I-GENE
relationship I-GENE
between I-GENE
an I-GENE
apolipoprotein I-GENE
( I-GENE
Apo I-GENE
) I-GENE
E2 I-GENE
or I-GENE
an I-GENE
Apo I-GENE
E4 I-GENE
phenotype I-GENE
and I-GENE
a I-GENE
favorable I-GENE
outcome I-GENE
3 I-GENE
months I-GENE
after I-GENE
stroke I-GENE
, I-GENE
the I-GENE
risk I-GENE
of I-GENE
intracerebral I-GENE
hemorrhage I-GENE
, I-GENE
and I-GENE
the I-GENE
response I-GENE
to I-GENE
intravenous I-GENE
t I-GENE
- I-GENE
PA I-GENE
therapy I-GENE
. I-GENE

These O
results O
were O
robust O
to O
changes O
in O
the O
baseline O
assumptions O
of O
the O
model O
. O

Cis O
- O
acting O
CCAAT O
elements O
are O
frequently O
found O
in O
eukaryotic O
promoter O
regions O
. O

The O
binary O
and O
tertiary O
combinations O
of O
plant O
- I-GENE
derived I-GENE
molluscicides I-GENE
Azadirachta I-GENE
indica I-GENE
and I-GENE
Cedrus I-GENE
deodara I-GENE
oil I-GENE
with I-GENE
synergists I-GENE
MGK I-GENE
- I-GENE
264 I-GENE
, I-GENE
piperonyl I-GENE
butoxide I-GENE
( I-GENE
PB I-GENE
) I-GENE
and I-GENE
fruit I-GENE
powder I-GENE
of I-GENE
Embelia I-GENE
ribes I-GENE
were I-GENE
used I-GENE
against I-GENE
the I-GENE
Lymnaea I-GENE
acuminata I-GENE
. I-GENE

This I-GENE
article I-GENE
reports I-GENE
the I-GENE
design I-GENE
and I-GENE
development I-GENE
of I-GENE
an I-GENE
ECG I-GENE
simulator I-GENE
intended I-GENE
for I-GENE
use I-GENE
in I-GENE
the I-GENE
testing I-GENE
, I-GENE
calibration I-GENE
and I-GENE
maintenance I-GENE
of I-GENE
electrocardiographic I-GENE
equipment I-GENE
. I-GENE

Exchanging I-GENE
the I-GENE
human I-GENE
propeptide I-GENE
in I-GENE
this I-GENE
chimera I-GENE
with I-GENE
either I-GENE
the I-GENE
murine I-GENE
MIC I-GENE
- I-GENE
1 I-GENE
or I-GENE
TGF I-GENE
- I-GENE
beta1 I-GENE
propeptide I-GENE
resulted I-GENE
in I-GENE
secretion I-GENE
of I-GENE
the I-GENE
unprocessed I-GENE
, I-GENE
monomeric I-GENE
chimera I-GENE
, I-GENE
suggesting I-GENE
a I-GENE
specific I-GENE
interaction I-GENE
between I-GENE
the I-GENE
human I-GENE
MIC I-GENE
- I-GENE
1 I-GENE
propeptide I-GENE
and I-GENE
mature I-GENE
peptide I-GENE
. I-GENE

RESULTS I-GENE
: I-GENE
The I-GENE
analyzed I-GENE
fragment I-GENE
has I-GENE
significant I-GENE
activity I-GENE
in I-GENE
EpCAM I-GENE
positive I-GENE
cells I-GENE
, I-GENE
and I-GENE
it I-GENE
is I-GENE
regulated I-GENE
negatively I-GENE
by I-GENE
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
( I-GENE
TNFalpha I-GENE
). I-GENE

The O
mutant O
receptors O
, O
as O
well I-GENE
as I-GENE
sBMPR I-GENE
- I-GENE
IA I-GENE
, I-GENE
were I-GENE
expressed I-GENE
as I-GENE
fusion I-GENE
proteins I-GENE
with I-GENE
thioredoxin I-GENE
in I-GENE
Escherichia I-GENE
coli I-GENE
, I-GENE
and I-GENE
purified I-GENE
using I-GENE
reverse I-GENE
phase I-GENE
high I-GENE
performance I-GENE
liquid I-GENE
chromatography I-GENE
( I-GENE
RP I-GENE
- I-GENE
HPLC I-GENE
) I-GENE
after I-GENE
digestion I-GENE
with I-GENE
enterokinase I-GENE
. I-GENE

The O
dual O
specificity O
kinases I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( I-GENE
MAPK I-GENE
) I-GENE
kinase I-GENE
( I-GENE
MKK I-GENE
) I-GENE
7 I-GENE
and I-GENE
MKK4 I-GENE
are I-GENE
the I-GENE
only I-GENE
molecules I-GENE
known I-GENE
to I-GENE
directly I-GENE
activate I-GENE
the I-GENE
stress I-GENE
kinases I-GENE
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinases I-GENE
( I-GENE
SAPKs I-GENE
)/ I-GENE
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinases I-GENE
( I-GENE
JNKs I-GENE
) I-GENE
in I-GENE
response I-GENE
to I-GENE
environmental I-GENE
or I-GENE
mitogenic I-GENE
stimuli I-GENE
. I-GENE

This I-GENE
unique I-GENE
work I-GENE
needs I-GENE
to I-GENE
be I-GENE
edited I-GENE
critically I-GENE
and I-GENE
afterwards I-GENE
translated I-GENE
into I-GENE
Urdu I-GENE
and I-GENE
other I-GENE
languages I-GENE
for I-GENE
the I-GENE
benefit I-GENE
of I-GENE
the I-GENE
present I-GENE
day I-GENE
students I-GENE
and I-GENE
scholars I-GENE
. I-GENE

RANTES I-GENE
( I-GENE
regulated I-GENE
upon I-GENE
activation I-GENE
, I-GENE
normally I-GENE
T I-GENE
- I-GENE
cell I-GENE
expressed I-GENE
and I-GENE
presumably I-GENE
secreted I-GENE
) I-GENE
is I-GENE
a I-GENE
CC I-GENE
chemokine I-GENE
which I-GENE
recruits I-GENE
and I-GENE
activates I-GENE
monocytes I-GENE
, I-GENE
lymphocytes I-GENE
, I-GENE
and I-GENE
eosinophils I-GENE
, I-GENE
all I-GENE
cell I-GENE
types I-GENE
present I-GENE
in I-GENE
the I-GENE
lung I-GENE
inflammatory I-GENE
infiltrate I-GENE
induced I-GENE
by I-GENE
RSV I-GENE
infection I-GENE
. I-GENE

Gabapentin I-GENE
for I-GENE
opiod I-GENE
- I-GENE
related I-GENE
myoclonus I-GENE
in I-GENE
cancer I-GENE
patients I-GENE
. I-GENE

Recently O
, O
it O
was O
shown O
that O
purified O
RAG1 I-GENE
/ I-GENE
2 I-GENE
proteins I-GENE
can O
cleave O
DNA O
hairpins O
in O
vitro O
, O
but O
the O
same O
activity O
was O
also O
described O
for O
a O
protein O
complex O
of O
the O
DNA O
repair I-GENE
proteins I-GENE
Nbs1 I-GENE
/ I-GENE
Mre11 I-GENE
/ I-GENE
Rad50 I-GENE
. I-GENE

APC I-GENE
- I-GENE
resistance O
was O
determined O
with O
a O
functional O
method O
with O
high O
sensitivity O
and O
specificity O
for O
the O
factor O
V O
Leiden O
mutation O
. O

A O
picture O
is O
emerging O
showing O
a O
gradient O
of O
function O
among O
p53 I-GENE
, O
p73 I-GENE
, I-GENE
p63 I-GENE
ranging I-GENE
from I-GENE
tumor I-GENE
suppression I-GENE
to I-GENE
development I-GENE
. I-GENE

High O
plasma O
AVP I-GENE
levels O
observed O
in I-GENE
the I-GENE
two I-GENE
cases I-GENE
suggest I-GENE
that I-GENE
SSRIs I-GENE
stimulate I-GENE
AVP I-GENE
secretion I-GENE
, I-GENE
thereby I-GENE
causing I-GENE
SIADH I-GENE
. I-GENE

Mutation O
of O
the O
octamer O
element O
also O
significantly O
reduced O
the O
ability O
of O
HDAC1 I-GENE
to O
confer O
repression O
of O
inducible O
HLA I-GENE
- I-GENE
DRA I-GENE
promoter I-GENE
activation O
. O

Requirements I-GENE
for I-GENE
the I-GENE
nuclear I-GENE
- I-GENE
cytoplasmic I-GENE
translocation I-GENE
of I-GENE
infected I-GENE
- I-GENE
cell I-GENE
protein I-GENE
0 I-GENE
of I-GENE
herpes I-GENE
simplex I-GENE
virus I-GENE
1 I-GENE
. I-GENE

The O
system O
, O
designed O
to O
exploit O
the O
relatively O
constant O
small O
intestine O
transit O
time O
, O
consists O
of O
a O
drug O
- O
containing O
core O
coated O
with O
a O
polymeric O
matrix O
formed O
by O
a O
channeling O
agent O
( O
NaCl O
, O
mannitol O
, I-GENE
and I-GENE
Emdex I-GENE
) I-GENE
and I-GENE
an I-GENE
inert I-GENE
polymer I-GENE
( I-GENE
Eudragit I-GENE
RS100 I-GENE
). I-GENE

The O
activity O
of O
Rac1 I-GENE
leads O
to O
STAT3 I-GENE
translocation O
to O
the O
nucleus O
coincident O
with O
STAT3 I-GENE
- I-GENE
dependent I-GENE
gene I-GENE
expression O
. O

Treatment O
of O
ischemic O
heart O
disease O
in O
the O
elderly O

To I-GENE
avoid I-GENE
misinterpretations I-GENE
, I-GENE
special I-GENE
reference I-GENE
values I-GENE
should I-GENE
be I-GENE
applied I-GENE
for I-GENE
preadolescents I-GENE
, I-GENE
at I-GENE
least I-GENE
with I-GENE
regard I-GENE
to I-GENE
FVC I-GENE
and I-GENE
FEV1 I-GENE
. I-GENE

STUDY O
OBJECTIVE O
: O
This O
study O
assessed O
several O
methodological O
aspects O
related I-GENE
to I-GENE
the I-GENE
quality I-GENE
of I-GENE
published I-GENE
controlled I-GENE
clinical I-GENE
trials I-GENE
( I-GENE
CCTs I-GENE
) I-GENE
in I-GENE
relation I-GENE
to I-GENE
the I-GENE
participation I-GENE
of I-GENE
an I-GENE
epidemiologist I-GENE
/ I-GENE
biostatistician I-GENE
( I-GENE
E I-GENE
/ I-GENE
B I-GENE
). I-GENE

To I-GENE
the I-GENE
best I-GENE
of I-GENE
our I-GENE
knowledge I-GENE
, I-GENE
SNTCS I-GENE
is I-GENE
highly I-GENE
malignant I-GENE
. I-GENE

Northern O
blot O
analysis O
with O
one O
of I-GENE
the I-GENE
PARNAs I-GENE
revealed I-GENE
a I-GENE
highly I-GENE
abundant I-GENE
signal I-GENE
of I-GENE
approximately I-GENE
2 I-GENE
. I-GENE
0 I-GENE
kilobases I-GENE
( I-GENE
kb I-GENE
) I-GENE
present I-GENE
in I-GENE
all I-GENE
cell I-GENE
lines I-GENE
tested I-GENE
. I-GENE

The I-GENE
effect I-GENE
of I-GENE
crude I-GENE
oil I-GENE
spillage I-GENE
on I-GENE
growth I-GENE
, I-GENE
productivity I-GENE
and I-GENE
nutrient I-GENE
uptake I-GENE
of I-GENE
maize I-GENE
( I-GENE
Zea I-GENE
mays I-GENE
L I-GENE
.) I-GENE
was I-GENE
assessed I-GENE
in I-GENE
a I-GENE
pot I-GENE
experiment I-GENE
using I-GENE
an I-GENE
Evwreni I-GENE
manifold I-GENE
sample I-GENE
of I-GENE
a I-GENE
petroleum I-GENE
development I-GENE
company I-GENE
, I-GENE
which I-GENE
had I-GENE
a I-GENE
specific I-GENE
gravity I-GENE
of I-GENE
0 I-GENE
. I-GENE
8778 I-GENE
. I-GENE

10 O
. O
0 O
+/- O
2 O
. O
0 O
pmol O
/ O
24 O
h O
, O
P O
< O
0 O
. O
01 O
) O
and O
remained O
elevated O
. O

Pitx2 I-GENE
rescues I-GENE
the I-GENE
GABAergic I-GENE
differentiation I-GENE
defect I-GENE
and I-GENE
partially I-GENE
rescues I-GENE
the I-GENE
axon I-GENE
guidance I-GENE
and I-GENE
behavioral I-GENE
phenotypes I-GENE
of I-GENE
unc I-GENE
- I-GENE
30 I-GENE
mutants I-GENE
, I-GENE
indicating I-GENE
a I-GENE
high I-GENE
degree I-GENE
of I-GENE
functional I-GENE
conservation I-GENE
between I-GENE
these I-GENE
evolutionarily I-GENE
related I-GENE
genes I-GENE
. I-GENE

Phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
potentiates O
, O
but O
does O
not O
trigger O
, O
T O
cell O
proliferation O
mediated O
by O
the O
IL I-GENE
- I-GENE
2 I-GENE
receptor I-GENE
. O

In I-GENE
addition I-GENE
, I-GENE
stonin I-GENE
2 I-GENE
binds I-GENE
to I-GENE
the I-GENE
C2B I-GENE
domains I-GENE
of I-GENE
synaptotagmins I-GENE
I I-GENE
and I-GENE
II I-GENE
. I-GENE

Sequence O
comparison O
and O
binding O
studies O
of O
the O
18 O
- I-GENE
bp I-GENE
MOK2 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
present I-GENE
in I-GENE
intron I-GENE
2 I-GENE
of I-GENE
human I-GENE
, I-GENE
bovine I-GENE
, I-GENE
and I-GENE
mouse I-GENE
IRBP I-GENE
genes I-GENE
show I-GENE
that I-GENE
the I-GENE
3 I-GENE
'- I-GENE
half I-GENE
sequence I-GENE
is I-GENE
the I-GENE
essential I-GENE
core I-GENE
element I-GENE
for I-GENE
MOK2 I-GENE
binding I-GENE
. I-GENE

Measurements O
were O
obtained O
: O
( O
i I-GENE
) I-GENE
just I-GENE
after I-GENE
the I-GENE
traumatic I-GENE
exposure I-GENE
( I-GENE
D0 I-GENE
); I-GENE
( I-GENE
ii I-GENE
) I-GENE
3 I-GENE
days I-GENE
after I-GENE
this I-GENE
first I-GENE
measurement I-GENE
( I-GENE
D3 I-GENE
); I-GENE
and I-GENE
( I-GENE
iii I-GENE
) I-GENE
30 I-GENE
days I-GENE
after I-GENE
( I-GENE
D30 I-GENE
). I-GENE

Long I-GENE
- I-GENE
term I-GENE
results I-GENE
with I-GENE
MACOP I-GENE
- I-GENE
B I-GENE
and I-GENE
radiation I-GENE
therapy I-GENE
for I-GENE
aggressive I-GENE
lymphomas I-GENE
] I-GENE
BACKGROUND I-GENE
: I-GENE
Long I-GENE
- I-GENE
term I-GENE
results I-GENE
are I-GENE
needed I-GENE
to I-GENE
evaluate I-GENE
chemotherapy I-GENE
regimens I-GENE
and I-GENE
prognostic I-GENE
factors I-GENE
in I-GENE
non I-GENE
- I-GENE
Hodgkin I-GENE
' I-GENE
s I-GENE
lymphomas I-GENE
( I-GENE
NHL I-GENE
). I-GENE

From O
the O
above O
results O
, O
we O
might O
infer O
that O
the O
seizure O
type O
of O
TLE O
and O
a O
high O
frequency O
of O
seizure O
are O
two O
major O
independent O
precipitate O
factors O
for O
abnormal O
latencies O
of O
P300 O
in I-GENE
the I-GENE
epileptic I-GENE
patients I-GENE
. I-GENE

Rapamycin I-GENE
( I-GENE
FRAP I-GENE
/ I-GENE
mTOR I-GENE
inhibitor I-GENE
) I-GENE
blocked I-GENE
4E I-GENE
- I-GENE
BP1 I-GENE
phosphorylation I-GENE
causing I-GENE
a I-GENE
predominance I-GENE
of I-GENE
the I-GENE
alpha I-GENE
( I-GENE
hypophosphorylated I-GENE
) I-GENE
band I-GENE
. I-GENE

We O
investigate O
the O
reaction O
kinetics O
of I-GENE
small I-GENE
spherical I-GENE
particles I-GENE
with I-GENE
inertia I-GENE
, I-GENE
obeying I-GENE
coalescence I-GENE
type I-GENE
of I-GENE
reaction I-GENE
, I-GENE
B I-GENE
+ I-GENE
B I-GENE
--> I-GENE
B I-GENE
, I-GENE
and I-GENE
being I-GENE
advected I-GENE
by I-GENE
hydrodynamical I-GENE
flows I-GENE
with I-GENE
time I-GENE
- I-GENE
periodic I-GENE
forcing I-GENE
. I-GENE

Corticosteroid O
- O
mediated O
transcriptional O
inhibition O
was O
greater O
for O
MR O
/ O
GR I-GENE
in O
combination O
than O
for O
MR O
or O
GR I-GENE
alone O
. O

These O
data O
define O
a O
conserved O
pathway O
wherein O
sequential O
histone I-GENE
modifications O
establish O
a O
" O
histone I-GENE
code O
" O
essential O
for O
the O
epigenetic O
inheritance O
of O
heterochromatin O
assembly O
. O

The I-GENE
bovine I-GENE
PGHS I-GENE
- I-GENE
2 I-GENE
cDNA I-GENE
was I-GENE
cloned I-GENE
by I-GENE
a I-GENE
combination I-GENE
of I-GENE
reverse I-GENE
transcription I-GENE
- I-GENE
polymerase I-GENE
chain I-GENE
reaction I-GENE
and I-GENE
cDNA I-GENE
library I-GENE
screening I-GENE
. I-GENE

Telomerase I-GENE
is I-GENE
a I-GENE
ribonucleoprotein I-GENE
complex I-GENE
that I-GENE
synthesizes I-GENE
telomeric I-GENE
DNA I-GENE
onto I-GENE
chromosomes I-GENE
using I-GENE
its I-GENE
RNA I-GENE
component I-GENE
as I-GENE
template I-GENE
. I-GENE

The I-GENE
iterative I-GENE
method I-GENE
proposed I-GENE
by I-GENE
Bengtsson I-GENE
[ I-GENE
Appl I-GENE
. I-GENE

Several O
distinct O
apoptotic O
stimuli O
induce O
the O
expression O
and O
caspase I-GENE
- I-GENE
dependent I-GENE
cleavage I-GENE
of O
hTAF I-GENE
( I-GENE
II I-GENE
) I-GENE
80 O
delta I-GENE
. O
hTAF I-GENE
( I-GENE
II I-GENE
) O
80 O
delta O
, O
unlike O
hTAF I-GENE
( I-GENE
II I-GENE
) O
80 O
, O
forms O
a O
TFIID I-GENE
- I-GENE
like I-GENE
complex I-GENE
lacking O
hTAF I-GENE
( I-GENE
II I-GENE
) O
31 O
. O

With I-GENE
NEU I-GENE
overexpression I-GENE
, I-GENE
nodal I-GENE
control I-GENE
decreased I-GENE
from I-GENE
72 I-GENE
% I-GENE
to I-GENE
34 I-GENE
% I-GENE
( I-GENE
p I-GENE
= I-GENE
. I-GENE
008 I-GENE
). I-GENE

The O
mouse I-GENE
platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
( I-GENE
PDGF I-GENE
) I-GENE
beta I-GENE
- I-GENE
receptor I-GENE
promoter I-GENE
contains O
a O
CCAAT O
motif O
, O
and O
NF I-GENE
- I-GENE
Y I-GENE
plays O
an O
essential O
role O
in O
its O
transcription O
. O

Biol O
. O

The O
loop O
domain O
of O
heat I-GENE
shock I-GENE
transcription I-GENE
factor I-GENE
1 I-GENE
dictates I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
specificity I-GENE
and I-GENE
responses I-GENE
to I-GENE
heat I-GENE
stress I-GENE
. I-GENE

This I-GENE
activation I-GENE
was I-GENE
then I-GENE
blocked I-GENE
by I-GENE
CGS I-GENE
12066A I-GENE
. I-GENE

Among O
the O
transcription O
factors O
known O
to O
interact O
with O
Groucho I-GENE
- I-GENE
related I-GENE
protein I-GENE
, I-GENE
only I-GENE
RUNX1 I-GENE
was I-GENE
appreciably I-GENE
downregulated I-GENE
by I-GENE
E2A I-GENE
- I-GENE
HLF I-GENE
. I-GENE

A O
new O
intron O
of O
476 O
base O
pairs O
was O
found O
in O
the O
middle O
of O
the O
5 O
'- O
untranslated O
leader O
sequence I-GENE
and I-GENE
was I-GENE
shown I-GENE
to I-GENE
robustly I-GENE
enhance I-GENE
the I-GENE
promoter I-GENE
activity I-GENE
. I-GENE

Our O
findings O
further O
our O
understanding O
of O
how O
ZBP I-GENE
- I-GENE
89 O
modulates O
cell O
proliferation O
and O
reveals O
a O
novel O
mechanism O
by O
which O
the O
p53 I-GENE
protein I-GENE
is O
stabilized O
. O

In I-GENE
the I-GENE
free I-GENE
- I-GENE
swimming I-GENE
rotatory I-GENE
test I-GENE
mice I-GENE
spend I-GENE
most I-GENE
of I-GENE
the I-GENE
time I-GENE
swimming I-GENE
close I-GENE
to I-GENE
the I-GENE
wall I-GENE
of I-GENE
the I-GENE
container I-GENE
attempting I-GENE
to I-GENE
escape I-GENE
from I-GENE
an I-GENE
aversive I-GENE
test I-GENE
situation I-GENE
. I-GENE

As O
well O
, O
mixtures O
of O
( O
LA O
)( I-GENE
12 I-GENE
) I-GENE
with I-GENE
the I-GENE
longer I-GENE
chain I-GENE
PEs I-GENE
exhibit I-GENE
unusual I-GENE
biomodal I-GENE
enthalpy I-GENE
variations I-GENE
, I-GENE
suggesting I-GENE
peptide I-GENE
immiscibility I-GENE
in I-GENE
thicker I-GENE
gel I-GENE
state I-GENE
bilayers I-GENE
. I-GENE

At O
the O
time O
of O
the O
blind O
therapeutic O
doses O
, O
Tg O
- O
off O
values O
ranged O
from O
8 O
to O
608 O
microg O
/ O
l O
. O

Nephrotoxicity I-GENE
after I-GENE
orthotopic I-GENE
liver I-GENE
transplantation I-GENE
in I-GENE
cyclosporin I-GENE
A I-GENE
and I-GENE
FK I-GENE
506 I-GENE
- I-GENE
treated I-GENE
patients I-GENE
. I-GENE

In I-GENE
contrast I-GENE
to I-GENE
MPc3 I-GENE
, I-GENE
data I-GENE
indicate I-GENE
that I-GENE
the I-GENE
Pc I-GENE
protein I-GENE
M33 I-GENE
does I-GENE
not I-GENE
interact I-GENE
with I-GENE
AF9 I-GENE
. I-GENE

Hydrocoele I-GENE
is I-GENE
common I-GENE
in I-GENE
men I-GENE
in I-GENE
Wuchereria I-GENE
bancrofti I-GENE
- I-GENE
endemic I-GENE
areas I-GENE
, I-GENE
the I-GENE
treatment I-GENE
for I-GENE
which I-GENE
is I-GENE
currently I-GENE
surgical I-GENE
intervention I-GENE
. I-GENE

Of O
the O
patients O
in O
each O
regimen O
who O
reached O
study O
end O
points O
, O
17 O
of O
29 O
( O
59 O
%) O
were O
in O
regimen O
A O
, O
11 O
of O
20 O
( O
55 O
%) O
were O
in O
regimen O
B O
, O
and O
28 O
of O
43 O
( O
65 O
%) O
were O
in O
regimen O
C O
met O
the O
treatment O
success O
criterion O
. O

One O
maternal O
death O
, O
reduced O
body O
weight O
, O
and O
reduced O
weight O
gain O
were O
noted O
at O
the O
high O
dose O
; O
confirmed O
pregnancy O
rates O
were O
84 O
to O
100 O
% O
for O
each O
group O
. O

Karger O
AG O
, O
Basel O

In O
regards O
to O
the O
latter O
activity O
, O
it O
has O
been O
shown O
that O
S3 O
contains O
vigorous O
N I-GENE
- I-GENE
glycosylase I-GENE
activity O
for O
the O
removal O
of O
8 O
- O
oxoguanine O
residues O
in I-GENE
DNA I-GENE
that I-GENE
leaves I-GENE
baseless I-GENE
sites I-GENE
in I-GENE
their I-GENE
places I-GENE
. I-GENE

We O
describe O
a O
total O
of O
39 O
DEAH I-GENE
helicases I-GENE
in O
these O
four O
species O
. O

A O
prospective O
trial O
was O
undertaken O
to O
determine O
( O
1 O
) O
clinical O
characteristics O
of O
patients O
with O
chest O
pain O
; O
( O
2 O
) O
value O
of O
cardiac O
markers O
troponin I-GENE
T I-GENE
, O
myoglobin I-GENE
and O
CK I-GENE
- I-GENE
MB I-GENE
mass O
in O
differentiating O
cardiac I-GENE
and I-GENE
noncardiac I-GENE
chest I-GENE
pain I-GENE
; I-GENE
( I-GENE
3 I-GENE
) I-GENE
the I-GENE
proportion I-GENE
of I-GENE
patients I-GENE
with I-GENE
ACS I-GENE
in I-GENE
whom I-GENE
these I-GENE
markers I-GENE
provided I-GENE
helpful I-GENE
additional I-GENE
information I-GENE
on I-GENE
admission I-GENE
and I-GENE
afterwards I-GENE
. I-GENE

Inactivity I-GENE
of I-GENE
the I-GENE
human I-GENE
cytomegalovirus I-GENE
( I-GENE
HCMV I-GENE
) I-GENE
major I-GENE
immediate I-GENE
- I-GENE
early I-GENE
regulatory I-GENE
region I-GENE
( I-GENE
MIERR I-GENE
), I-GENE
which I-GENE
is I-GENE
composed I-GENE
of I-GENE
promoter I-GENE
, I-GENE
enhancer I-GENE
, I-GENE
unique I-GENE
region I-GENE
, I-GENE
and I-GENE
modulator I-GENE
, I-GENE
is I-GENE
linked I-GENE
to I-GENE
lack I-GENE
of I-GENE
HCMV I-GENE
replication I-GENE
in I-GENE
latently I-GENE
infected I-GENE
cells I-GENE
and I-GENE
in I-GENE
other I-GENE
nonpermissive I-GENE
cell I-GENE
types I-GENE
, I-GENE
including I-GENE
human I-GENE
embryonal I-GENE
NTera2 I-GENE
carcinoma I-GENE
( I-GENE
NT2 I-GENE
) I-GENE
cells I-GENE
. I-GENE

The O
observed O
triplexes O
depend O
on O
the O
length O
of O
the O
repeat O
. O

Statistical O
Analysis O
included O
ANOVA I-GENE
, I-GENE
the I-GENE
Pearson I-GENE
Product I-GENE
Moment I-GENE
Correlation I-GENE
Coefficient I-GENE
, I-GENE
Principal I-GENE
Components I-GENE
Analysis I-GENE
and I-GENE
Discriminant I-GENE
Function I-GENE
Analysis I-GENE
and I-GENE
the I-GENE
calculation I-GENE
of I-GENE
Cronbach I-GENE
' I-GENE
s I-GENE
alpha I-GENE
( I-GENE
alpha I-GENE
) I-GENE
RESULTS I-GENE
: I-GENE
Both I-GENE
Sensitivity I-GENE
and I-GENE
specificity I-GENE
exceed I-GENE
90 I-GENE
. I-GENE
00 I-GENE
at I-GENE
23 I-GENE
/ I-GENE
24 I-GENE
, I-GENE
Chronbach I-GENE
' I-GENE
s I-GENE
alpha I-GENE
for I-GENE
the I-GENE
total I-GENE
scale I-GENE
was I-GENE
equal I-GENE
to I-GENE
0 I-GENE
. I-GENE
95 I-GENE
. I-GENE

BACKGROUND O
: O
Previous O
studies O
have O
indicated O
that O
the O
60 O
-, O
30 O
-, O
28 O
- O
and O
12 O
- O
item O
versions O
of I-GENE
the I-GENE
General I-GENE
Health I-GENE
Questionnaire I-GENE
( I-GENE
GHQ I-GENE
) I-GENE
are I-GENE
liable I-GENE
to I-GENE
retest I-GENE
effects I-GENE
, I-GENE
especially I-GENE
when I-GENE
administered I-GENE
multiple I-GENE
times I-GENE
with I-GENE
short I-GENE
intervals I-GENE
. I-GENE

Cross I-GENE
- I-GENE
linking I-GENE
FcalphaR I-GENE
on I-GENE
wt I-GENE
- I-GENE
ITAM I-GENE
or I-GENE
IIA I-GENE
- I-GENE
ITAM I-GENE
cells I-GENE
triggered I-GENE
equivalent I-GENE
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
- I-GENE
dependent I-GENE
activation I-GENE
of I-GENE
PKBalpha I-GENE
. I-GENE

An I-GENE
F222W I-GENE
: I-GENE
W21F I-GENE
rGST I-GENE
A1 I-GENE
- I-GENE
1 I-GENE
double I-GENE
mutant I-GENE
provides I-GENE
a I-GENE
direct I-GENE
fluorescence I-GENE
probe I-GENE
of I-GENE
changes I-GENE
in I-GENE
the I-GENE
environment I-GENE
of I-GENE
the I-GENE
C I-GENE
- I-GENE
terminal I-GENE
residue I-GENE
. I-GENE

Binding O
of O
serum O
response O
factor O
to O
CArG O
box O
sequences O
is O
necessary O
but O
not O
sufficient O
to O
restrict O
gene O
expression O
to O
arterial O
smooth O
muscle O
cells O
. O

They O
consist O
of O
at O
least O
two O
separable O
components O
, O
one O
heat O
stable O
and O
the O
other O
heat O
labile O
. O

No O
preferential O
VH I-GENE
/ I-GENE
VL I-GENE
- I-GENE
chains I-GENE
correlated O
with O
any O
of O
the I-GENE
12 I-GENE
different I-GENE
antigen I-GENE
reactivities I-GENE
, I-GENE
even I-GENE
for I-GENE
mAbs I-GENE
with I-GENE
nearly I-GENE
identical I-GENE
cross I-GENE
- I-GENE
reactivities I-GENE
. I-GENE

These O
results O
were O
compared O
with O
the O
estimates O
of O
penetration O
from O
steady O
- O
state O
calculations O
, O
square O
root O
of O
time O
calculations O
, O
and I-GENE
a I-GENE
biologically I-GENE
based I-GENE
mathematical I-GENE
model I-GENE
. I-GENE

Based O
on O
this O
analysis O
, O
we O
propose O
that O
the O
interactions O
of O
Sos I-GENE
with O
the O
switch O
1 O
and O
switch O
2 O
regions O
of O
Ras I-GENE
have O
distinct O
functional O
consequences O
: O
the O
interaction O
with O
switch O
2 O
mediates O
the O
anchoring O
of O
Ras I-GENE
to O
Sos I-GENE
, O
whereas O
the O
interaction O
with O
switch O
1 O
leads O
to O
disruption O
of O
the O
nucleotide O
- O
binding O
site O
and O
GDP O
dissociation O
. O

Thus O
, O
the O
interaction O
of O
Tat I-GENE
with O
the O
components O
of O
this O
rel I-GENE
/ I-GENE
AP1 I-GENE
cooperative O
complex O
seems O
to O
induce O
quantitative O
and O
qualitative O
alterations O
of O
this O
complex O
as O
activation O
progresses O
, O
resulting O
in O
a O
decrease O
of O
IL I-GENE
- I-GENE
2 I-GENE
gene I-GENE
transcription I-GENE
. O

SIT I-GENE
( I-GENE
SHP2 I-GENE
- I-GENE
interacting I-GENE
transmembrane I-GENE
adaptor I-GENE
protein I-GENE
) I-GENE
is I-GENE
a I-GENE
recently I-GENE
identified I-GENE
transmembrane I-GENE
adaptor I-GENE
protein I-GENE
, I-GENE
which I-GENE
is I-GENE
expressed I-GENE
in I-GENE
lymphocytes I-GENE
. I-GENE

In I-GENE
this I-GENE
manuscript I-GENE
we I-GENE
demonstrate I-GENE
that I-GENE
two I-GENE
tandem I-GENE
Ets I-GENE
sites I-GENE
in I-GENE
the I-GENE
mouse I-GENE
GL I-GENE
alpha I-GENE
promoter I-GENE
bind I-GENE
the I-GENE
transcription I-GENE
factors I-GENE
Elf I-GENE
- I-GENE
1 I-GENE
and I-GENE
PU I-GENE
. I-GENE
1 I-GENE
, I-GENE
and I-GENE
that I-GENE
the I-GENE
3 I-GENE
' I-GENE
site I-GENE
is I-GENE
essential I-GENE
for I-GENE
expression I-GENE
of I-GENE
a I-GENE
luciferase I-GENE
reporter I-GENE
gene I-GENE
driven I-GENE
by I-GENE
the I-GENE
GL I-GENE
alpha I-GENE
promoter I-GENE
. I-GENE

ICA O
in O
the O
reference O
solution O
was O
characterised O
by O
LC O
and O
time O
- I-GENE
of I-GENE
- I-GENE
flight I-GENE
( I-GENE
TOF I-GENE
) I-GENE
MS I-GENE
and I-GENE
quantified I-GENE
by I-GENE
LC I-GENE
chemiluminescent I-GENE
nitrogen I-GENE
detection I-GENE
( I-GENE
LC I-GENE
- I-GENE
CLND I-GENE
). I-GENE

These O
disorders O
include O
low I-GENE
- I-GENE
back I-GENE
pain I-GENE
, I-GENE
saddle I-GENE
anesthesia I-GENE
, I-GENE
bilateral I-GENE
sciatica I-GENE
, I-GENE
then I-GENE
motor I-GENE
weakness I-GENE
of I-GENE
the I-GENE
lower I-GENE
extremities I-GENE
or I-GENE
chronic I-GENE
paraplegia I-GENE
and I-GENE
, I-GENE
bladder I-GENE
dysfunction I-GENE
. I-GENE

C O
. O
elegans O
embryogenesis O
begins O
with O
a O
stereotyped O
sequence O
of O
asymmetric O
cell O
divisions O
that O
are O
largely O
responsible O
for O
establishing O
the O
nematode O
body O
plan O
. O

Additionally O
, O
a O
CaCO3 O
- O
CO2 O
/ O
N2 O
buffered O
solution O
was O
necessary O
to O
maintain O
a O
pH O
of O
8 O
. O

Mss4 I-GENE
also I-GENE
acts I-GENE
as I-GENE
a I-GENE
relatively I-GENE
inefficient I-GENE
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
( I-GENE
GEF I-GENE
). I-GENE

Effects O
of O
3 O
' O
terminus O
modifications O
on O
mRNA O
functional O
decay O
during O
in O
vitro O
protein O
synthesis O
. O

Disciplinary I-GENE
action I-GENE
for I-GENE
DNA I-GENE
violation I-GENE
. I-GENE

This O
is O
necessary O
if O
psychiatric O
diagnoses O
are O
ultimately O
going O
to O
be O
refined O
and O
validated O
against O
biological O
criteria O
. O

We I-GENE
also I-GENE
demonstrate I-GENE
that I-GENE
the I-GENE
spo20 I-GENE
(+) I-GENE
gene I-GENE
product I-GENE
is I-GENE
structurally I-GENE
homologous I-GENE
to I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
Sec14 I-GENE
, I-GENE
the I-GENE
major I-GENE
phosphatidylinositol I-GENE
transfer I-GENE
protein I-GENE
of I-GENE
budding I-GENE
yeast I-GENE
. I-GENE

In O
addition O
, O
another O
derivative I-GENE
of I-GENE
pCMVJS21 I-GENE
( I-GENE
pCMVJS21DeltaGP I-GENE
) I-GENE
in I-GENE
which I-GENE
the I-GENE
gag I-GENE
, I-GENE
pol I-GENE
( I-GENE
and I-GENE
orf I-GENE
- I-GENE
x I-GENE
) I-GENE
coding I-GENE
sequences I-GENE
were I-GENE
deleted I-GENE
also I-GENE
gave I-GENE
transformed I-GENE
foci I-GENE
. I-GENE

It O
is O
shown O
that O
, O
for O
any O
periodic O
input O
, O
the O
map O
representing O
the O
relation O
between O
input O
phases O
at O
consecutive O
discharge O
times O
can O
be O
restricted O
to I-GENE
a I-GENE
piecewise I-GENE
continuous I-GENE
, I-GENE
orientation I-GENE
preserving I-GENE
circle I-GENE
map I-GENE
. I-GENE

Decreased O
serum I-GENE
ceruloplasmin I-GENE
and I-GENE
copper I-GENE
levels I-GENE
in I-GENE
cervical I-GENE
dystonia I-GENE
. I-GENE

Northern O
blot O
analysis O
of O
RNAs O
from O
a O
number O
of I-GENE
mouse I-GENE
tissues I-GENE
reveals I-GENE
that I-GENE
Atp6i I-GENE
is I-GENE
expressed I-GENE
predominantly I-GENE
in I-GENE
osteoclasts I-GENE
, I-GENE
and I-GENE
this I-GENE
predominant I-GENE
expression I-GENE
was I-GENE
confirmed I-GENE
by I-GENE
reverse I-GENE
- I-GENE
transcription I-GENE
polymerase I-GENE
chain I-GENE
reaction I-GENE
( I-GENE
RT I-GENE
- I-GENE
PCR I-GENE
) I-GENE
assay I-GENE
and I-GENE
immunohistochemical I-GENE
analysis I-GENE
. I-GENE

Behavioural I-GENE
tests I-GENE
with I-GENE
192 I-GENE
specimen I-GENE
of I-GENE
the I-GENE
roman I-GENE
garden I-GENE
snail I-GENE
Helix I-GENE
pomatia I-GENE
L I-GENE
. I-GENE
were I-GENE
performed I-GENE
in I-GENE
order I-GENE
to I-GENE
clarify I-GENE
whether I-GENE
the I-GENE
thermopreferendum I-GENE
of I-GENE
this I-GENE
pulmonate I-GENE
is I-GENE
influenced I-GENE
not I-GENE
only I-GENE
by I-GENE
the I-GENE
temperature I-GENE
of I-GENE
the I-GENE
substratum I-GENE
but I-GENE
also I-GENE
by I-GENE
air I-GENE
temperature I-GENE
. I-GENE

As O
well O
, O
IFN I-GENE
- I-GENE
gamma I-GENE
- I-GENE
induced O
expression O
of O
IRF I-GENE
- I-GENE
1 I-GENE
and O
its O
binding O
to O
the O
IRF I-GENE
element I-GENE
is O
inhibited O
. O

Baseline O
BMD O
values O
were O
significantly O
lower O
in O
the O
oligo O
- O
amenorrheic O
group O
than O
in O
the O
two O
others O
at O
the O
level O
of O
lumbar O
spine O
( O
anteroposterior O
view O
: O
0 I-GENE
. I-GENE
941 I-GENE
+/- I-GENE
0 I-GENE
. I-GENE
039 I-GENE
in I-GENE
oligo I-GENE
- I-GENE
amenorrheic I-GENE
vs I-GENE
1 I-GENE
. I-GENE
077 I-GENE
+/- I-GENE
0 I-GENE
. I-GENE
029 I-GENE
or I-GENE
1 I-GENE
. I-GENE
051 I-GENE
+/- I-GENE
0 I-GENE
. I-GENE
017 I-GENE
g I-GENE
x I-GENE
cm I-GENE
(- I-GENE
2 I-GENE
), I-GENE
P I-GENE
< I-GENE
0 I-GENE
. I-GENE
005 I-GENE
, I-GENE
in I-GENE
the I-GENE
eumenorrheic I-GENE
and I-GENE
contraceptive I-GENE
user I-GENE
groups I-GENE
, I-GENE
respectively I-GENE
) I-GENE
but I-GENE
not I-GENE
in I-GENE
weight I-GENE
- I-GENE
bearing I-GENE
bone I-GENE
such I-GENE
as I-GENE
proximal I-GENE
and I-GENE
midshaft I-GENE
femur I-GENE
. I-GENE

The O
glucose O
/ O
insulin I-GENE
stimulation O
was O
inhibited O
by O
the O
addition O
of O
polyunsaturated O
fatty O
acids O
. O

We O
report O
the O
results O
of I-GENE
a I-GENE
detailed I-GENE
policy I-GENE
analysis I-GENE
comparing I-GENE
2 I-GENE
CJD I-GENE
- I-GENE
related I-GENE
decisions I-GENE
: I-GENE
a I-GENE
1995 I-GENE
recall I-GENE
of I-GENE
blood I-GENE
from I-GENE
a I-GENE
donor I-GENE
with I-GENE
classic I-GENE
CJD I-GENE
and I-GENE
the I-GENE
1999 I-GENE
decision I-GENE
to I-GENE
defer I-GENE
donations I-GENE
from I-GENE
individuals I-GENE
with I-GENE
a I-GENE
6 I-GENE
- I-GENE
month I-GENE
travel I-GENE
history I-GENE
to I-GENE
the I-GENE
UK I-GENE
between I-GENE
1980 I-GENE
and I-GENE
1996 I-GENE
due I-GENE
to I-GENE
concerns I-GENE
related I-GENE
to I-GENE
variant I-GENE
CJD I-GENE
. I-GENE

The O
5 O
' O
flanking O
sequence O
of O
the O
3B I-GENE
gene I-GENE
is O
extremely O
A O
+ O
T O
rich O
but O
contains O
five O
G I-GENE
/ I-GENE
C I-GENE
rich I-GENE
stretches I-GENE
, I-GENE
each I-GENE
approximately I-GENE
7bp I-GENE
long I-GENE
, I-GENE
which I-GENE
have I-GENE
strong I-GENE
sequence I-GENE
similarity I-GENE
to I-GENE
the I-GENE
G I-GENE
boxes I-GENE
found I-GENE
upstream I-GENE
of I-GENE
other I-GENE
developmentally I-GENE
regulated I-GENE
Dictyostelium I-GENE
genes I-GENE
. I-GENE

PACAP I-GENE
mRNA I-GENE
was I-GENE
widely I-GENE
expressed I-GENE
in I-GENE
most I-GENE
human I-GENE
tissues I-GENE
; I-GENE
in I-GENE
transfected I-GENE
cells I-GENE
, I-GENE
PACAP I-GENE
was I-GENE
diffusely I-GENE
expressed I-GENE
in I-GENE
the I-GENE
cytoplasm I-GENE
. I-GENE

The O
proportion O
of O
the O
biopsies O
found O
to O
be O
seropositive O
for O
HBs I-GENE
antigen I-GENE
was O
27 I-GENE
. I-GENE
9 I-GENE
%, I-GENE
and I-GENE
these I-GENE
showed I-GENE
either I-GENE
MGN I-GENE
or I-GENE
MPGN I-GENE
pattern I-GENE
. I-GENE

In O
the O
present O
study O
, O
we O
have O
determined O
the O
ICBP90 I-GENE
gene I-GENE
structure O
by O
screening O
of O
a O
human O
placenta O
genomic O
library O
and O
PCR O
analysis O
. O

In I-GENE
the I-GENE
stable I-GENE
transfectants I-GENE
( I-GENE
BM3 I-GENE
cells I-GENE
) I-GENE
expressing I-GENE
a I-GENE
mutant I-GENE
bacterial I-GENE
P450 I-GENE
AA I-GENE
epoxygenase I-GENE
, I-GENE
F87V I-GENE
BM3 I-GENE
, I-GENE
which I-GENE
was I-GENE
genetically I-GENE
engineered I-GENE
to I-GENE
metabolize I-GENE
arachidonic I-GENE
acid I-GENE
only I-GENE
to I-GENE
14 I-GENE
, I-GENE
15 I-GENE
- I-GENE
EET I-GENE
, I-GENE
AA I-GENE
did I-GENE
not I-GENE
induce I-GENE
apoptosis I-GENE
and I-GENE
protected I-GENE
against I-GENE
agonist I-GENE
- I-GENE
induced I-GENE
apoptosis I-GENE
. I-GENE

The I-GENE
revitalization I-GENE
of I-GENE
surgery I-GENE
for I-GENE
Parkinson I-GENE
' I-GENE
s I-GENE
disease I-GENE
( I-GENE
PD I-GENE
) I-GENE
has I-GENE
fueled I-GENE
discussion I-GENE
about I-GENE
the I-GENE
best I-GENE
methodology I-GENE
to I-GENE
define I-GENE
the I-GENE
target I-GENE
. I-GENE

Foreigners I-GENE
return I-GENE
. I-GENE

She O
drank O
alcohol O
once O
or O
twice O
a O
week O
and O
regularly O
took O
an O
analgesic O
preparation O
, O
containing O
aspirin O
and O
acetaminophen O
, O
for O
alleviation O
of O
headaches O
. O

The O
authors O
did O
not O
detect O
any O
significant O
correlations O
between O
parameters O
of O
the O
lipids O
of O
bone O
marrow O
and O
leptin I-GENE
levels O
in O
serum O
and O
bone O
marrow O
. O

When O
the O
blood O
clot O
is O
formed O
in O
the O
vitreous O
cavity O
, O
intravitreal O
injection O
of O
t O
- O
PA O
can O
convert O
plasminogen I-GENE
to O
plasmin I-GENE
and O
remove O
the O
clot O
. O

When O
this O
CCAAT O
box O
was O
inserted O
into O
a O
heterologous O
promoter O
construct O
, O
OA O
induction O
was O
dependent O
on O
an O
intact O
CCAAT O
box O
. O

Encouraged I-GENE
by I-GENE
a I-GENE
Dutch I-GENE
study I-GENE
using I-GENE
etidronate I-GENE
/ I-GENE
fluoride I-GENE
in I-GENE
corticoid I-GENE
- I-GENE
induced I-GENE
osteoporosis I-GENE
, I-GENE
we I-GENE
performed I-GENE
a I-GENE
pilot I-GENE
study I-GENE
in I-GENE
33 I-GENE
men I-GENE
with I-GENE
severe I-GENE
established I-GENE
primary I-GENE
osteoporosis I-GENE
giving I-GENE
cyclically I-GENE
etidronate I-GENE
for I-GENE
14 I-GENE
days I-GENE
followed I-GENE
by I-GENE
fluoride I-GENE
plus I-GENE
calcium I-GENE
/ I-GENE
vitamin I-GENE
D I-GENE
for I-GENE
76 I-GENE
days I-GENE
. I-GENE

Far O
Western O
blot O
analysis O
suggested O
that O
the O
tandem O
SH2 I-GENE
domains I-GENE
of I-GENE
SHP2 I-GENE
bind I-GENE
to I-GENE
Gab1 I-GENE
in I-GENE
a I-GENE
specific I-GENE
orientation I-GENE
, I-GENE
in I-GENE
which I-GENE
the I-GENE
N I-GENE
- I-GENE
SH2 I-GENE
domain I-GENE
binds I-GENE
to I-GENE
phosphotyrosine I-GENE
( I-GENE
Tyr I-GENE
( I-GENE
P I-GENE
))- I-GENE
627 I-GENE
and I-GENE
the I-GENE
C I-GENE
- I-GENE
SH2 I-GENE
domain I-GENE
binds I-GENE
to I-GENE
Tyr I-GENE
( I-GENE
P I-GENE
)- I-GENE
659 I-GENE
. I-GENE

Electrophoretic O
mobility O
shift O
assays O
and O
coimmunoprecipitation O
studies O
suggest O
that O
homo O
- I-GENE
and I-GENE
heterodimerization I-GENE
occurs I-GENE
between I-GENE
cKrox I-GENE
family I-GENE
members I-GENE
. I-GENE

Expression O
of O
human I-GENE
RACK1 I-GENE
efficiently O
relieves O
E1A I-GENE
- I-GENE
mediated I-GENE
growth I-GENE
inhibition I-GENE
in I-GENE
HF7c I-GENE
and I-GENE
protects I-GENE
human I-GENE
tumor I-GENE
cells I-GENE
from I-GENE
E1A I-GENE
- I-GENE
induced I-GENE
apoptosis I-GENE
. I-GENE

By I-GENE
using I-GENE
space I-GENE
- I-GENE
discrete I-GENE
/ I-GENE
continuous I-GENE
metapopulation I-GENE
dynamic I-GENE
models I-GENE
and I-GENE
computer I-GENE
simulations I-GENE
, I-GENE
we I-GENE
show I-GENE
that I-GENE
there I-GENE
can I-GENE
be I-GENE
two I-GENE
principally I-GENE
different I-GENE
regimes I-GENE
of I-GENE
metapopulation I-GENE
dynamics I-GENE
. I-GENE

Arterial O
blood O
gas O
tensions O
were O
similar O
across O
all O
ventilation O
modes O
. O

Four O
casein I-GENE
kinase I-GENE
I I-GENE
isoforms I-GENE
are I-GENE
differentially I-GENE
partitioned I-GENE
between I-GENE
nucleus I-GENE
and I-GENE
cytoplasm I-GENE
. I-GENE

CONCLUSION I-GENE
: I-GENE
Extrusion I-GENE
cooking I-GENE
is I-GENE
effective I-GENE
for I-GENE
the I-GENE
inactivation I-GENE
of I-GENE
DON I-GENE
but I-GENE
is I-GENE
of I-GENE
limited I-GENE
value I-GENE
for I-GENE
AFB1 I-GENE
, I-GENE
even I-GENE
if I-GENE
metabisulphite I-GENE
is I-GENE
added I-GENE
. I-GENE

Also O
, O
the O
EWS I-GENE
protein I-GENE
stimulates O
transcription O
mediated O
by O
the O
COOH O
- O
terminal O
transactivation O
domain O
of O
the O
cofactor I-GENE
CREB I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( I-GENE
CBP I-GENE
). O

HSF I-GENE
binds O
DNA O
as O
a O
trimer O
, O
and O
additional O
trimers O
can O
bind O
DNA O
co I-GENE
- I-GENE
operatively I-GENE
. I-GENE

Two I-GENE
cases I-GENE
with I-GENE
marked I-GENE
chronic I-GENE
arm I-GENE
lymphoedema I-GENE
reported I-GENE
major I-GENE
and I-GENE
persistent I-GENE
improvements I-GENE
in I-GENE
arm I-GENE
volume I-GENE
for I-GENE
at I-GENE
least I-GENE
12 I-GENE
months I-GENE
after I-GENE
treatment I-GENE
with I-GENE
HBO2 I-GENE
. I-GENE

Growth I-GENE
hormone I-GENE
and O
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
I I-GENE
receptors I-GENE
in I-GENE
the I-GENE
temporomandibular I-GENE
joint I-GENE
of I-GENE
the I-GENE
rat I-GENE
. I-GENE

Folate I-GENE
metabolism I-GENE
in I-GENE
the I-GENE
human I-GENE
malaria I-GENE
parasite I-GENE
Plasmodium I-GENE
falciparum I-GENE
is I-GENE
an I-GENE
essential I-GENE
activity I-GENE
for I-GENE
cell I-GENE
growth I-GENE
and I-GENE
replication I-GENE
, I-GENE
and I-GENE
the I-GENE
target I-GENE
of I-GENE
an I-GENE
important I-GENE
class I-GENE
of I-GENE
therapeutic I-GENE
agents I-GENE
in I-GENE
widespread I-GENE
use I-GENE
. I-GENE

These I-GENE
results I-GENE
indicate I-GENE
that I-GENE
BACM I-GENE
has I-GENE
antiplaque I-GENE
and I-GENE
stronger I-GENE
antidegradation I-GENE
effects I-GENE
than I-GENE
GLCM I-GENE
. I-GENE

A O
mutation O
in O
the O
C I-GENE
domain I-GENE
of O
Rb I-GENE
, I-GENE
L901Q I-GENE
, I-GENE
has I-GENE
been I-GENE
identified I-GENE
that I-GENE
completely I-GENE
abolishes I-GENE
cdk4 I-GENE
/ I-GENE
D1 I-GENE
phosphorylation I-GENE
of I-GENE
the I-GENE
isolated I-GENE
C I-GENE
domain I-GENE
. I-GENE

Homo I-GENE
- I-GENE
oligomerisation I-GENE
and I-GENE
nuclear I-GENE
localisation I-GENE
of I-GENE
mouse I-GENE
histone I-GENE
deacetylase I-GENE
1 I-GENE
. I-GENE

Energy I-GENE
expenditure I-GENE
was I-GENE
obtained I-GENE
using I-GENE
a I-GENE
primed I-GENE
, I-GENE
3 I-GENE
- I-GENE
hour I-GENE
infusion I-GENE
of I-GENE
NaH I-GENE
( I-GENE
13 I-GENE
) I-GENE
CO I-GENE
( I-GENE
3 I-GENE
'), I-GENE
breath I-GENE
( I-GENE
13 I-GENE
) I-GENE
CO I-GENE
( I-GENE
2 I-GENE
) I-GENE
enrichment I-GENE
determination I-GENE
by I-GENE
isotope I-GENE
ratio I-GENE
mass I-GENE
spectroscopy I-GENE
, I-GENE
and I-GENE
the I-GENE
application I-GENE
of I-GENE
a I-GENE
standard I-GENE
regression I-GENE
equation I-GENE
. I-GENE

Fasting O
gastrin I-GENE
levels O
( O
normal O
range O
: O
25 O
- I-GENE
110 I-GENE
mU I-GENE
/ I-GENE
L I-GENE
) I-GENE
varied I-GENE
from I-GENE
48 I-GENE
. I-GENE
78 I-GENE
mU I-GENE
/ I-GENE
L I-GENE
- I-GENE
168 I-GENE
. I-GENE
20 I-GENE
( I-GENE
mean I-GENE
: I-GENE
85 I-GENE
. I-GENE
23 I-GENE
mU I-GENE
/ I-GENE
L I-GENE
). I-GENE

Identification O
of O
pulmonary O
vein O
stenosis O
after O
radiofrequency O
ablation O
for O
atrial O
fibrillation O
using O
MRI O
. O

The I-GENE
continuing I-GENE
development I-GENE
of I-GENE
ligands I-GENE
that I-GENE
function I-GENE
as I-GENE
selective I-GENE
estrogens I-GENE
or I-GENE
antiestrogens I-GENE
for I-GENE
ERalpha I-GENE
or I-GENE
ERbeta I-GENE
should I-GENE
allow I-GENE
optimized I-GENE
tissue I-GENE
selectivity I-GENE
of I-GENE
these I-GENE
agents I-GENE
for I-GENE
menopausal I-GENE
hormone I-GENE
replacement I-GENE
therapy I-GENE
and I-GENE
the I-GENE
treatment I-GENE
and I-GENE
prevention I-GENE
of I-GENE
breast I-GENE
cancer I-GENE
. I-GENE

Baseline I-GENE
variables I-GENE
associated I-GENE
with I-GENE
CD I-GENE
included I-GENE
a I-GENE
less I-GENE
frequent I-GENE
use I-GENE
of I-GENE
prestroke I-GENE
aspirin I-GENE
and I-GENE
a I-GENE
higher I-GENE
incidence I-GENE
of I-GENE
early I-GENE
CT I-GENE
changes I-GENE
of I-GENE
edema I-GENE
or I-GENE
mass I-GENE
effect I-GENE
or I-GENE
dense I-GENE
middle I-GENE
cerebral I-GENE
artery I-GENE
sign I-GENE
. I-GENE

A O
peculiar O
people O
: O
" I-GENE
the I-GENE
physiological I-GENE
aspects I-GENE
of I-GENE
Mormonism I-GENE
1850 I-GENE
- I-GENE
1975 I-GENE
." I-GENE

SH2D1A I-GENE
protein I-GENE
levels I-GENE
are I-GENE
up I-GENE
- I-GENE
regulated I-GENE
by I-GENE
CD40 I-GENE
cross I-GENE
- I-GENE
linking I-GENE
and I-GENE
down I-GENE
- I-GENE
regulated I-GENE
by I-GENE
B I-GENE
cell I-GENE
receptor I-GENE
ligation I-GENE
. I-GENE

The I-GENE
Genescan I-GENE
program I-GENE
predicted I-GENE
an I-GENE
open I-GENE
reading I-GENE
frame I-GENE
of I-GENE
a I-GENE
novel I-GENE
, I-GENE
intron I-GENE
- I-GENE
less I-GENE
gene I-GENE
adjacent I-GENE
to I-GENE
the I-GENE
B236 I-GENE
spot I-GENE
that I-GENE
encodes I-GENE
a I-GENE
putative I-GENE
493 I-GENE
- I-GENE
amino I-GENE
acid I-GENE
protein I-GENE
containing I-GENE
the I-GENE
SNAG I-GENE
repressor I-GENE
motif I-GENE
in I-GENE
the I-GENE
NH2 I-GENE
- I-GENE
terminal I-GENE
region I-GENE
and I-GENE
five I-GENE
C2H2 I-GENE
- I-GENE
type I-GENE
zinc I-GENE
finger I-GENE
motifs I-GENE
in I-GENE
the I-GENE
COOH I-GENE
- I-GENE
terminal I-GENE
half I-GENE
. I-GENE

Under O
our O
conditions O
, O
the O
combination O
O3 O
/ O
UV O
did O
not O
improve O
the I-GENE
degradation I-GENE
rate I-GENE
obtained I-GENE
by I-GENE
ozonation I-GENE
. I-GENE

The O
metabolic O
events O
occurring O
at O
or O
near O
that O
structure O
and O
involving O
cyclin I-GENE
D3 I-GENE
cause O
the O
translocation O
of O
ICP0 I-GENE
to O
the O
cytoplasm O
. O

In O
the O
single O
case O
the O
restoration O
of I-GENE
a I-GENE
structured I-GENE
daily I-GENE
routine I-GENE
represents I-GENE
the I-GENE
presupposition I-GENE
for I-GENE
a I-GENE
cognitive I-GENE
therapy I-GENE
. I-GENE

Immunofluorescence O
studies O
in O
C2C12 O
myotubes O
show O
that O
Smad2 I-GENE
and I-GENE
MEF2A I-GENE
co I-GENE
- I-GENE
localise I-GENE
in I-GENE
the I-GENE
nucleus I-GENE
of I-GENE
multinuclear I-GENE
myotubes I-GENE
during I-GENE
differentiation I-GENE
. I-GENE

In O
35 I-GENE
of I-GENE
those I-GENE
patients I-GENE
DD I-GENE
was I-GENE
measured I-GENE
also I-GENE
with I-GENE
microlatex I-GENE
tests I-GENE
-- I-GENE
Tinaquant I-GENE
and I-GENE
BC I-GENE
d I-GENE
- I-GENE
dimer I-GENE
. I-GENE

Simulating I-GENE
the I-GENE
impact I-GENE
during I-GENE
human I-GENE
jumping I-GENE
by I-GENE
means I-GENE
of I-GENE
a I-GENE
4 I-GENE
- I-GENE
degrees I-GENE
- I-GENE
of I-GENE
- I-GENE
freedom I-GENE
model I-GENE
with I-GENE
time I-GENE
- I-GENE
dependent I-GENE
properties I-GENE
. I-GENE

A O
novel O
approach O
was O
developed O
for O
identifying O
transcription O
factor O
activities O
associated O
with O
NGF I-GENE
- I-GENE
activated I-GENE
, O
but O
not O
EGF I-GENE
- I-GENE
activated I-GENE
, O
signaling O
, O
using O
random O
oligonucleotide O
clones O
from O
a O
DNA O
recognition O
library O
to O
isolate O
specific O
DNA O
binding O
proteins O
from O
PC12 O
nuclear O
extracts O
. O

Atheroma I-GENE
appears I-GENE
as I-GENE
a I-GENE
very I-GENE
low I-GENE
signal I-GENE
intensity I-GENE
area I-GENE
on I-GENE
2 I-GENE
- I-GENE
dimensional I-GENE
time I-GENE
- I-GENE
of I-GENE
- I-GENE
flight I-GENE
( I-GENE
TOF I-GENE
) I-GENE
magnetic I-GENE
resonance I-GENE
( I-GENE
MR I-GENE
) I-GENE
images I-GENE
, I-GENE
and I-GENE
its I-GENE
components I-GENE
have I-GENE
various I-GENE
signal I-GENE
intensities I-GENE
on I-GENE
spin I-GENE
- I-GENE
echo I-GENE
( I-GENE
SE I-GENE
) I-GENE
images I-GENE
. I-GENE

Finally O
a O
10 O
- O
nucleotide O
region O
flanking O
the O
exon O
4 I-GENE
protein I-GENE
- I-GENE
binding I-GENE
site I-GENE
is O
homologous O
to O
instability O
elements O
within O
five O
other O
transcripts O
, O
suggesting O
that O
a O
common O
coding O
region O
determinant O
may O
exist O
. O

Chronic O
nutritional O
diseases O
of O
infectious O
origin O
: O
an O
assessment O
of O
a O
nascent O
field O
. O

The O
cut O
- O
off O
percentage O
positivity O
value O
was O
established O
using O
500 O
brucellosis O
- O
positive O
and O
500 O
brucellosis O
- O
negative O
serum O
samples O
, O
confirmed O
with O
reference O
to O
the O
sample O
data O
using O
the O
indirect O
ELISA O
kit O
. O

PROCEDURE I-GENE
: I-GENE
Cannulas I-GENE
were I-GENE
surgically I-GENE
positioned I-GENE
in I-GENE
the I-GENE
abomasal I-GENE
body I-GENE
and I-GENE
pyloric I-GENE
antrum I-GENE
of I-GENE
each I-GENE
calf I-GENE
. I-GENE

The I-GENE
utilities I-GENE
measured I-GENE
in I-GENE
our I-GENE
study I-GENE
can I-GENE
be I-GENE
applied I-GENE
directly I-GENE
to I-GENE
quality I-GENE
- I-GENE
of I-GENE
- I-GENE
life I-GENE
determinations I-GENE
in I-GENE
clinical I-GENE
trials I-GENE
of I-GENE
adjuvant I-GENE
IFN I-GENE
alpha I-GENE
- I-GENE
2b I-GENE
to I-GENE
measure I-GENE
the I-GENE
net I-GENE
benefit I-GENE
of I-GENE
therapy I-GENE
. I-GENE

Cells O
lacking O
p116 I-GENE
exhibit O
a O
striking O
defect O
in I-GENE
the I-GENE
formation I-GENE
of I-GENE
these I-GENE
macropinocytic I-GENE
structures I-GENE
, I-GENE
a I-GENE
concomitant I-GENE
reduction I-GENE
in I-GENE
the I-GENE
rate I-GENE
of I-GENE
fluid I-GENE
phase I-GENE
pinocytosis I-GENE
, I-GENE
a I-GENE
significant I-GENE
decrease I-GENE
in I-GENE
the I-GENE
efficiency I-GENE
of I-GENE
chemotactic I-GENE
aggregation I-GENE
, I-GENE
and I-GENE
a I-GENE
decrease I-GENE
in I-GENE
cellular I-GENE
F I-GENE
- I-GENE
actin I-GENE
content I-GENE
. I-GENE

Ectopic O
expression O
of O
the O
dominant I-GENE
mutant I-GENE
Lg3 I-GENE
allele I-GENE
is I-GENE
believed I-GENE
to I-GENE
cause I-GENE
the I-GENE
phenotype I-GENE
. I-GENE

Specimen I-GENE
mass I-GENE
reduction I-GENE
increased I-GENE
with I-GENE
irradiance I-GENE
from I-GENE
19 I-GENE
to I-GENE
72 I-GENE
% I-GENE
of I-GENE
the I-GENE
initial I-GENE
mass I-GENE
for I-GENE
9 I-GENE
-- I-GENE
31 I-GENE
W I-GENE
/ I-GENE
cm I-GENE
( I-GENE
2 I-GENE
), I-GENE
respectively I-GENE
. I-GENE

Analysis O
of O
the O
genome O
sequence O
revealed O
26 O
, O
588 O
protein I-GENE
- I-GENE
encoding I-GENE
transcripts I-GENE
for I-GENE
which I-GENE
there I-GENE
was I-GENE
strong I-GENE
corroborating I-GENE
evidence I-GENE
and I-GENE
an I-GENE
additional I-GENE
approximately I-GENE
12 I-GENE
, I-GENE
000 I-GENE
computationally I-GENE
derived I-GENE
genes I-GENE
with I-GENE
mouse I-GENE
matches I-GENE
or I-GENE
other I-GENE
weak I-GENE
supporting I-GENE
evidence I-GENE
. I-GENE

The O
other O
inhibitor O
was O
a O
single O
TAR O
decoy O
, O
driven O
by O
the O
U6 I-GENE
small I-GENE
nuclear I-GENE
RNA I-GENE
promoter I-GENE
( I-GENE
U6 I-GENE
- I-GENE
P I-GENE
). O

By O
comparison O
, O
in O
nontumorigenic O
Ad5 O
cells O
, O
class O
I O
expression O
is O
high O
due O
to O
negligible O
binding O
of O
COUP I-GENE
- I-GENE
TF I-GENE
and O
strong O
binding O
of O
NF I-GENE
- I-GENE
kappaB I-GENE
. O

Moreover O
, O
a O
complex O
containing O
PTP I-GENE
phi I-GENE
, O
paxillin I-GENE
, O
and O
a O
paxillin I-GENE
- I-GENE
associated I-GENE
tyrosine I-GENE
kinase I-GENE
, O
Pyk2 I-GENE
, O
can O
be O
immunoprecipitated O
from O
macrophage O
lysates O
, O
and O
the O
catalytic O
domain O
of O
PTP I-GENE
phi I-GENE
selectively O
binds O
paxillin I-GENE
and O
Pyk2 I-GENE
in O
vitro O
. O

Our O
previous O
studies O
have O
shown O
that O
SHP I-GENE
- I-GENE
1 I-GENE
, O
a O
SH2 I-GENE
domain I-GENE
- I-GENE
containing I-GENE
protein I-GENE
- I-GENE
tyrosine I-GENE
phosphatase I-GENE
, O
is O
expressed O
not O
only O
in O
cells O
of O
hematopoietic O
lineages O
, O
but O
also O
in O
many O
non O
- O
hematopoietic O
cells O
under O
the O
control O
of O
an O
alternative O
tissue O
- O
specific O
promoter O
, O
P1 O
. O

Whereas O
Smad2 I-GENE
was O
rapidly O
phosphorylated O
by O
TGF I-GENE
- I-GENE
beta I-GENE
and O
involved O
in O
the O
initial O
activation I-GENE
of I-GENE
Agc I-GENE
expression I-GENE
in I-GENE
confluent I-GENE
cells I-GENE
, I-GENE
Smad2 I-GENE
activation I-GENE
was I-GENE
not I-GENE
required I-GENE
for I-GENE
maintaining I-GENE
the I-GENE
high I-GENE
level I-GENE
of I-GENE
Agc I-GENE
expression I-GENE
. I-GENE

The I-GENE
astronaut I-GENE
crew I-GENE
operates I-GENE
the I-GENE
payload I-GENE
and I-GENE
documents I-GENE
its I-GENE
operation I-GENE
. I-GENE

This O
molecule I-GENE
, I-GENE
wH22xeGFP I-GENE
, I-GENE
consists I-GENE
of I-GENE
the I-GENE
entire I-GENE
humanized I-GENE
anti I-GENE
- I-GENE
FcgammaRI I-GENE
mAb I-GENE
H22 I-GENE
with I-GENE
eGFP I-GENE
genetically I-GENE
fused I-GENE
to I-GENE
the I-GENE
C I-GENE
- I-GENE
terminal I-GENE
end I-GENE
of I-GENE
each I-GENE
CH3 I-GENE
domain I-GENE
. I-GENE
wH22xeGFP I-GENE
binds I-GENE
within I-GENE
the I-GENE
ligand I-GENE
- I-GENE
binding I-GENE
region I-GENE
by I-GENE
its I-GENE
Fc I-GENE
end I-GENE
, I-GENE
as I-GENE
well I-GENE
as I-GENE
outside I-GENE
the I-GENE
ligand I-GENE
- I-GENE
binding I-GENE
region I-GENE
by I-GENE
its I-GENE
Fab I-GENE
ends I-GENE
, I-GENE
thereby I-GENE
cross I-GENE
- I-GENE
linking I-GENE
FcgammaRI I-GENE
. I-GENE

On O
the O
other O
hand O
, O
hepatic O
arterial O
infusion O
therapy O
prolongs O
the O
survival O
of O
H3 O
patients O
only O
. O

Hepatitis O
B O
and O
C O
seroprevalence O
rates O
among O
high O
- O
risk O
adolescents O
are O
lower O
in O
El O
Paso O
than O
in O
other O
similar O
US O
populations O
, I-GENE
presenting I-GENE
an I-GENE
ideal I-GENE
climate I-GENE
for I-GENE
prevention I-GENE
programs I-GENE
. I-GENE

We O
found O
that O
the O
SOCS I-GENE
box I-GENE
interacted I-GENE
with I-GENE
Cullin I-GENE
- I-GENE
2 I-GENE
and I-GENE
promoted I-GENE
ubiquitination I-GENE
of I-GENE
TEL I-GENE
- I-GENE
JAK2 I-GENE
. I-GENE

A O
patient O
is O
described O
with O
skin O
lesions O
resembling O
Kaposi O
' O
s O
sarcoma O
( O
KS O
). O

Special I-GENE
issues I-GENE
devoted I-GENE
to I-GENE
the I-GENE
biosynthesis I-GENE
of I-GENE
woody I-GENE
plant I-GENE
biopolymers I-GENE
and I-GENE
related I-GENE
substances I-GENE
. I-GENE

These I-GENE
data I-GENE
suggest I-GENE
that I-GENE
ADAM I-GENE
- I-GENE
TS12 I-GENE
may I-GENE
play I-GENE
roles I-GENE
in I-GENE
pulmonary I-GENE
cells I-GENE
during I-GENE
fetal I-GENE
development I-GENE
or I-GENE
in I-GENE
tumor I-GENE
processes I-GENE
through I-GENE
its I-GENE
proteolytic I-GENE
activity I-GENE
or I-GENE
as I-GENE
a I-GENE
molecule I-GENE
potentially I-GENE
involved I-GENE
in I-GENE
regulation I-GENE
of I-GENE
cell I-GENE
adhesion I-GENE
. I-GENE

Progressive I-GENE
study I-GENE
and I-GENE
robustness I-GENE
test I-GENE
of I-GENE
QSAR I-GENE
model I-GENE
based I-GENE
on I-GENE
quantum I-GENE
chemical I-GENE
parameters I-GENE
for I-GENE
predicting I-GENE
BCF I-GENE
of I-GENE
selected I-GENE
polychlorinated I-GENE
organic I-GENE
compounds I-GENE
( I-GENE
PCOCs I-GENE
). I-GENE

Additional O
deletion O
mutations O
revealed O
a O
new O
, O
67 O
- O
amino O
- O
acid O
functional O
domain O
within O
the O
proline O
- O
rich O
region O
of O
SLP I-GENE
- I-GENE
76 I-GENE
, O
which O
we O
have O
termed O
the O
P I-GENE
- I-GENE
1 I-GENE
domain I-GENE
. O

Patients O
with O
type I-GENE
III I-GENE
SOD I-GENE
may I-GENE
have I-GENE
visceral I-GENE
hyperalgesia I-GENE
; I-GENE
a I-GENE
trial I-GENE
of I-GENE
antidepressants I-GENE
or I-GENE
a I-GENE
therapeutic I-GENE
trial I-GENE
with I-GENE
botulinum I-GENE
toxin I-GENE
injection I-GENE
into I-GENE
the I-GENE
ampulla I-GENE
should I-GENE
be I-GENE
considered I-GENE
prior I-GENE
to I-GENE
more I-GENE
invasive I-GENE
endoscopic I-GENE
therapy I-GENE
. I-GENE

We O
have O
now O
tested O
all O
known O
mammalian I-GENE
Groucho I-GENE
family I-GENE
members O
for O
their O
ability O
to O
interact O
specifically O
with O
individual O
Tcf I-GENE
/ I-GENE
Lef I-GENE
family I-GENE
members I-GENE
. O

Body O
weight O
reduction O
increases O
insulin I-GENE
sensitivity O
and O
improves O
both O
blood O
glucose O
and O
blood O
pressure O
control O
. O

Sequence I-GENE
analysis I-GENE
indicates I-GENE
that I-GENE
RBP21 I-GENE
shares I-GENE
homology I-GENE
with I-GENE
other I-GENE
retinoblastoma I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
in I-GENE
the I-GENE
pRb I-GENE
- I-GENE
binding I-GENE
motif I-GENE
LxCxE I-GENE
at I-GENE
the I-GENE
C I-GENE
- I-GENE
terminal I-GENE
region I-GENE
. I-GENE

Tolerance O
in O
renal O
transplantation O
after O
allogeneic O
bone O
marrow O
transplantation O
- O
6 O
- O
year O
follow O
- O
up O
. O

By O
analyzing O
5 O
'- O
deletion O
insulin I-GENE
promoter I-GENE
- I-GENE
reporter I-GENE
constructs O
in O
transient O
transfections O
of O
clonal O
INS O
- I-GENE
1 I-GENE
beta I-GENE
- I-GENE
cells O
, O
we O
located O
activating I-GENE
Hh I-GENE
- I-GENE
responsive I-GENE
regions O
within O
the O
rat I-GENE
insulin I-GENE
I I-GENE
promoter I-GENE
that O
include O
the O
glucose O
- O
response O
elements O
Far O
( O
E2 I-GENE
) I-GENE
and I-GENE
Flat I-GENE
( I-GENE
A2 I-GENE
/ I-GENE
A3 I-GENE
). I-GENE

However O
, O
when O
directed O
to O
the O
nucleosome O
by O
fusion O
to O
core I-GENE
histone I-GENE
H2A I-GENE
or O
H2B I-GENE
, O
the O
non O
- I-GENE
histone I-GENE
tail O
forms O
an O
MCB I-GENE
that O
appears O
identical O
to O
that O
of O
the O
endogenous O
protein O
. O

Data O
were O
obtained O
from I-GENE
2 I-GENE
undergraduate I-GENE
student I-GENE
samples I-GENE
, I-GENE
a I-GENE
self I-GENE
- I-GENE
report I-GENE
group I-GENE
( I-GENE
n I-GENE
= I-GENE
132 I-GENE
) I-GENE
who I-GENE
provided I-GENE
NEO I-GENE
- I-GENE
PI I-GENE
- I-GENE
R I-GENE
self I-GENE
- I-GENE
ratings I-GENE
on I-GENE
2 I-GENE
occasions I-GENE
separated I-GENE
by I-GENE
a I-GENE
7 I-GENE
- I-GENE
to I-GENE
14 I-GENE
- I-GENE
day I-GENE
interval I-GENE
and I-GENE
an I-GENE
informant I-GENE
group I-GENE
( I-GENE
n I-GENE
= I-GENE
109 I-GENE
) I-GENE
who I-GENE
provided I-GENE
ratings I-GENE
of I-GENE
well I-GENE
- I-GENE
known I-GENE
friends I-GENE
or I-GENE
relatives I-GENE
on I-GENE
2 I-GENE
occasions I-GENE
separated I-GENE
by I-GENE
a I-GENE
6 I-GENE
month I-GENE
interval I-GENE
. I-GENE

Pulmonary I-GENE
embolectomy I-GENE
and I-GENE
lung I-GENE
transplantation I-GENE
are I-GENE
the I-GENE
main I-GENE
indications I-GENE
for I-GENE
the I-GENE
use I-GENE
of I-GENE
heart I-GENE
- I-GENE
lung I-GENE
- I-GENE
machine I-GENE
. I-GENE

Comparison O
of O
German O
language O
versions O
of I-GENE
the I-GENE
QWB I-GENE
- I-GENE
SA I-GENE
and I-GENE
SF I-GENE
- I-GENE
36 I-GENE
evaluating I-GENE
outcomes I-GENE
for I-GENE
patients I-GENE
with I-GENE
prostate I-GENE
disease I-GENE
. I-GENE

The O
median O
preoperative O
best O
- O
corrected O
visual O
acuity O
of O
0 I-GENE
. I-GENE
08 I-GENE
( I-GENE
range I-GENE
hand I-GENE
motions I-GENE
/ I-GENE
0 I-GENE
. I-GENE
003 I-GENE
to I-GENE
0 I-GENE
. I-GENE
4 I-GENE
), I-GENE
improved I-GENE
by I-GENE
5 I-GENE
lines I-GENE
to I-GENE
a I-GENE
median I-GENE
final I-GENE
postoperative I-GENE
best I-GENE
- I-GENE
corrected I-GENE
visual I-GENE
acuity I-GENE
of I-GENE
0 I-GENE
. I-GENE
25 I-GENE
( I-GENE
range I-GENE
0 I-GENE
. I-GENE
025 I-GENE
- I-GENE
0 I-GENE
. I-GENE
5 I-GENE
) I-GENE
( I-GENE
P I-GENE
= I-GENE
0 I-GENE
. I-GENE
001 I-GENE
). I-GENE

Angina O
( O
Q O
) O
persistence O
showed O
marked O
associations O
with O
previous O
myocardial O
infarction O
, O
diagnosed O
angina O
, O
electrocardiogram O
ischemia O
, O
and O
subsequent O
major O
ischemic O
heart I-GENE
disease I-GENE
events I-GENE
from I-GENE
Q5 I-GENE
onward I-GENE
. I-GENE

Site I-GENE
- I-GENE
directed I-GENE
mutagenesis I-GENE
of I-GENE
CAR I-GENE
revealed I-GENE
that I-GENE
CAR I-GENE
residues I-GENE
Leu73 I-GENE
and I-GENE
Lys121 I-GENE
and I-GENE
/ I-GENE
or I-GENE
Lys123 I-GENE
are I-GENE
critical I-GENE
contact I-GENE
residues I-GENE
, I-GENE
with I-GENE
Tyr80 I-GENE
and I-GENE
Tyr83 I-GENE
being I-GENE
peripherally I-GENE
involved I-GENE
in I-GENE
the I-GENE
binding I-GENE
interaction I-GENE
with I-GENE
the I-GENE
Ad5 I-GENE
, I-GENE
Ad9 I-GENE
, I-GENE
Ad12 I-GENE
, I-GENE
and I-GENE
Ad41L I-GENE
fiber I-GENE
knobs I-GENE
. I-GENE

Transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta I-GENE
( I-GENE
TGF I-GENE
- I-GENE
beta I-GENE
) O
induced O
growth O
arrest O
of O
cells O
involves O
regulation O
of O
the O
activities O
of O
both O
D O
- O
and O
E I-GENE
- I-GENE
type I-GENE
cyclin I-GENE
kinase I-GENE
complexes I-GENE
thought O
to O
be O
mediated O
primarily O
by O
the O
regulation O
of O
p15 I-GENE
( I-GENE
Ink4b I-GENE
) I-GENE
and I-GENE
p27 I-GENE
( I-GENE
Kip1 I-GENE
) I-GENE
cyclin I-GENE
kinase I-GENE
inhibitors I-GENE
. I-GENE

These I-GENE
data I-GENE
indicate I-GENE
that I-GENE
the I-GENE
SmSmad2 I-GENE
responds I-GENE
to I-GENE
the I-GENE
TGF I-GENE
- I-GENE
beta I-GENE
signals I-GENE
by I-GENE
interaction I-GENE
with I-GENE
receptor I-GENE
I I-GENE
, I-GENE
which I-GENE
phosphorylates I-GENE
it I-GENE
, I-GENE
whereupon I-GENE
it I-GENE
translocates I-GENE
into I-GENE
the I-GENE
nucleus I-GENE
presumably I-GENE
to I-GENE
regulate I-GENE
target I-GENE
gene I-GENE
transcription I-GENE
and I-GENE
consequently I-GENE
elicit I-GENE
a I-GENE
specific I-GENE
TGF I-GENE
- I-GENE
beta I-GENE
effect I-GENE
. I-GENE

We O
propose O
that O
TFOs O
represent O
a O
therapeutic O
potential O
to O
specifically O
diminish O
the O
expression O
of O
c I-GENE
- I-GENE
sis I-GENE
/ I-GENE
PDGF I-GENE
- I-GENE
B I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
in O
various O
pathologic O
settings O
where O
constitutive O
expression O
of O
this O
gene O
has O
been O
observed O
. O

The I-GENE
increased I-GENE
clearance I-GENE
observed I-GENE
in I-GENE
young I-GENE
infants I-GENE
is I-GENE
in I-GENE
contrast I-GENE
to I-GENE
other I-GENE
opioids I-GENE
. I-GENE

Peripheral I-GENE
metabolism I-GENE
of I-GENE
androgens I-GENE
takes I-GENE
place I-GENE
in I-GENE
various I-GENE
areas I-GENE
within I-GENE
the I-GENE
pilosebaceous I-GENE
unit I-GENE
, I-GENE
as I-GENE
indicated I-GENE
by I-GENE
local I-GENE
differences I-GENE
in I-GENE
the I-GENE
activities I-GENE
of I-GENE
aromatase I-GENE
, I-GENE
5alpha I-GENE
- I-GENE
reductase I-GENE
as I-GENE
well I-GENE
as I-GENE
of I-GENE
the I-GENE
presence I-GENE
of I-GENE
the I-GENE
androgen I-GENE
receptors I-GENE
. I-GENE

This O
unique O
location O
of O
cavernous O
malformation O
is O
associated O
with O
a O
risk O
of O
permanent O
loss O
of O
the O
vision O
. O

The I-GENE
JHRLSS I-GENE
has I-GENE
been I-GENE
used I-GENE
in I-GENE
prior I-GENE
studies I-GENE
to I-GENE
assess I-GENE
RLS I-GENE
severity I-GENE
, I-GENE
but I-GENE
has I-GENE
not I-GENE
previously I-GENE
been I-GENE
validated I-GENE
in I-GENE
relation I-GENE
to I-GENE
direct I-GENE
measures I-GENE
of I-GENE
the I-GENE
morbidity I-GENE
associated I-GENE
with I-GENE
RLS I-GENE
. I-GENE

Consistent I-GENE
effects I-GENE
on I-GENE
pVHL I-GENE
function I-GENE
were I-GENE
observed I-GENE
for I-GENE
all I-GENE
mutations I-GENE
within I-GENE
each I-GENE
subclass I-GENE
. I-GENE

Interestingly O
, I-GENE
the I-GENE
CYP71D20 I-GENE
- I-GENE
encoded I-GENE
enzyme I-GENE
activity I-GENE
was I-GENE
capable I-GENE
of I-GENE
converting I-GENE
both I-GENE
5 I-GENE
- I-GENE
epi I-GENE
- I-GENE
aristolochene I-GENE
and I-GENE
1 I-GENE
- I-GENE
deoxycapsidiol I-GENE
to I-GENE
capsidiol I-GENE
in I-GENE
vitro I-GENE
, I-GENE
consistent I-GENE
with I-GENE
the I-GENE
notion I-GENE
that I-GENE
this I-GENE
P450 I-GENE
enzyme I-GENE
catalyzes I-GENE
both I-GENE
hydroxylations I-GENE
of I-GENE
its I-GENE
hydrocarbon I-GENE
substrate I-GENE
. I-GENE

A I-GENE
new I-GENE
species I-GENE
of I-GENE
Euspondylus I-GENE
is I-GENE
described I-GENE
based I-GENE
on I-GENE
a I-GENE
female I-GENE
( I-GENE
taken I-GENE
within I-GENE
a I-GENE
bromeliad I-GENE
) I-GENE
from I-GENE
Cerro I-GENE
El I-GENE
Humo I-GENE
, I-GENE
Sucre I-GENE
, I-GENE
northeastern I-GENE
Venezuela I-GENE
. I-GENE

The I-GENE
most I-GENE
important I-GENE
finding I-GENE
, I-GENE
however I-GENE
, I-GENE
was I-GENE
that I-GENE
IMT I-GENE
values I-GENE
were I-GENE
related I-GENE
with I-GENE
24 I-GENE
h I-GENE
SBP I-GENE
or I-GENE
PP I-GENE
standard I-GENE
deviation I-GENE
( I-GENE
P I-GENE
< I-GENE
0 I-GENE
. I-GENE
001 I-GENE
), I-GENE
a I-GENE
measure I-GENE
of I-GENE
overall I-GENE
SBP I-GENE
or I-GENE
PP I-GENE
variability I-GENE
. I-GENE

In O
addition O
, O
severe O
vision O
loss O
can O
be O
seen O
with O
interferon I-GENE
alfa I-GENE
- I-GENE
2b I-GENE
- I-GENE
associated O
retinopathy O
. O

FLP I-GENE
and I-GENE
Cre I-GENE
recombinase I-GENE
function I-GENE
in I-GENE
Xenopus I-GENE
embryos I-GENE
. I-GENE

Keratoconjunctivitis I-GENE
sicca I-GENE
appears I-GENE
to I-GENE
be I-GENE
a I-GENE
common I-GENE
ocular I-GENE
complication I-GENE
and I-GENE
all I-GENE
children I-GENE
with I-GENE
JRA I-GENE
should I-GENE
be I-GENE
screened I-GENE
for I-GENE
it I-GENE
with I-GENE
a I-GENE
comprehensive I-GENE
battery I-GENE
of I-GENE
tests I-GENE
. I-GENE

Moreover I-GENE
, I-GENE
PTax I-GENE
expressed I-GENE
higher I-GENE
background I-GENE
activities I-GENE
than I-GENE
PTF I-GENE
, I-GENE
indicating I-GENE
that I-GENE
the I-GENE
sequence I-GENE
of I-GENE
the I-GENE
synthetic I-GENE
regulatory I-GENE
region I-GENE
can I-GENE
influence I-GENE
background I-GENE
levels I-GENE
. I-GENE

After I-GENE
allowing I-GENE
time I-GENE
for I-GENE
absorption I-GENE
, I-GENE
participants I-GENE
completed I-GENE
a I-GENE
bridge I-GENE
simulator I-GENE
task I-GENE
. I-GENE

The O
cleavage O
site O
between O
VPg I-GENE
and O
RNA I-GENE
dependent I-GENE
RNA I-GENE
polymerase I-GENE
was I-GENE
predicted I-GENE
to I-GENE
be I-GENE
E445 I-GENE
- I-GENE
T446 I-GENE
based I-GENE
on I-GENE
the I-GENE
amino I-GENE
acid I-GENE
sequence I-GENE
analysis I-GENE
of I-GENE
the I-GENE
polyprotein I-GENE
from I-GENE
different I-GENE
sobemoviruses I-GENE
. I-GENE

Conformational O
changes O
of I-GENE
the I-GENE
ferric I-GENE
uptake I-GENE
regulation I-GENE
protein I-GENE
upon I-GENE
metal I-GENE
activation I-GENE
and I-GENE
DNA I-GENE
binding I-GENE
; I-GENE
first I-GENE
evidence I-GENE
of I-GENE
structural I-GENE
homologies I-GENE
with I-GENE
the I-GENE
diphtheria I-GENE
toxin I-GENE
repressor I-GENE
. I-GENE

At O
visit O
5 O
, I-GENE
the I-GENE
isokinetic I-GENE
test I-GENE
showed I-GENE
impaired I-GENE
muscle I-GENE
function I-GENE
recovery I-GENE
from I-GENE
23 I-GENE
% I-GENE
to I-GENE
32 I-GENE
%, I-GENE
while I-GENE
the I-GENE
manual I-GENE
test I-GENE
showed I-GENE
almost I-GENE
full I-GENE
recovery I-GENE
. I-GENE

Constitutive O
phosphorylation O
and O
nuclear O
localization O
of O
Smad3 I-GENE
are O
correlated O
with O
increased O
collagen I-GENE
gene I-GENE
transcription I-GENE
in O
activated O
hepatic O
stellate O
cells O
. O

Cholesteryl I-GENE
ester I-GENE
transfer I-GENE
protein I-GENE
and I-GENE
atherosclerosis I-GENE
in I-GENE
Japanese I-GENE
subjects I-GENE
: I-GENE
a I-GENE
study I-GENE
based I-GENE
on I-GENE
coronary I-GENE
angiography I-GENE
. I-GENE

And O
, O
most O
importantly O
, O
reconstitution O
of O
a O
consensus O
CRE O
, O
within O
the O
21 O
- O
bp O
enhancers O
increases O
binding O
of O
CREB I-GENE
/ I-GENE
ATF I-GENE
proteins I-GENE
but O
abrogates O
basal O
repression O
of O
LTR O
- O
directed O
transcription O
in O
vitro O
. O

Stable O
transfection O
of O
human I-GENE
CHOP I-GENE
cDNA I-GENE
into O
mammary O
carcinoma O
cells O
demonstrated O
that O
CHOP O
functioned O
not O
as O
a O
mediator O
of O
hGH I-GENE
- I-GENE
stimulated O
mitogenesis O
but O
rather O
enhanced O
the O
protection O
from O
apoptosis O
afforded O
by O
hGH I-GENE
in O
a O
p38 I-GENE
MAPK I-GENE
- I-GENE
dependent I-GENE
manner O
. O

The O
combination O
of O
ifosfamide O
, O
epirubicin O
and O
etoposide O
( O
IEV O
) O
is O
an O
effective O
salvage O
regimen O
for O
lymphoproliferative O
disease O
. O

Interestingly O
, O
the O
activity O
of O
IkappaB I-GENE
kinase I-GENE
( I-GENE
IKK I-GENE
- I-GENE
beta I-GENE
), O
which O
plays O
an O
essential O
role O
in O
NF I-GENE
- I-GENE
kappaB I-GENE
activation I-GENE
through O
IkappaB I-GENE
phosphorylation O
, O
was O
largely O
enhanced O
in O
paclitaxel O
- O
treated O
cells O
, O
detected O
as O
IkappaBalpha I-GENE
phosphorylation O
. O

The I-GENE
recessive I-GENE
hos1 I-GENE
mutation I-GENE
causes I-GENE
enhanced I-GENE
induction I-GENE
of I-GENE
the I-GENE
CBF I-GENE
transcription I-GENE
factors I-GENE
by I-GENE
low I-GENE
temperature I-GENE
as I-GENE
well I-GENE
as I-GENE
of I-GENE
their I-GENE
downstream I-GENE
cold I-GENE
- I-GENE
responsive I-GENE
genes I-GENE
. I-GENE

Apart O
from O
antimicrobial O
properties O
, O
recent O
data O
indicate O
that O
PMN O
also O
exert O
anti O
- O
inflammatory O
effects O
by O
stimulation O
and O
release O
of O
cytokine O
antagonists O
such O
as O
interleukin I-GENE
- I-GENE
1 I-GENE
receptor I-GENE
antagonist O
( I-GENE
IL I-GENE
- I-GENE
1ra I-GENE
). I-GENE

Early O
indicators O
of O
the O
effect O
of O
a O
breast O
cancer O
screening O
program O
for O
low O
- O
income O
women O
. O

An O
association O
was O
demonstrated O
between O
the O
expression O
of O
aberrantly O
and O
/ O
or O
alternatively I-GENE
spliced I-GENE
mdm2 I-GENE
mRNAs I-GENE
and I-GENE
a I-GENE
lack I-GENE
of I-GENE
progesterone I-GENE
receptor I-GENE
. I-GENE

BACKGROUND I-GENE
: I-GENE
Dermoscopy I-GENE
is I-GENE
a I-GENE
noninvasive I-GENE
technique I-GENE
that I-GENE
increases I-GENE
the I-GENE
diagnostic I-GENE
accuracy I-GENE
of I-GENE
pigmented I-GENE
skin I-GENE
lesions I-GENE
, I-GENE
particularly I-GENE
improving I-GENE
the I-GENE
diagnosis I-GENE
of I-GENE
patients I-GENE
with I-GENE
cutaneous I-GENE
melanoma I-GENE
in I-GENE
situ I-GENE
( I-GENE
CMIS I-GENE
) I-GENE
and I-GENE
early I-GENE
invasive I-GENE
melanoma I-GENE
. I-GENE

Increased O
erythropoietin I-GENE
synthesis I-GENE
in I-GENE
patients I-GENE
with I-GENE
COLD I-GENE
or I-GENE
left I-GENE
heart I-GENE
failure I-GENE
is I-GENE
related I-GENE
to I-GENE
alterations I-GENE
in I-GENE
renal I-GENE
haemodynamics I-GENE
. I-GENE

The O
( O
two O
- O
motif O
) O
domain O
fold O
contains O
a O
pair O
of O
calcium O
binding O
sites O
very O
similar O
to O
those O
found O
in O
a O
two O
- I-GENE
domain I-GENE
prokaryotic I-GENE
betagamma I-GENE
- I-GENE
crystallin I-GENE
fold O
family I-GENE
member I-GENE
, O
Protein I-GENE
S I-GENE
. O

Twenty O
- O
five O
patients O
also O
received O
PET O
examinations O
during O
the O
staging O
procedures O
. O

In I-GENE
the I-GENE
last I-GENE
case I-GENE
, I-GENE
both I-GENE
hydroxychloroquine I-GENE
, I-GENE
carbamazepine I-GENE
and I-GENE
fluvoxamine I-GENE
had I-GENE
a I-GENE
common I-GENE
imputability I-GENE
which I-GENE
was I-GENE
plausible I-GENE
. I-GENE

In O
all O
of O
these O
cases O
, O
expression O
of O
the O
implicated O
genes O
was O
absent O
. O

A O
subset O
of O
patients O
( O
n O
= O
30 I-GENE
) I-GENE
underwent I-GENE
multichannel I-GENE
pressure I-GENE
flow I-GENE
studies I-GENE
, I-GENE
which I-GENE
demonstrated I-GENE
that I-GENE
transrectal I-GENE
HIFU I-GENE
reduces I-GENE
bladder I-GENE
outflow I-GENE
obstruction I-GENE
. I-GENE

Biochemical I-GENE
experiments I-GENE
have I-GENE
shown I-GENE
that I-GENE
CopG I-GENE
co I-GENE
- I-GENE
operatively I-GENE
associates I-GENE
to I-GENE
its I-GENE
target I-GENE
DNA I-GENE
at I-GENE
low I-GENE
protein I-GENE
: I-GENE
DNA I-GENE
ratios I-GENE
, I-GENE
completely I-GENE
protecting I-GENE
four I-GENE
helical I-GENE
turns I-GENE
on I-GENE
the I-GENE
same I-GENE
face I-GENE
of I-GENE
the I-GENE
double I-GENE
helix I-GENE
in I-GENE
both I-GENE
directions I-GENE
from I-GENE
the I-GENE
inverted I-GENE
repeat I-GENE
that I-GENE
constitutes I-GENE
the I-GENE
CopG I-GENE
primary I-GENE
target I-GENE
. I-GENE

The O
mechanism O
of O
ligand O
- I-GENE
activated I-GENE
estrogen I-GENE
receptor I-GENE
alpha I-GENE
( I-GENE
ERalpha I-GENE
)- I-GENE
dependent I-GENE
activation O
of O
gene O
expression O
through O
the O
SRE O
was O
determined O
by O
mutational O
analysis O
of O
the O
promoter O
, O
analysis O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( I-GENE
MAPK I-GENE
) O
pathway O
activation O
by O
E2 O
, O
and O
transforming I-GENE
growth I-GENE
factor I-GENE
alpha I-GENE
( I-GENE
TGF I-GENE
- I-GENE
alpha I-GENE
) O
as O
a O
positive O
control O
. O

This I-GENE
study I-GENE
investigated I-GENE
whether I-GENE
boron I-GENE
would I-GENE
enhance I-GENE
the I-GENE
ability I-GENE
of I-GENE
17beta I-GENE
- I-GENE
estradiol I-GENE
( I-GENE
E2 I-GENE
) I-GENE
or I-GENE
parathyroid I-GENE
hormone I-GENE
( I-GENE
PTH I-GENE
) I-GENE
to I-GENE
improve I-GENE
bone I-GENE
quality I-GENE
in I-GENE
ovariectomized I-GENE
OVX I-GENE
rats I-GENE
. I-GENE

2001 I-GENE
. I-GENE

The I-GENE
Gap69C I-GENE
is I-GENE
a I-GENE
single I-GENE
- I-GENE
copy I-GENE
gene I-GENE
producing I-GENE
a I-GENE
major I-GENE
2 I-GENE
. I-GENE
1 I-GENE
- I-GENE
kb I-GENE
mRNA I-GENE
throughout I-GENE
development I-GENE
, I-GENE
but I-GENE
its I-GENE
amount I-GENE
is I-GENE
decreased I-GENE
in I-GENE
larvae I-GENE
. I-GENE

In O
the O
long O
term O
, O
questions O
still O
remain O
about O
whether O
pre O
- O
dialysis O
rHu I-GENE
EPO I-GENE
either O
speeds O
up O
or O
delays O
the O
onset O
of O
dialysis O
. O

The O
validity O
of O
the O
FPS I-GENE
- I-GENE
R I-GENE
was I-GENE
further I-GENE
supported I-GENE
by I-GENE
strong I-GENE
positive I-GENE
correlations I-GENE
with I-GENE
the I-GENE
VAS I-GENE
( I-GENE
r I-GENE
= I-GENE
0 I-GENE
. I-GENE
92 I-GENE
, I-GENE
N I-GENE
= I-GENE
45 I-GENE
) I-GENE
and I-GENE
the I-GENE
CAS I-GENE
( I-GENE
r I-GENE
= I-GENE
0 I-GENE
. I-GENE
84 I-GENE
, I-GENE
N I-GENE
= I-GENE
45 I-GENE
) I-GENE
in I-GENE
this I-GENE
clinical I-GENE
sample I-GENE
. I-GENE

The I-GENE
BFA I-GENE
System I-GENE
reads I-GENE
a I-GENE
text I-GENE
file I-GENE
with I-GENE
flows I-GENE
, I-GENE
measured I-GENE
with I-GENE
fluorescent I-GENE
microsphere I-GENE
technique I-GENE
, I-GENE
and I-GENE
constructs I-GENE
the I-GENE
lung I-GENE
anatomy I-GENE
with I-GENE
volumetric I-GENE
pixels I-GENE
showing I-GENE
the I-GENE
flows I-GENE
with I-GENE
a I-GENE
color I-GENE
schema I-GENE
. I-GENE

Therefore O
, O
to O
understand O
how O
ErbB1 I-GENE
/ I-GENE
ErbB2 I-GENE
signaling O
contributes O
to O
this O
process O
, O
we O
used O
the O
ErbB I-GENE
kinase I-GENE
inhibitor I-GENE
AG1478in I-GENE
ErbB2 I-GENE
- I-GENE
dependent I-GENE
BT I-GENE
- I-GENE
474 I-GENE
and I-GENE
SKBR I-GENE
- I-GENE
3 I-GENE
human I-GENE
breast I-GENE
cancer I-GENE
cells I-GENE
. I-GENE

Deletion O
analyses O
implicate O
the O
N O
- O
terminal O
110 O
amino O
acids I-GENE
of I-GENE
Grb14 I-GENE
and I-GENE
ankyrin I-GENE
repeats I-GENE
10 I-GENE
- I-GENE
19 I-GENE
of I-GENE
tankyrase I-GENE
2 I-GENE
in I-GENE
mediating I-GENE
this I-GENE
interaction I-GENE
. I-GENE

Hormonal I-GENE
regulation I-GENE
of I-GENE
multiple I-GENE
promoters I-GENE
of I-GENE
the I-GENE
rat I-GENE
mitochondrial I-GENE
glycerol I-GENE
- I-GENE
3 I-GENE
- I-GENE
phosphate I-GENE
dehydrogenase I-GENE
gene I-GENE
: I-GENE
identification I-GENE
of I-GENE
a I-GENE
complex I-GENE
hormone I-GENE
- I-GENE
response I-GENE
element I-GENE
in I-GENE
the I-GENE
ubiquitous I-GENE
promoter I-GENE
B I-GENE
. I-GENE

SAMPLE I-GENE
POPULATION I-GENE
: I-GENE
MCB I-GENE
from I-GENE
7 I-GENE
racing I-GENE
Greyhounds I-GENE
euthanatized I-GENE
for I-GENE
reasons I-GENE
unrelated I-GENE
to I-GENE
MCB I-GENE
abnormalities I-GENE
. I-GENE

Structural O
studies O
have O
shown O
that O
class I-GENE
I I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
( I-GENE
MHC I-GENE
)- I-GENE
restricted O
peptide I-GENE
- I-GENE
specific I-GENE
T I-GENE
cell I-GENE
receptor I-GENE
( I-GENE
TCR I-GENE
)- I-GENE
alpha I-GENE
/ I-GENE
betas I-GENE
make I-GENE
multiple I-GENE
contacts I-GENE
with I-GENE
the I-GENE
alpha1 I-GENE
and I-GENE
alpha2 I-GENE
helices I-GENE
of I-GENE
the I-GENE
MHC I-GENE
, I-GENE
but I-GENE
it I-GENE
is I-GENE
unclear I-GENE
which I-GENE
or I-GENE
how I-GENE
many I-GENE
of I-GENE
these I-GENE
interactions I-GENE
contribute I-GENE
to I-GENE
functional I-GENE
binding I-GENE
. I-GENE

Fans I-GENE
in I-GENE
tunnels I-GENE
and I-GENE
open I-GENE
windows I-GENE
at I-GENE
aboveground I-GENE
locations I-GENE
appeared I-GENE
to I-GENE
greatly I-GENE
reduce I-GENE
the I-GENE
likelihood I-GENE
of I-GENE
high I-GENE
PH3 I-GENE
concentrations I-GENE
in I-GENE
enclosed I-GENE
areas I-GENE
. I-GENE

In O
DNA O
strand I-GENE
exchange I-GENE
reactions I-GENE
using I-GENE
oligonucleotides I-GENE
, I-GENE
we I-GENE
found I-GENE
that I-GENE
Rec2 I-GENE
exhibited I-GENE
a I-GENE
pairing I-GENE
bias I-GENE
that I-GENE
is I-GENE
opposite I-GENE
that I-GENE
of I-GENE
RecA I-GENE
. I-GENE

A O
major O
mechanism O
by O
which O
estrogens O
prevent O
osteoporosis O
seems O
to O
be O
repression O
of O
transcription O
of O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
target I-GENE
genes I-GENE
, O
such O
as O
the O
osteoclast O
- I-GENE
activating I-GENE
cytokines I-GENE
interleukin I-GENE
- I-GENE
6 I-GENE
and O
interleukin I-GENE
- I-GENE
1 I-GENE
. O

Linear O
eight O
- O
or O
nine O
- O
residue O
D O
- O
peptides O
derived O
from O
the O
pocket O
- O
binding O
domain O
of O
the O
cyclic O
molecules O
also O
bind O
specifically O
. O

As O
expected O
, I-GENE
homologous I-GENE
loxP I-GENE
sequences I-GENE
efficiently I-GENE
underwent I-GENE
Cre I-GENE
- I-GENE
mediated I-GENE
recombination I-GENE
. I-GENE

Multistage I-GENE
models I-GENE
and I-GENE
the I-GENE
A I-GENE
- I-GENE
bomb I-GENE
survivor I-GENE
data I-GENE
: I-GENE
implications I-GENE
for I-GENE
carcinogenic I-GENE
mechanisms I-GENE
? I-GENE

The O
results O
indicate O
that O
a O
more O
differentiated O
diagnosis O
of O
the O
molar O
relationship O
will O
allow O
for I-GENE
a I-GENE
more I-GENE
causally I-GENE
directed I-GENE
correction I-GENE
of I-GENE
Class I-GENE
II I-GENE
molar I-GENE
relationship I-GENE
. I-GENE

It I-GENE
is I-GENE
surprising I-GENE
that I-GENE
dnaE173 I-GENE
, I-GENE
a I-GENE
potent I-GENE
mutator I-GENE
mutation I-GENE
specific I-GENE
for I-GENE
sequence I-GENE
substitution I-GENE
as I-GENE
well I-GENE
as I-GENE
single I-GENE
- I-GENE
base I-GENE
frameshift I-GENE
, I-GENE
did I-GENE
not I-GENE
enhance I-GENE
the I-GENE
frequency I-GENE
of I-GENE
the I-GENE
hot I-GENE
- I-GENE
spot I-GENE
frameshift I-GENE
mutation I-GENE
. I-GENE

Hypercalcemia I-GENE
associated I-GENE
with I-GENE
elevated I-GENE
serum I-GENE
PTH I-GENE
concentration I-GENE
indicating I-GENE
primary I-GENE
hyperparathyroidism I-GENE
was I-GENE
found I-GENE
in I-GENE
7 I-GENE
BC I-GENE
patients I-GENE
( I-GENE
7 I-GENE
%) I-GENE
and I-GENE
in I-GENE
none I-GENE
of I-GENE
healthy I-GENE
women I-GENE
or I-GENE
patients I-GENE
with I-GENE
thyroid I-GENE
cancer I-GENE
. I-GENE

[ I-GENE
figure I-GENE
: I-GENE
see I-GENE
text I-GENE
] I-GENE
The I-GENE
Stille I-GENE
coupling I-GENE
reaction I-GENE
has I-GENE
been I-GENE
performed I-GENE
in I-GENE
1 I-GENE
- I-GENE
butyl I-GENE
- I-GENE
3 I-GENE
- I-GENE
methylimidazolium I-GENE
tetrafluoroborate I-GENE
( I-GENE
BMIM I-GENE
BF4 I-GENE
), I-GENE
a I-GENE
room I-GENE
- I-GENE
temperature I-GENE
ionic I-GENE
liquid I-GENE
( I-GENE
RTIL I-GENE
). I-GENE

Examination O
of O
various O
promoter O
deletion O
mutants O
indicated O
that O
SF I-GENE
- I-GENE
1 I-GENE
acts O
through O
the O
proximal O
promoter O
region O
and O
upstream O
promoter O
sequences O
. O

ORF1 I-GENE
( I-GENE
1029 I-GENE
bp I-GENE
; I-GENE
EMBL I-GENE
databank I-GENE
, I-GENE
Accession I-GENE
No I-GENE
. I-GENE

Vector I-GENE
stocks I-GENE
containing I-GENE
envelope I-GENE
proteins I-GENE
from I-GENE
three I-GENE
different I-GENE
SIVmac I-GENE
clones I-GENE
, I-GENE
namely I-GENE
, I-GENE
SIVmac239 I-GENE
( I-GENE
T I-GENE
- I-GENE
lymphocyte I-GENE
tropic I-GENE
[ I-GENE
T I-GENE
- I-GENE
tropic I-GENE
]), I-GENE
SIVmac316 I-GENE
( I-GENE
macrophage I-GENE
tropic I-GENE
[ I-GENE
M I-GENE
- I-GENE
tropic I-GENE
]), I-GENE
and I-GENE
SIVmac1A11 I-GENE
( I-GENE
dualtropic I-GENE
), I-GENE
were I-GENE
tested I-GENE
. I-GENE

ISS O
and O
the O
acute O
physiology O
and O
chronic O
health O
evaluation O
( O
APACHE O
II O
) O
calculated O
on O
admission O
. O

Ga O
- O
67 O
and O
Tl O
- I-GENE
201 I-GENE
scintigraphy I-GENE
in I-GENE
extramedullary I-GENE
plasmacytoma I-GENE
: I-GENE
a I-GENE
case I-GENE
report I-GENE
. I-GENE

Finally O
, O
there O
are O
a O
growing O
number O
of O
arguments O
favouring O
the O
use O
of O
ACE I-GENE
inhibitors O
very O
early O
in O
patients O
with O
diabetes O
mellitus O
. O

This O
paper O
describes O
the O
results O
of O
an O
initial O
study O
on O
the O
application O
of I-GENE
linear I-GENE
solvation I-GENE
energy I-GENE
relationships I-GENE
( I-GENE
LSERs I-GENE
) I-GENE
to I-GENE
the I-GENE
prediction I-GENE
of I-GENE
internal I-GENE
standard I-GENE
compounds I-GENE
in I-GENE
reversed I-GENE
- I-GENE
phase I-GENE
liquid I-GENE
chromatographic I-GENE
( I-GENE
RPLC I-GENE
) I-GENE
method I-GENE
development I-GENE
. I-GENE

A O
38 O
- O
year O
- O
old O
woman O
with O
ulcerative O
colitis O
subsequently O
developed O
sarcoidosis O
. O

Blood O
from O
dams O
was O
collected O
prior O
to O
inoculation O
and O
at O
time O
of O
necropsy O
for O
measurement O
of O
IgM I-GENE
and O
IgG I-GENE
antibodies I-GENE
to O
M O
. O
pulmonis O
. O

She O
has O
since O
developed O
a O
positive O
anti I-GENE
- I-GENE
cardiolipin I-GENE
antibody I-GENE
but I-GENE
does I-GENE
not I-GENE
meet I-GENE
diagnostic I-GENE
criteria I-GENE
for I-GENE
systemic I-GENE
lupus I-GENE
erythematosis I-GENE
. I-GENE
CONCLUSION I-GENE
: I-GENE
The I-GENE
presence I-GENE
of I-GENE
known I-GENE
autoimmune I-GENE
disease I-GENE
in I-GENE
a I-GENE
woman I-GENE
with I-GENE
POF I-GENE
should I-GENE
not I-GENE
dissuade I-GENE
the I-GENE
clinician I-GENE
from I-GENE
evaluating I-GENE
for I-GENE
a I-GENE
potential I-GENE
genetic I-GENE
cause I-GENE
. I-GENE

The O
mutation O
experiments O
showed O
that O
the O
most O
critical O
sequence O
for O
the O
repression O
of O
PTH I-GENE
was O
5 I-GENE
'- I-GENE
GGGGGAGGGGAG I-GENE
- I-GENE
3 I-GENE
' I-GENE
(+ I-GENE
1 I-GENE
to I-GENE
+ I-GENE
12 I-GENE
) I-GENE
of I-GENE
PTHSR I-GENE
. I-GENE

Thus O
, O
while O
the O
folds O
of O
all O
Myb I-GENE
domains I-GENE
resemble O
each O
other O
closely O
, O
the O
function O
of O
each O
Myb I-GENE
domain I-GENE
depends O
on O
the O
amino O
acid O
residues O
that O
are O
located O
on O
the O
surface O
of O
each O
protein O
. O

A O
cDNA O
clone O
encoding O
C2H2 I-GENE
- I-GENE
type I-GENE
zinc I-GENE
finger I-GENE
protein I-GENE
, I-GENE
SCOF I-GENE
- I-GENE
1 I-GENE
, I-GENE
was I-GENE
isolated I-GENE
from I-GENE
soybean I-GENE
. I-GENE

The I-GENE
purpose I-GENE
of I-GENE
this I-GENE
study I-GENE
was I-GENE
to I-GENE
evaluate I-GENE
simplified I-GENE
methods I-GENE
for I-GENE
estimation I-GENE
of I-GENE
Technetium I-GENE
Tc I-GENE
99m I-GENE
( I-GENE
99mTc I-GENE
)- I-GENE
pentetate I-GENE
and I-GENE
orthoiodohippurate I-GENE
I I-GENE
131 I-GENE
( I-GENE
131I I-GENE
- I-GENE
OIH I-GENE
) I-GENE
plasma I-GENE
clearance I-GENE
in I-GENE
dogs I-GENE
and I-GENE
cats I-GENE
with I-GENE
1 I-GENE
and I-GENE
2 I-GENE
blood I-GENE
samples I-GENE
. I-GENE

Sevelamer I-GENE
hydrochloride I-GENE
( I-GENE
Renagel I-GENE
) I-GENE
is I-GENE
a I-GENE
nonabsorbed I-GENE
phosphate I-GENE
- I-GENE
binding I-GENE
polymer I-GENE
marketed I-GENE
for I-GENE
the I-GENE
treatment I-GENE
of I-GENE
hyperphosphatemia I-GENE
in I-GENE
adult I-GENE
patients I-GENE
receiving I-GENE
hemodialysis I-GENE
. I-GENE

Using O
a O
novel O
method O
combining O
chromatin O
immunoprecipitation O
and O
genomic O
array O
hybridization O
, O
we O
have O
identified O
a O
460 O
- I-GENE
kb I-GENE
CENP I-GENE
- I-GENE
A I-GENE
- I-GENE
binding I-GENE
DNA I-GENE
domain I-GENE
of I-GENE
a I-GENE
neocentromere I-GENE
derived I-GENE
from I-GENE
the I-GENE
20p12 I-GENE
region I-GENE
of I-GENE
an I-GENE
invdup I-GENE
( I-GENE
20p I-GENE
) I-GENE
human I-GENE
marker I-GENE
chromosome I-GENE
. I-GENE

Cases I-GENE
of I-GENE
lung I-GENE
cancer I-GENE
with I-GENE
intramedullary I-GENE
metastasis I-GENE
are I-GENE
rare I-GENE
, I-GENE
especially I-GENE
those I-GENE
diagnosed I-GENE
before I-GENE
death I-GENE
. I-GENE

Direct I-GENE
current I-GENE
polarography I-GENE
and I-GENE
differential I-GENE
pulse I-GENE
polarographic I-GENE
methods I-GENE
have I-GENE
been I-GENE
developed I-GENE
for I-GENE
the I-GENE
qualitative I-GENE
as I-GENE
well I-GENE
as I-GENE
quantitative I-GENE
analysis I-GENE
of I-GENE
vitamin I-GENE
B1 I-GENE
, I-GENE
B2 I-GENE
and I-GENE
B6 I-GENE
. I-GENE

Fluorimetric I-GENE
determination I-GENE
of I-GENE
methylmercury I-GENE
as I-GENE
an I-GENE
ion I-GENE
- I-GENE
association I-GENE
complex I-GENE
with I-GENE
rhodamine I-GENE
B I-GENE
in I-GENE
the I-GENE
presence I-GENE
of I-GENE
iodide I-GENE
. I-GENE

The O
corresponding O
genotype O
was O
determined O
with O
a O
restriction O
enzyme O
- O
based O
assay O
. O

Patients O
were O
divided O
into O
two O
group O
; O
Control O
group O
A O
in O
which O
a O
hot O
- O
water O
circulating O
system O
was O
used O
and O
group O
B I-GENE
in I-GENE
which I-GENE
a I-GENE
transtracheal I-GENE
heating I-GENE
and I-GENE
humidification I-GENE
system I-GENE
by I-GENE
ANAMED I-GENE
HUMITUBE I-GENE
was I-GENE
used I-GENE
, I-GENE
during I-GENE
gastric I-GENE
cancer I-GENE
operation I-GENE
. I-GENE

Mental O
rotation O
of I-GENE
paired I-GENE
figures I-GENE
engendered I-GENE
activation I-GENE
in I-GENE
the I-GENE
left I-GENE
superior I-GENE
parietal I-GENE
lobule I-GENE
and I-GENE
the I-GENE
right I-GENE
frontal I-GENE
medial I-GENE
gyrus I-GENE
. I-GENE

Here O
we O
demonstrate O
that O
the O
Ras I-GENE
- I-GENE
activated I-GENE
Raf I-GENE
- I-GENE
MEK I-GENE
- I-GENE
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
( I-GENE
ERK I-GENE
) O
signaling O
pathway O
can O
specifically O
control O
the O
expression O
of O
individual O
integrin I-GENE
subunits I-GENE
in O
a O
variety O
of O
human O
and O
mouse O
cell O
lines O
. O

These I-GENE
TxRE I-GENE
contain I-GENE
cyclic I-GENE
AMP I-GENE
- I-GENE
responsive I-GENE
elements I-GENE
( I-GENE
CRE I-GENE
), I-GENE
but I-GENE
, I-GENE
remarkably I-GENE
, I-GENE
the I-GENE
" I-GENE
TGACGTCA I-GENE
" I-GENE
consensus I-GENE
is I-GENE
never I-GENE
strictly I-GENE
conserved I-GENE
in I-GENE
any I-GENE
viral I-GENE
strain I-GENE
( I-GENE
e I-GENE
. I-GENE
g I-GENE
., I-GENE
AGACGTCA I-GENE
, I-GENE
TGACGGCA I-GENE
, I-GENE
TGACCTCA I-GENE
). I-GENE

The I-GENE
hatcher I-GENE
incubators I-GENE
of I-GENE
both I-GENE
companies I-GENE
were I-GENE
also I-GENE
persistently I-GENE
contaminated I-GENE
with I-GENE
Salmonella I-GENE
livingstone I-GENE
and I-GENE
Salmonella I-GENE
thomasville I-GENE
in I-GENE
company I-GENE
A I-GENE
and I-GENE
with I-GENE
Salmonella I-GENE
senftenberg I-GENE
in I-GENE
company I-GENE
B I-GENE
. I-GENE

Binding O
of O
cell O
type O
- O
specific O
nuclear O
proteins O
to O
the O
5 O
'- O
flanking O
region O
of O
maize I-GENE
C4 I-GENE
phosphoenolpyruvate I-GENE
carboxylase I-GENE
gene I-GENE
confers O
its O
differential O
transcription O
in O
mesophyll O
cells O
. O

Susceptibility O
to O
ischemia O
- O
induced O
arrhythmias O
was O
lower O
in O
1 O
- O
week O
diabetics O
: O
only O
42 O
% O
of O
diabetic O
hearts O
exhibited O
ventricular O
tachycardia O
( O
VT O
) O
and O
16 O
% O
had O
short O
episodes O
of O
ventricular O
fibrillation O
( O
VF O
) O
as O
compared O
to O
VT O
100 O
% O
and O
VF O
70 O
% O
( O
including O
sustained O
VF O
36 O
%) O
in O
the O
non O
- O
diabetics O
( O
P O
< O
0 O
. O
05 O
). O

CONCLUSIONS O
: O
The O
methodology O
of O
LHR I-GENE
measurement O
significantly O
influences O
the O
clinical O
contribution O
of O
Tl O
- O
201 O
lung O
uptake O
evaluation O
. O

The I-GENE
authors I-GENE
made I-GENE
an I-GENE
analysis I-GENE
of I-GENE
social I-GENE
- I-GENE
economical I-GENE
conditions I-GENE
limiting I-GENE
the I-GENE
possibilities I-GENE
of I-GENE
rendering I-GENE
cardiosurgical I-GENE
care I-GENE
to I-GENE
children I-GENE
. I-GENE

METHODS O
: O
Experiments O
testing O
the O
new O
catheter O
and O
comparing O
it O
to O
the O
existing O
catheter O
included O
: O
( O
1 O
) O
measurement O
of I-GENE
the I-GENE
laser I-GENE
output I-GENE
beam I-GENE
sizes I-GENE
and I-GENE
divergences I-GENE
; I-GENE
( I-GENE
2 I-GENE
) I-GENE
evaluation I-GENE
of I-GENE
particulate I-GENE
matter I-GENE
generation I-GENE
during I-GENE
ablation I-GENE
of I-GENE
atherosclerotic I-GENE
tissue I-GENE
; I-GENE
( I-GENE
3 I-GENE
) I-GENE
measurement I-GENE
of I-GENE
ablation I-GENE
hole I-GENE
sizes I-GENE
and I-GENE
tissue I-GENE
penetration I-GENE
rates I-GENE
; I-GENE
( I-GENE
4 I-GENE
) I-GENE
histopathologic I-GENE
examination I-GENE
of I-GENE
laser I-GENE
- I-GENE
induced I-GENE
in I-GENE
vivo I-GENE
vessel I-GENE
wall I-GENE
injury I-GENE
. I-GENE

The O
reproductive O
effects O
of O
the O
administration O
of O
4 O
- O
chloro O
- I-GENE
2 I-GENE
- I-GENE
methylphenoxyacetic I-GENE
acid I-GENE
( I-GENE
MCPA I-GENE
) I-GENE
to I-GENE
rats I-GENE
were I-GENE
evaluated I-GENE
through I-GENE
two I-GENE
generations I-GENE
, I-GENE
from I-GENE
prior I-GENE
to I-GENE
mating I-GENE
, I-GENE
throughout I-GENE
mating I-GENE
, I-GENE
to I-GENE
gestation I-GENE
and I-GENE
lactation I-GENE
. I-GENE

Here I-GENE
we I-GENE
suggest I-GENE
that I-GENE
uvrA I-GENE
and I-GENE
the I-GENE
nucleotide I-GENE
excision I-GENE
repair I-GENE
pathway I-GENE
are I-GENE
involved I-GENE
in I-GENE
the I-GENE
repair I-GENE
of I-GENE
acid I-GENE
- I-GENE
induced I-GENE
DNA I-GENE
damage I-GENE
and I-GENE
are I-GENE
associated I-GENE
with I-GENE
successful I-GENE
adaptation I-GENE
of I-GENE
S I-GENE
. I-GENE
mutans I-GENE
to I-GENE
low I-GENE
pH I-GENE
. I-GENE

The I-GENE
improved I-GENE
CSF I-GENE
outflow I-GENE
conductance I-GENE
may I-GENE
increase I-GENE
the I-GENE
intracranial I-GENE
compliance I-GENE
and I-GENE
thereby I-GENE
dampen I-GENE
a I-GENE
pathological I-GENE
ICP I-GENE
waveform I-GENE
. I-GENE

These O
studies O
demonstrate O
that O
site I-GENE
- I-GENE
specific I-GENE
recognition I-GENE
of I-GENE
the I-GENE
bxd I-GENE
PRE I-GENE
by I-GENE
d I-GENE
( I-GENE
GA I-GENE
)( I-GENE
n I-GENE
) I-GENE
repeat I-GENE
binding I-GENE
activities I-GENE
mediates I-GENE
PcG I-GENE
- I-GENE
dependent I-GENE
silencing I-GENE
. I-GENE

The O
gonadotrope O
- O
specific O
and O
regulated O
expression O
of O
the O
GnRH I-GENE
receptor I-GENE
( I-GENE
GnRH I-GENE
- I-GENE
R I-GENE
) I-GENE
gene I-GENE
is O
dependent O
on O
multiple O
transcription O
factors O
that O
interact O
with O
the O
noncanonical O
GnRH I-GENE
- I-GENE
R I-GENE
activating I-GENE
sequence I-GENE
( I-GENE
GRAS I-GENE
), I-GENE
the I-GENE
activator I-GENE
protein I-GENE
- I-GENE
1 I-GENE
( I-GENE
AP I-GENE
- I-GENE
1 I-GENE
) I-GENE
element I-GENE
, I-GENE
and I-GENE
the I-GENE
steroidogenic I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( I-GENE
SF I-GENE
- I-GENE
1 I-GENE
) I-GENE
binding I-GENE
site I-GENE
. I-GENE

Before I-GENE
PO3 I-GENE
administration I-GENE
, I-GENE
more I-GENE
than I-GENE
half I-GENE
( I-GENE
57 I-GENE
. I-GENE
4 I-GENE
%) I-GENE
of I-GENE
the I-GENE
patients I-GENE
received I-GENE
only I-GENE
1 I-GENE
or I-GENE
2 I-GENE
antituberculous I-GENE
drugs I-GENE
( I-GENE
ethambutole I-GENE
and I-GENE
ethionamide I-GENE
or I-GENE
ethambutole I-GENE
and I-GENE
oprofloxacin I-GENE
). I-GENE

Using I-GENE
the I-GENE
presented I-GENE
categorical I-GENE
structure I-GENE
as I-GENE
domain I-GENE
model I-GENE
a I-GENE
prototype I-GENE
DSS I-GENE
for I-GENE
dipslide I-GENE
urine I-GENE
cultures I-GENE
has I-GENE
been I-GENE
developed I-GENE
. I-GENE

Conclusion O
: O
The O
Lp I-GENE
( I-GENE
a I-GENE
) I-GENE
levels I-GENE
in I-GENE
these I-GENE
children I-GENE
were I-GENE
the I-GENE
lower I-GENE
ever I-GENE
reported I-GENE
. I-GENE

Foxp1 I-GENE
and I-GENE
Foxp2 I-GENE
are I-GENE
expressed I-GENE
at I-GENE
high I-GENE
levels I-GENE
in I-GENE
the I-GENE
lung I-GENE
as I-GENE
early I-GENE
as I-GENE
E12 I-GENE
. I-GENE
5 I-GENE
of I-GENE
mouse I-GENE
development I-GENE
with I-GENE
Foxp2 I-GENE
expression I-GENE
restricted I-GENE
to I-GENE
the I-GENE
airway I-GENE
epithelium I-GENE
. I-GENE

Audiological I-GENE
findings I-GENE
in I-GENE
pregnancy I-GENE
. I-GENE

Children O
who O
developed O
lower O
respiratory O
tract O
infections O
or O
PCP O
had O
increased O
rates O
of O
decline O
of O
CD4 I-GENE
cell O
counts O
during O
the O
first O
6 O
months O
of O
life O
. O

A O
randomized O
mix O
of O
180 O
sections O
( O
10 O
samples O
x O
3 O
tissues O
x O
3 O
stains O
x O
2 O
) O
gave O
90 O
matched O
pairs O
. O

Sural I-GENE
nerve I-GENE
biopsy I-GENE
showed I-GENE
mild I-GENE
thickening I-GENE
of I-GENE
the I-GENE
perineurium I-GENE
, I-GENE
vascular I-GENE
alterations I-GENE
with I-GENE
inflammatory I-GENE
cell I-GENE
infiltration I-GENE
in I-GENE
the I-GENE
perineurium I-GENE
, I-GENE
and I-GENE
remarkable I-GENE
loss I-GENE
of I-GENE
large I-GENE
and I-GENE
small I-GENE
myelinated I-GENE
fibers I-GENE
. I-GENE

OBJECTIVES O
: O
The O
objective O
of O
this O
review O
was O
to O
assess O
the O
effects O
of O
prophylactic O
prostaglandin O
use O
in O
the O
third O
stage O
of O
labour O
. O

Testing I-GENE
was I-GENE
associated I-GENE
with I-GENE
a I-GENE
history I-GENE
of I-GENE
nonsexual I-GENE
risk I-GENE
behavior I-GENE
, I-GENE
increased I-GENE
knowledge I-GENE
of I-GENE
the I-GENE
hepatitis I-GENE
C I-GENE
virus I-GENE
, I-GENE
and I-GENE
healthcare I-GENE
provider I-GENE
communication I-GENE
. I-GENE

Cytomegalovirus I-GENE
, I-GENE
Chlamydia I-GENE
pneumoniae I-GENE
, I-GENE
and I-GENE
Helicobacter I-GENE
pylori I-GENE
IgG I-GENE
antibodies I-GENE
and I-GENE
restenosis I-GENE
after I-GENE
stent I-GENE
implantation I-GENE
: I-GENE
an I-GENE
angiographic I-GENE
and I-GENE
intravascular I-GENE
ultrasound I-GENE
study I-GENE
. I-GENE

A I-GENE
5 I-GENE
- I-GENE
month I-GENE
- I-GENE
old I-GENE
infant I-GENE
with I-GENE
persistent I-GENE
congenital I-GENE
stridor I-GENE
and I-GENE
acute I-GENE
respiratory I-GENE
distress I-GENE
is I-GENE
presented I-GENE
. I-GENE

OBJECTIVE I-GENE
: I-GENE
To I-GENE
determine I-GENE
whether I-GENE
RSTD I-GENE
predicts I-GENE
coronary I-GENE
anatomy I-GENE
during I-GENE
acute I-GENE
coronary I-GENE
occlusion I-GENE
. I-GENE

Even I-GENE
if I-GENE
the I-GENE
electrocardiographic I-GENE
signs I-GENE
are I-GENE
subdued I-GENE
, I-GENE
the I-GENE
underlying I-GENE
blockade I-GENE
of I-GENE
I I-GENE
( I-GENE
Kr I-GENE
) I-GENE
current I-GENE
may I-GENE
precipitate I-GENE
the I-GENE
occurrence I-GENE
of I-GENE
arrhythmia I-GENE
. I-GENE

Acetoin I-GENE
can I-GENE
be I-GENE
reused I-GENE
by I-GENE
the I-GENE
bacteria I-GENE
during I-GENE
stationary I-GENE
phase I-GENE
when I-GENE
other I-GENE
carbon I-GENE
sources I-GENE
have I-GENE
been I-GENE
depleted I-GENE
. I-GENE

Analysis O
of O
the O
promoter O
sequence O
revealed O
the O
presence O
of O
a O
major O
transcriptional O
start O
site O
, O
a O
canonical O
TATA O
box O
and O
putative O
cis O
regulatory O
elements O
for O
pituitary O
specific O
expression O
as O
well O
as O
an O
E I-GENE
- I-GENE
responsive I-GENE
element I-GENE
. O

IL I-GENE
- I-GENE
1beta I-GENE
was O
significantly O
higher I-GENE
in I-GENE
endometrioma I-GENE
than I-GENE
in I-GENE
lesions I-GENE
of I-GENE
other I-GENE
localizations I-GENE
. I-GENE

An I-GENE
economic I-GENE
analysis I-GENE
using I-GENE
West I-GENE
of I-GENE
Scotland I-GENE
Coronary I-GENE
Prevention I-GENE
Study I-GENE
( I-GENE
WOSCOPS I-GENE
) I-GENE
findings I-GENE
indicates I-GENE
that I-GENE
statin I-GENE
treatment I-GENE
would I-GENE
have I-GENE
prevented I-GENE
318 I-GENE
events I-GENE
per I-GENE
10 I-GENE
, I-GENE
000 I-GENE
patients I-GENE
in I-GENE
a I-GENE
population I-GENE
similar I-GENE
to I-GENE
that I-GENE
in I-GENE
WOSCOPS I-GENE
( I-GENE
average I-GENE
1 I-GENE
. I-GENE
5 I-GENE
% I-GENE
annual I-GENE
risk I-GENE
of I-GENE
a I-GENE
cardiovascular I-GENE
event I-GENE
) I-GENE
at I-GENE
a I-GENE
discounted I-GENE
cost I-GENE
per I-GENE
life I-GENE
- I-GENE
year I-GENE
gained I-GENE
of I-GENE
20 I-GENE
, I-GENE
375 I-GENE
pounds I-GENE
($ I-GENE
31 I-GENE
, I-GENE
818 I-GENE
). I-GENE

Hydrogels I-GENE
for I-GENE
tissue I-GENE
engineering I-GENE
. I-GENE

No O
mutation I-GENE
of I-GENE
the I-GENE
NRL I-GENE
gene I-GENE
was I-GENE
found I-GENE
in I-GENE
any I-GENE
of I-GENE
the I-GENE
two I-GENE
families I-GENE
. I-GENE

However O
, O
most O
produced O
significant O
alteration O
of O
small O
intestinal O
permeability O
. O

Our I-GENE
results I-GENE
show I-GENE
that I-GENE
CVN I-GENE
specifically I-GENE
recognizes I-GENE
with I-GENE
nanomolar I-GENE
affinity I-GENE
Man I-GENE
( I-GENE
9 I-GENE
) I-GENE
GlcNAc I-GENE
( I-GENE
2 I-GENE
) I-GENE
and I-GENE
the I-GENE
D1D3 I-GENE
isomer I-GENE
of I-GENE
Man I-GENE
( I-GENE
8 I-GENE
) I-GENE
GlcNAc I-GENE
( I-GENE
2 I-GENE
). I-GENE

Saccharomyces O
cerevisiae O
activates O
a O
regulatory O
network O
called O
" O
general O
control O
" O
that O
provides O
the O
cell O
with O
sufficient O
amounts O
of O
protein O
precursors O
during O
amino O
acid O
starvation O
. O

In O
Saccharomyces O
cerevisiae O
, O
entry O
into O
mitosis O
requires O
activation O
of O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
Cdc28 I-GENE
in O
its O
cyclin I-GENE
B I-GENE
( I-GENE
Clb I-GENE
)- I-GENE
associated O
form O
. O

Data O
from O
in O
vitro O
splicing O
assays O
, O
UV O
crosslinking O
and O
RNA O
- O
binding O
competition O
experiments O
indicates O
a O
strong O
correlation O
between O
the O
binding O
affinities O
of O
PSI I-GENE
for I-GENE
the I-GENE
SELEX I-GENE
sequences I-GENE
and I-GENE
their I-GENE
ability I-GENE
to I-GENE
modulate I-GENE
splicing I-GENE
of I-GENE
P I-GENE
element I-GENE
IVS3 I-GENE
in I-GENE
vitro I-GENE
. I-GENE

The O
sensitivity O
of O
human O
neuroblastoma O
cells O
SK O
- I-GENE
N I-GENE
- I-GENE
SH I-GENE
to O
undergo O
apoptosis O
induced O
by O
thapsigargin O
was O
examined O
. O

A I-GENE
., I-GENE
Slatkin I-GENE
, I-GENE
D I-GENE
. I-GENE

Multiparous I-GENE
women I-GENE
presented I-GENE
higher I-GENE
BMI I-GENE
( I-GENE
P I-GENE
= I-GENE
0 I-GENE
. I-GENE
01 I-GENE
) I-GENE
and I-GENE
PBF I-GENE
( I-GENE
P I-GENE
= I-GENE
0 I-GENE
. I-GENE
03 I-GENE
) I-GENE
compared I-GENE
with I-GENE
primi I-GENE
- I-GENE
and I-GENE
nulliparous I-GENE
groups I-GENE
. I-GENE

CONCLUSIONS I-GENE
AND I-GENE
CLINICAL I-GENE
RELEVANCE I-GENE
: I-GENE
Increased I-GENE
cortical I-GENE
thickness I-GENE
and I-GENE
geometric I-GENE
properties I-GENE
of I-GENE
left I-GENE
MCB I-GENE
- I-GENE
IV I-GENE
and I-GENE
- I-GENE
V I-GENE
of I-GENE
Greyhounds I-GENE
, I-GENE
together I-GENE
with I-GENE
altered I-GENE
turnover I-GENE
and I-GENE
orientation I-GENE
of I-GENE
osteons I-GENE
in I-GENE
the I-GENE
dorsal I-GENE
quadrants I-GENE
of I-GENE
left I-GENE
MCB I-GENE
, I-GENE
are I-GENE
site I-GENE
- I-GENE
specific I-GENE
adaptive I-GENE
responses I-GENE
associated I-GENE
with I-GENE
asymmetric I-GENE
cyclic I-GENE
loading I-GENE
as I-GENE
a I-GENE
result I-GENE
of I-GENE
racing I-GENE
on I-GENE
circular I-GENE
tracks I-GENE
. I-GENE

To O
examine O
transcriptional O
regulation O
of O
the O
rat I-GENE
eIF4E I-GENE
gene I-GENE
, O
2 I-GENE
. O
1 I-GENE
kB I-GENE
of O
the O
rat I-GENE
eIF4E I-GENE
promoter I-GENE
region O
was O
cloned O
and O
the O
contribution O
of O
specific O
elements O
in O
regulating O
transcription O
was O
determined O
in O
primary O
cultures O
of I-GENE
rat I-GENE
cardiocytes I-GENE
and I-GENE
in I-GENE
a I-GENE
murine I-GENE
C I-GENE
( I-GENE
2 I-GENE
) I-GENE
C I-GENE
( I-GENE
12 I-GENE
) I-GENE
myoblast I-GENE
cell I-GENE
line I-GENE
. I-GENE

The O
prevalence O
of O
tobacco O
dependence O
diagnosed O
according O
to O
the O
ICD O
- O
10 O
criteria O
was O
higher O
in O
alcohol O
- O
dependent O
individuals O
( O
58 O
. I-GENE
1 I-GENE
%) I-GENE
than I-GENE
in I-GENE
nondrinkers I-GENE
or I-GENE
social I-GENE
drinkers I-GENE
( I-GENE
12 I-GENE
. I-GENE
8 I-GENE
%). I-GENE

Management I-GENE
of I-GENE
postvitrectomy I-GENE
diabetic I-GENE
vitreous I-GENE
hemorrhage I-GENE
with I-GENE
tissue I-GENE
plasminogen I-GENE
activator I-GENE
( I-GENE
t I-GENE
- I-GENE
PA I-GENE
) I-GENE
and I-GENE
volume I-GENE
homeostatic I-GENE
fluid I-GENE
- I-GENE
fluid I-GENE
exchanger I-GENE
. I-GENE

Transactivation O
of O
oIFNtau I-GENE
enhancer I-GENE
- I-GENE
reporter I-GENE
constructs O
was O
primarily O
regulated O
by O
three O
regions O
containing O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
, O
GATA I-GENE
like I-GENE
sequence O
and O
site O
( O
s O
) O
unidentified O
. O

SELECTION O
CRITERIA O
: O
Randomised O
controlled O
trials O
of O
cabergoline O
versus O
placebo O
in O
patients O
with O
a O
clinical O
diagnosis O
of O
idiopathic O
Parkinson O
' O
s O
disease O
and O
long O
- O
term O
complications O
of O
levodopa O
therapy O
. O

0 O
%) O
and O
IL I-GENE
- I-GENE
12 O
( O
42 O
. O
6 O
% O
vs O
. O

Copyright I-GENE
2000 I-GENE
John I-GENE
Wiley I-GENE
& I-GENE
Sons I-GENE
, I-GENE
Ltd I-GENE
. I-GENE

Here I-GENE
we I-GENE
demonstrate I-GENE
that I-GENE
native I-GENE
MRCK I-GENE
exists I-GENE
in I-GENE
high I-GENE
- I-GENE
molecular I-GENE
- I-GENE
weight I-GENE
complexes I-GENE
. I-GENE

METHODS I-GENE
: I-GENE
This I-GENE
retrospective I-GENE
review I-GENE
comprised I-GENE
2711 I-GENE
eyes I-GENE
that I-GENE
had I-GENE
LASIK I-GENE
between I-GENE
September I-GENE
1996 I-GENE
and I-GENE
September I-GENE
1999 I-GENE
. I-GENE

Sixty O
- O
one O
cases O
of O
cholera O
, O
all O
caused O
by O
V O
. O
cholerae O
O1 O
, O
were O
reported O
. O

This I-GENE
could I-GENE
lead I-GENE
to I-GENE
subsequent I-GENE
outbreaks I-GENE
if I-GENE
Babesia I-GENE
carrier I-GENE
animals I-GENE
were I-GENE
to I-GENE
be I-GENE
introduced I-GENE
into I-GENE
the I-GENE
herd I-GENE
. I-GENE

Instead I-GENE
, I-GENE
TRPS1 I-GENE
potently I-GENE
and I-GENE
specifically I-GENE
represses I-GENE
transcriptional I-GENE
activation I-GENE
mediated I-GENE
by I-GENE
other I-GENE
GATA I-GENE
factors I-GENE
. I-GENE

Eliminating I-GENE
any I-GENE
subset I-GENE
of I-GENE
ASCUS I-GENE
reduces I-GENE
the I-GENE
ASCUS I-GENE
/ I-GENE
SIL I-GENE
ratio I-GENE
but I-GENE
also I-GENE
significantly I-GENE
diminishes I-GENE
the I-GENE
sensitivity I-GENE
of I-GENE
the I-GENE
Papanicolaou I-GENE
test I-GENE
. I-GENE

In I-GENE
order I-GENE
to I-GENE
overcome I-GENE
the I-GENE
false I-GENE
positive I-GENE
readings I-GENE
that I-GENE
are I-GENE
possible I-GENE
in I-GENE
sphincter I-GENE
manometry I-GENE
, I-GENE
we I-GENE
proposed I-GENE
to I-GENE
use I-GENE
secretin I-GENE
stimulated I-GENE
endoscopic I-GENE
ultrasound I-GENE
( I-GENE
SSEUS I-GENE
) I-GENE
to I-GENE
measure I-GENE
pancreatic I-GENE
ductal I-GENE
response I-GENE
as I-GENE
an I-GENE
adjunctive I-GENE
method I-GENE
to I-GENE
aid I-GENE
and I-GENE
supplement I-GENE
the I-GENE
diagnosis I-GENE
. I-GENE

Endovascular I-GENE
aneurysm I-GENE
repair I-GENE
with I-GENE
the I-GENE
AneuRx I-GENE
stent I-GENE
- I-GENE
graft I-GENE
is I-GENE
safe I-GENE
, I-GENE
but I-GENE
is I-GENE
it I-GENE
effective I-GENE
? I-GENE

The I-GENE
difference I-GENE
of I-GENE
hardness I-GENE
over I-GENE
time I-GENE
of I-GENE
composite I-GENE
specimens I-GENE
was I-GENE
measured I-GENE
using I-GENE
Knoop I-GENE
hardness I-GENE
measurements I-GENE
taken I-GENE
at I-GENE
the I-GENE
top I-GENE
and I-GENE
bottom I-GENE
surfaces I-GENE
of I-GENE
resin I-GENE
specimens I-GENE
made I-GENE
in I-GENE
a I-GENE
Teflon I-GENE
mold I-GENE
the I-GENE
same I-GENE
dimensions I-GENE
as I-GENE
the I-GENE
cavity I-GENE
prepared I-GENE
in I-GENE
dentin I-GENE
. I-GENE

Implications I-GENE
in I-GENE
biomonitoring I-GENE
of I-GENE
the I-GENE
observed I-GENE
accumulation I-GENE
patterns I-GENE
, I-GENE
especially I-GENE
in I-GENE
the I-GENE
different I-GENE
tissues I-GENE
of I-GENE
Posidonia I-GENE
oceanica I-GENE
, I-GENE
are I-GENE
discussed I-GENE
. I-GENE

Based O
on O
mutational O
data O
and O
possible O
mRNA O
structure O
, O
we O
hypothesized O
about O
the O
effect O
of O
mRNA O
structure O
on O
translation O
of O
the O
two O
major O
C I-GENE
/ I-GENE
EBPepsilon I-GENE
isoforms I-GENE
: I-GENE
p32 I-GENE
and I-GENE
p30 I-GENE
. I-GENE

Retinoids I-GENE
participate I-GENE
in I-GENE
the I-GENE
onset I-GENE
of I-GENE
differentiation I-GENE
, I-GENE
apoptosis I-GENE
and I-GENE
the I-GENE
inhibition I-GENE
of I-GENE
growth I-GENE
in I-GENE
a I-GENE
wide I-GENE
variety I-GENE
of I-GENE
normal I-GENE
and I-GENE
cancerous I-GENE
cells I-GENE
. I-GENE

We I-GENE
conclude I-GENE
that I-GENE
RPMS I-GENE
acts I-GENE
as I-GENE
a I-GENE
negative I-GENE
regulator I-GENE
of I-GENE
EBNA2 I-GENE
and I-GENE
Notch I-GENE
activity I-GENE
through I-GENE
its I-GENE
interactions I-GENE
with I-GENE
the I-GENE
CBF1 I-GENE
- I-GENE
associated I-GENE
corepressor I-GENE
complex I-GENE
. I-GENE

Isolated I-GENE
Systolic I-GENE
Hypertension I-GENE
: I-GENE
An I-GENE
Update I-GENE
. I-GENE

Transfection O
of O
EGFP I-GENE
- I-GENE
tagged I-GENE
DENTT I-GENE
NLS I-GENE
deletion I-GENE
constructs I-GENE
lacking I-GENE
the I-GENE
bipartite I-GENE
NLS I-GENE
- I-GENE
1 I-GENE
were I-GENE
excluded I-GENE
from I-GENE
the I-GENE
nucleolus I-GENE
. I-GENE

VE I-GENE
- I-GENE
DEF I-GENE
animals I-GENE
had I-GENE
significantly I-GENE
higher I-GENE
( I-GENE
p I-GENE
< I-GENE
0 I-GENE
. I-GENE
05 I-GENE
) I-GENE
levels I-GENE
of I-GENE
myocardial I-GENE
lipid I-GENE
peroxidation I-GENE
and I-GENE
lower I-GENE
( I-GENE
p I-GENE
< I-GENE
0 I-GENE
. I-GENE
05 I-GENE
) I-GENE
protein I-GENE
thiols I-GENE
following I-GENE
I I-GENE
- I-GENE
R I-GENE
compared I-GENE
to I-GENE
the I-GENE
CON I-GENE
animals I-GENE
. I-GENE

The O
position O
of I-GENE
the I-GENE
analyst I-GENE
as I-GENE
expert I-GENE
: I-GENE
yesterday I-GENE
and I-GENE
today I-GENE
. I-GENE

Furthermore I-GENE
, I-GENE
we I-GENE
showed I-GENE
that I-GENE
ERSF I-GENE
including I-GENE
NF I-GENE
- I-GENE
Y I-GENE
and I-GENE
ATF6alpha I-GENE
and I-GENE
/ I-GENE
or I-GENE
beta I-GENE
and I-GENE
capable I-GENE
of I-GENE
binding I-GENE
to I-GENE
ERSE I-GENE
is I-GENE
indeed I-GENE
formed I-GENE
when I-GENE
the I-GENE
cellular I-GENE
UPR I-GENE
is I-GENE
activated I-GENE
. I-GENE

We I-GENE
performed I-GENE
the I-GENE
present I-GENE
study I-GENE
to I-GENE
clarify I-GENE
the I-GENE
relationship I-GENE
between I-GENE
the I-GENE
DOX I-GENE
binding I-GENE
ability I-GENE
(% I-GENE
DB I-GENE
) I-GENE
and I-GENE
the I-GENE
histologic I-GENE
response I-GENE
, I-GENE
rate I-GENE
of I-GENE
decrease I-GENE
in I-GENE
tumor I-GENE
volume I-GENE
of I-GENE
malignant I-GENE
soft I-GENE
tissue I-GENE
tumors I-GENE
after I-GENE
preoperative I-GENE
chemotherapy I-GENE
and I-GENE
prognosis I-GENE
. I-GENE

We O
have O
also O
isolated O
and O
analyzed O
the O
5 O
' O
flanking O
region O
of O
the I-GENE
pea I-GENE
33RNP I-GENE
gene I-GENE
. I-GENE

We O
have O
previously O
shown O
that O
the O
adenoviral O
12S I-GENE
E1A I-GENE
protein I-GENE
modulates O
the O
phosphorylation O
status O
of O
p130 I-GENE
and O
p107 I-GENE
without O
apparent O
changes O
in O
the O
cell O
cycle O
dependent O
phosphorylation O
of O
the O
retinoblastoma I-GENE
protein I-GENE
. O

Baseline O
MBF O
in O
females O
was O
significantly O
( O
P O
< O
0 O
. O
001 O
) O
higher O
than O
in O
males O
. O

Only O
nine O
patients O
were O
offered O
surgery O
( O
six O
were O
resected O
and O
three O
were O
found O
inoperable O
). O

The I-GENE
deubiquitinating I-GENE
enzyme I-GENE
DUB I-GENE
- I-GENE
2 I-GENE
is I-GENE
induced I-GENE
in I-GENE
response I-GENE
to I-GENE
IL I-GENE
- I-GENE
2 I-GENE
but I-GENE
as I-GENE
yet I-GENE
its I-GENE
function I-GENE
has I-GENE
not I-GENE
been I-GENE
determined I-GENE
. I-GENE

A O
split O
motor O
domain O
in O
a O
cytoplasmic O
dynein I-GENE
. O

Immunological O
and O
biochemical O
characterization O
of O
streptococcal I-GENE
pyrogenic I-GENE
exotoxins I-GENE
I I-GENE
and I-GENE
J I-GENE
( I-GENE
SPE I-GENE
- I-GENE
I I-GENE
and I-GENE
SPE I-GENE
- I-GENE
J I-GENE
) I-GENE
from I-GENE
Streptococcus I-GENE
pyogenes I-GENE
. I-GENE

Five I-GENE
modalities I-GENE
of I-GENE
nonpharmacologic I-GENE
approaches I-GENE
are I-GENE
recommended I-GENE
at I-GENE
present I-GENE
for I-GENE
lifestyle I-GENE
modification I-GENE
and I-GENE
control I-GENE
of I-GENE
arterial I-GENE
blood I-GENE
pressure I-GENE
elevation I-GENE
: I-GENE
1 I-GENE
) I-GENE
weight I-GENE
reduction I-GENE
to I-GENE
ideal I-GENE
body I-GENE
weight I-GENE
, I-GENE
since I-GENE
it I-GENE
reduces I-GENE
risk I-GENE
of I-GENE
hypertension I-GENE
as I-GENE
well I-GENE
as I-GENE
overall I-GENE
cardiovascular I-GENE
morbidity I-GENE
and I-GENE
mortality I-GENE
; I-GENE
2 I-GENE
) I-GENE
dietary I-GENE
sodium I-GENE
restriction I-GENE
to I-GENE
less I-GENE
than I-GENE
2 I-GENE
g I-GENE
a I-GENE
day I-GENE
, I-GENE
without I-GENE
assurance I-GENE
that I-GENE
it I-GENE
will I-GENE
normalize I-GENE
arterial I-GENE
pressure I-GENE
although I-GENE
it I-GENE
may I-GENE
help I-GENE
reduce I-GENE
dosage I-GENE
and I-GENE
numbers I-GENE
of I-GENE
prescribed I-GENE
antihypertensive I-GENE
drugs I-GENE
; I-GENE
3 I-GENE
) I-GENE
moderation I-GENE
of I-GENE
alcohol I-GENE
consumption I-GENE
to I-GENE
less I-GENE
than I-GENE
1 I-GENE
ounce I-GENE
a I-GENE
day I-GENE
; I-GENE
4 I-GENE
) I-GENE
a I-GENE
regular I-GENE
isotonic I-GENE
exercise I-GENE
program I-GENE
; I-GENE
and I-GENE
5 I-GENE
) I-GENE
cessation I-GENE
of I-GENE
tobacco I-GENE
consumption I-GENE
. I-GENE

Descriptions I-GENE
of I-GENE
this I-GENE
locus I-GENE
would I-GENE
allow I-GENE
comparison I-GENE
with I-GENE
functionally I-GENE
relevant I-GENE
molecular I-GENE
genetic I-GENE
features I-GENE
of I-GENE
other I-GENE
species I-GENE
' I-GENE
homologous I-GENE
loci I-GENE
including I-GENE
the I-GENE
single I-GENE
- I-GENE
copy I-GENE
equid I-GENE
LH I-GENE
/ I-GENE
CGbeta I-GENE
gene I-GENE
and I-GENE
the I-GENE
primate I-GENE
LHbeta I-GENE
- I-GENE
CGbeta I-GENE
gene I-GENE
cluster I-GENE
locus I-GENE
. I-GENE

METHODS O
: O
One O
hundred O
fourteen O
consecutive O
patients O
( O
mean O
age O
61 O
years O
) O
with O
focal O
pancreatic O
masses O
, O
detected O
on O
CT I-GENE
, I-GENE
underwent I-GENE
EUS I-GENE
- I-GENE
FNA I-GENE
by I-GENE
using I-GENE
a I-GENE
linear I-GENE
- I-GENE
array I-GENE
echoendoscope I-GENE
and I-GENE
22 I-GENE
- I-GENE
gauge I-GENE
needles I-GENE
. I-GENE

The I-GENE
effects I-GENE
of I-GENE
chlordiazepoxide I-GENE
( I-GENE
2 I-GENE
. I-GENE
5 I-GENE
- I-GENE
15 I-GENE
. I-GENE
0mg I-GENE
/ I-GENE
kg I-GENE
), I-GENE
a I-GENE
full I-GENE
benzodiazepine I-GENE
receptor I-GENE
agonist I-GENE
, I-GENE
and I-GENE
bretazenil I-GENE
( I-GENE
5 I-GENE
. I-GENE
0 I-GENE
- I-GENE
30 I-GENE
. I-GENE
0mg I-GENE
/ I-GENE
kg I-GENE
), I-GENE
a I-GENE
partial I-GENE
benzodiazepine I-GENE
receptor I-GENE
agonist I-GENE
, I-GENE
were I-GENE
examined I-GENE
in I-GENE
the I-GENE
murine I-GENE
elevated I-GENE
plus I-GENE
- I-GENE
maze I-GENE
paradigm I-GENE
. I-GENE

Acute O
effects O
of O
LI O
160 O
( O
extract I-GENE
of I-GENE
Hypericum I-GENE
perforatum I-GENE
, I-GENE
St I-GENE
John I-GENE
' I-GENE
s I-GENE
wort I-GENE
) I-GENE
and I-GENE
two I-GENE
of I-GENE
its I-GENE
constituents I-GENE
on I-GENE
neuroendocrine I-GENE
responses I-GENE
in I-GENE
the I-GENE
rat I-GENE
. I-GENE

Guidelines I-GENE
for I-GENE
performing I-GENE
a I-GENE
routine I-GENE
spiral I-GENE
assay I-GENE
are I-GENE
presented I-GENE
, I-GENE
and I-GENE
alternative I-GENE
test I-GENE
methods I-GENE
intended I-GENE
to I-GENE
overcome I-GENE
a I-GENE
variety I-GENE
of I-GENE
technical I-GENE
difficulties I-GENE
( I-GENE
such I-GENE
as I-GENE
restricted I-GENE
sample I-GENE
availability I-GENE
, I-GENE
sample I-GENE
viscosity I-GENE
or I-GENE
volatility I-GENE
, I-GENE
etc I-GENE
.) I-GENE
are I-GENE
recommended I-GENE
. I-GENE

An O
additional O
9 O
patients O
achieved O
normal O
levels O
with O
adjunctive O
drug O
therapy O
. O

Anti I-GENE
- I-GENE
nucleolin I-GENE
mAb I-GENE
was O
used O
to O
confirm O
the I-GENE
antigenic I-GENE
properties I-GENE
of I-GENE
this I-GENE
p95 I-GENE
component I-GENE
. I-GENE

Eliminating I-GENE
any I-GENE
subset I-GENE
of I-GENE
ASCUS I-GENE
reduces I-GENE
the I-GENE
ASCUS I-GENE
/ I-GENE
SIL I-GENE
ratio I-GENE
but I-GENE
also I-GENE
significantly I-GENE
diminishes I-GENE
the I-GENE
sensitivity I-GENE
of I-GENE
the I-GENE
Papanicolaou I-GENE
test I-GENE
. I-GENE

Prrp I-GENE
can I-GENE
also I-GENE
associate I-GENE
with I-GENE
the I-GENE
EVH1 I-GENE
domain I-GENE
of I-GENE
Mena I-GENE
, I-GENE
another I-GENE
microfilament I-GENE
- I-GENE
associated I-GENE
protein I-GENE
. I-GENE

Experience O
with O
xylene O
- O
free O
sections O
since O
1995 O
at I-GENE
the I-GENE
Vrinnevi I-GENE
Hospital I-GENE
is I-GENE
favorable I-GENE
. I-GENE

Acquired O
antithrombin I-GENE
deficiency O
in O
sepsis O
. O

SIP1 I-GENE
( I-GENE
Smad I-GENE
interacting I-GENE
protein I-GENE
1 I-GENE
) I-GENE
and I-GENE
deltaEF1 I-GENE
( I-GENE
delta I-GENE
- I-GENE
crystallin I-GENE
enhancer I-GENE
binding I-GENE
factor I-GENE
) I-GENE
are I-GENE
structurally I-GENE
similar I-GENE
transcriptional I-GENE
repressors I-GENE
. I-GENE

SERS I-GENE
spectra I-GENE
were I-GENE
obtained I-GENE
by I-GENE
vacuum I-GENE
evaporation I-GENE
and I-GENE
casting I-GENE
of I-GENE
p I-GENE
- I-GENE
NTP I-GENE
onto I-GENE
silver I-GENE
island I-GENE
films I-GENE
, I-GENE
and I-GENE
also I-GENE
from I-GENE
colloidal I-GENE
silver I-GENE
solutions I-GENE
. I-GENE

The I-GENE
moduli I-GENE
of I-GENE
elasticity I-GENE
of I-GENE
the I-GENE
gray I-GENE
and I-GENE
white I-GENE
matter I-GENE
were I-GENE
3 I-GENE
. I-GENE
4 I-GENE
+/- I-GENE
1 I-GENE
. I-GENE
4 I-GENE
kPa I-GENE
( I-GENE
mean I-GENE
+/- I-GENE
standard I-GENE
deviation I-GENE
) I-GENE
and I-GENE
3 I-GENE
. I-GENE
4 I-GENE
+/- I-GENE
0 I-GENE
. I-GENE
9 I-GENE
kPa I-GENE
in I-GENE
the I-GENE
axial I-GENE
section I-GENE
, I-GENE
3 I-GENE
+/- I-GENE
0 I-GENE
. I-GENE
3 I-GENE
kPa I-GENE
and I-GENE
3 I-GENE
. I-GENE
5 I-GENE
+/- I-GENE
0 I-GENE
. I-GENE
5 I-GENE
kPa I-GENE
in I-GENE
the I-GENE
frontal I-GENE
section I-GENE
, I-GENE
and I-GENE
3 I-GENE
. I-GENE
5 I-GENE
+/- I-GENE
0 I-GENE
. I-GENE
9 I-GENE
kPa I-GENE
and I-GENE
2 I-GENE
. I-GENE
8 I-GENE
+/- I-GENE
0 I-GENE
. I-GENE
4 I-GENE
kPa I-GENE
in I-GENE
the I-GENE
sagittal I-GENE
section I-GENE
, I-GENE
respectively I-GENE
. I-GENE

[ O
Clinical O
and O
epidemiological O
characteristics O
of O
squamous O
cell O
carcinoma O
of I-GENE
the I-GENE
oral I-GENE
cavity I-GENE
in I-GENE
women I-GENE
] I-GENE
BACKGROUND I-GENE
: I-GENE
Squamous I-GENE
cell I-GENE
carcinoma I-GENE
( I-GENE
SCC I-GENE
) I-GENE
of I-GENE
the I-GENE
oral I-GENE
cavity I-GENE
occurs I-GENE
mainly I-GENE
in I-GENE
the I-GENE
male I-GENE
population I-GENE
. I-GENE

The O
core I-GENE
promoter I-GENE
of O
human I-GENE
thioredoxin I-GENE
reductase I-GENE
1 I-GENE
: O
cloning O
, O
transcriptional O
activity O
, O
and O
Oct I-GENE
- I-GENE
1 I-GENE
, O
Sp1 I-GENE
, O
and O
Sp3 I-GENE
binding I-GENE
reveal O
a O
housekeeping O
- O
type O
promoter O
for O
the O
AU O
- I-GENE
rich I-GENE
element I-GENE
- I-GENE
regulated I-GENE
gene I-GENE
. O

Phase O
II O
trial O
of O
the O
anti I-GENE
- I-GENE
G I-GENE
( I-GENE
D2 I-GENE
) I-GENE
monoclonal I-GENE
antibody I-GENE
3F8 I-GENE
and I-GENE
granulocyte I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
for I-GENE
neuroblastoma I-GENE
. I-GENE

A O
log O
- O
linear O
dose O
- O
response O
was O
obtained O
for O
the O
average O
increase O
in O
FEV1 O
up O
to O
6 O
h O
( O
AUC0 O
- O
6 O
h O
) I-GENE
and I-GENE
peak I-GENE
FEV1 I-GENE
across I-GENE
the I-GENE
dose I-GENE
range I-GENE
administered I-GENE
by I-GENE
Respimat I-GENE
. I-GENE

Plasma O
DHE O
concentration O
rose O
promptly O
above O
5 O
ng O
/ O
ml O
after O
the O
application O
of O
the O
PSA I-GENE
tape O
onto O
the O
damaged O
skin I-GENE
in I-GENE
hairless I-GENE
rat I-GENE
. I-GENE

A I-GENE
complete I-GENE
drug I-GENE
history I-GENE
was I-GENE
compiled I-GENE
, I-GENE
specifying I-GENE
the I-GENE
amount I-GENE
and I-GENE
duration I-GENE
of I-GENE
VGB I-GENE
medication I-GENE
. I-GENE

Epithelial O
cytotoxicity O
of O
combined O
antibiotics O
was O
additive O
, O
with O
no O
evidence O
of O
competition O
or O
synergism O
. O

In I-GENE
Cd I-GENE
- I-GENE
spiked I-GENE
OECD I-GENE
soil I-GENE
, I-GENE
internal I-GENE
Cd I-GENE
levels I-GENE
were I-GENE
linearly I-GENE
related I-GENE
to I-GENE
external I-GENE
Cd I-GENE
concentrations I-GENE
, I-GENE
whereas I-GENE
the I-GENE
springtails I-GENE
maintained I-GENE
fixed I-GENE
internal I-GENE
levels I-GENE
of I-GENE
Cu I-GENE
and I-GENE
Zn I-GENE
regardless I-GENE
of I-GENE
spiked I-GENE
concentrations I-GENE
. I-GENE

Interestingly O
, I-GENE
the I-GENE
similarities I-GENE
with I-GENE
the I-GENE
endophilin I-GENE
proteins I-GENE
cover I-GENE
the I-GENE
entire I-GENE
sequence I-GENE
of I-GENE
the I-GENE
SH3GLB I-GENE
family I-GENE
, I-GENE
suggesting I-GENE
a I-GENE
common I-GENE
fold I-GENE
and I-GENE
presumably I-GENE
a I-GENE
common I-GENE
mode I-GENE
of I-GENE
action I-GENE
. I-GENE

Reovirus I-GENE
mRNAs I-GENE
are I-GENE
efficiently I-GENE
translated I-GENE
within I-GENE
host I-GENE
cells I-GENE
despite I-GENE
the I-GENE
absence I-GENE
of I-GENE
3 I-GENE
' I-GENE
polyadenylated I-GENE
tails I-GENE
. I-GENE

Grippers I-GENE
with I-GENE
integrated I-GENE
piezoresistive I-GENE
force I-GENE
sensors I-GENE
and I-GENE
with I-GENE
attached I-GENE
strain I-GENE
gauges I-GENE
have I-GENE
been I-GENE
reported I-GENE
. I-GENE

Both O
Z O
and O
R O
expression O
resulted O
in O
PML O
dispersion O
in O
EBV O
- O
positive O
cells O
. O

The I-GENE
small I-GENE
copepod I-GENE
Pseudonychocamptus I-GENE
proximus I-GENE
progressively I-GENE
replaced I-GENE
the I-GENE
large I-GENE
Tisbe I-GENE
furcata I-GENE
in I-GENE
sand I-GENE
filters I-GENE
during I-GENE
the I-GENE
fall I-GENE
of I-GENE
1995 I-GENE
and I-GENE
was I-GENE
responsible I-GENE
for I-GENE
the I-GENE
large I-GENE
increase I-GENE
in I-GENE
meiofaunal I-GENE
biomass I-GENE
observed I-GENE
after I-GENE
spring I-GENE
1996 I-GENE
. I-GENE

Evidence O
- O
based O
care O
: O
a O
new O
formula O
for O
an O
old O
problem O
? O

Nrf2 I-GENE
regulates I-GENE
expression I-GENE
of I-GENE
genes I-GENE
encoding I-GENE
enzymes I-GENE
with I-GENE
antioxidant I-GENE
( I-GENE
e I-GENE
. I-GENE
g I-GENE
. I-GENE
heme I-GENE
oxygenase I-GENE
- I-GENE
1 I-GENE
( I-GENE
HO I-GENE
- I-GENE
1 I-GENE
)) I-GENE
or I-GENE
xenobiotic I-GENE
detoxification I-GENE
( I-GENE
e I-GENE
. I-GENE
g I-GENE
. I-GENE

Workload I-GENE
, I-GENE
UAPs I-GENE
, I-GENE
and I-GENE
you I-GENE
. I-GENE

RESULTS I-GENE
: I-GENE
At I-GENE
latest I-GENE
examination I-GENE
, I-GENE
mean I-GENE
UPDRS I-GENE
II I-GENE
and I-GENE
III I-GENE
scores I-GENE
had I-GENE
improved I-GENE
by I-GENE
30 I-GENE
% I-GENE
( I-GENE
on I-GENE
stimulation I-GENE
, I-GENE
off I-GENE
therapy I-GENE
) I-GENE
with I-GENE
mean I-GENE
50 I-GENE
% I-GENE
reduction I-GENE
in I-GENE
daily I-GENE
off I-GENE
time I-GENE
. I-GENE

Perfusion I-GENE
technique I-GENE
for I-GENE
perfusion I-GENE
- I-GENE
assisted I-GENE
direct I-GENE
coronary I-GENE
artery I-GENE
bypass I-GENE
( I-GENE
PADCAB I-GENE
). I-GENE

Copyright I-GENE
2001 I-GENE
Academic I-GENE
Press I-GENE
. I-GENE

The I-GENE
amount I-GENE
of I-GENE
drained I-GENE
effusion I-GENE
was I-GENE
measured I-GENE
, I-GENE
and I-GENE
fluid I-GENE
was I-GENE
sent I-GENE
for I-GENE
diagnostic I-GENE
assessment I-GENE
. I-GENE

